Peptidomimetic macrocycles as modulators of mcl-1

ABSTRACT

The disclosed peptidomimetic macrocycles modulate the activity of MCL-1. Myeloid cell leukemia 1 (MCL-1) is a protein that inhibits cell death. Peptidomimetic macrocycles, pharmaceutical compositions, and methods disclosed herein can be used for the treatment of disease in which MCL-1 is over-expressed, such as cancer. In particular, MCL-1-modulating peptidomimetic macrocycles disclosed herein can be applied in the setting of resistance to BCL-2 family inhibitors, which is often engendered by MCL-1 over-expression or hyper-activation.

CROSS-REFERENCE

This application is a continuation of U.S. application Ser. No. 15/259,947, filed Sep. 8, 2016, which claims priority to U.S. Provisional Application No. 62/216,683, filed Sep. 10, 2015, each of which is incorporated herein by reference in their entirety.

SEQUENCE LISTING

The instant application contains a Sequence Listing, which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on May 17, 2018, is named 35224796301_SL.TXT and is 1,592,917 bytes in size.

BACKGROUND OF THE INVENTION

Myeloid cell leukemia 1 (MCL-1) is a protein that inhibits cell death by binding and inhibiting pro-death factors, such as BCL-2 interacting mediator (BIM). When MCL-1 is over-expressed, the rate of cell death in a cell or tissue is reduced.

SUMMARY OF THE INVENTION

In some embodiments, the invention provides a peptidomimetic macrocycle of Formula (Ic):

wherein the peptidomimetic macrocycle binds MCL-1 selectively over another protein that has a BH3 domain, wherein:

each A, C, D, and E is independently a natural or non-natural amino acid;

each B is independently a natural or non-natural amino acid, amino acid analog,

[—NH-L₃-CO—], [—NH-L₃-SO₂—], or [—NH-L₃-];

each L is independently a macrocycle-forming linker;

each L′ is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene, each being optionally substituted with R₅, or a bond, or together with R₁ and the atom to which both R₁ and L′ are bound forms a ring;

each L″ is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene, each being optionally substituted with R₅, or a bond, or together with R₂ and the atom to which both R₂ and L″ are bound forms a ring;

each R₁ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-, or together with L′ and the atom to which both R₁ and L′ are bound forms a ring;

each R₂ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-, or together with L″ and the atom to which both R₂ and L″ are bound forms a ring;

each R₃ is independently hydrogen, alkyl, alkenyl, alkynyl, arylalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, aryl, or heteroaryl, optionally substituted with R₅;

each L₃ is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene, or [—R₄—K—R₄—]_(n), each being optionally substituted with R₅;

each R₄ is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene;

each K is independently O, S, SO, SO₂, CO, CO₂, or CONR₃;

each n is independently an integer from 1-5;

each R₅ is independently halogen, alkyl, —OR₆, —N(R₆)₂, —SR₆, —SOR₆, —SO₂R₆, —CO₂R₆, a fluorescent moiety, a radioisotope, or a therapeutic agent;

each R₆ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope, or a therapeutic agent;

each R₇ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, optionally substituted with R₅, or part of a cyclic structure with a D residue;

each R₈ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, optionally substituted with R₅, or part of a cyclic structure with an E residue;

each v and w is independently an integer from 1-1000;

u is an integer from 1-10; and

each x, y and z is independently an integer from 0-10, or a pharmaceutically-acceptable salt thereof.

In some embodiments, the invention provides a peptidomimetic macrocycle having the formula:

wherein:

each D and E is independently an amino acid residue;

R¹ and R² are independently alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, each being optionally substituted with halo-; —H, or at least one of R¹ and R² forms a macrocycle-forming linker L′ connected to the alpha position of one of the D or E amino acid residues;

L is a macrocycle-forming linker of the formula -L¹-L²-or -L¹-L²-L³-;

each L¹, L², and L³ is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene, or [—R⁴—K—R⁴—]_(n), each being optionally substituted with R⁵;

each R³ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, each being optionally substituted with R⁵;

each R⁴ is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene, each being optionally substituted with R⁵;

each K is independently O, S, SO, SO₂, CO, CO₂, or CONR³;

each R⁵ is independently halogen, alkyl, —OR⁶, —N(R⁶)₂, —SR⁶, —SOR⁶, —SO₂R⁶, —CO₂R⁶, a fluorescent moiety, a radioisotope, or a therapeutic agent;

each R⁶ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope, or a therapeutic agent;

R⁷ is —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, each being optionally substituted with R⁵, or part of a cyclic structure with a D residue;

R⁸ is —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, each being optionally substituted with R⁵, or part of a cyclic structure with an E residue;

each of Xaa¹ and Xaa² is independently an amino acid residue or absent;

Xaa³ is Ala, Aib, Asp, Asn, Cys, Glu, Gln, His, Ile, Lys, Leu, Met, Arg, Ser, Thr, Val, Trp, Tyr, or an analog of any of the foregoing;

v is an integer from 1-1000;

w is an integer from 0-1000; and

n is an integer from 1-5, or

a pharmaceutically-acceptable salt thereof.

In some embodiments, the invention provides a peptidomimetic macrocycle of the formula (SEQ ID NO: 1783):

wherein:

each D and E is independently an amino acid residue;

R¹ and R² are independently alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, each being optionally substituted with halo-; —H, or at least one of R¹ and R² forms a macrocycle-forming linker L′ connected to the alpha position of one of the D or E amino acid residues;

each L or L′ is independently a macrocycle-forming linker of the formula -L¹-L²-or -L¹-L²-L³-;

each L¹, L², and L³ is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene, or [—R⁴—K—R⁴—]_(n), each being optionally substituted with R⁵;

each R³ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, each being optionally substituted with R⁵;

each R⁴ is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene, each being optionally substituted with R⁵;

each K is independently O, S, SO, SO₂, CO, CO₂, or CONR³;

each R⁵ is independently halogen, alkyl, —OR⁶, —N(R⁶)₂, —SR⁶, —SOR⁶, —SO₂R⁶, —CO₂R⁶, a fluorescent moiety, a radioisotope, or a therapeutic agent;

each R⁶ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope, or a therapeutic agent;

R⁷ is —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, each being optionally substituted with R⁵, or part of a cyclic structure with a D residue;

R⁸ is —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, each being optionally substituted with R⁵, or part of a cyclic structure with an E residue;

each of Xaa¹ and Xaa² is independently an amino acid residue or absent;

v is an integer from 1-1000;

w is an integer from 0-1000; and

n is an integer from 1-5, or

a pharmaceutically-acceptable salt thereof.

In some embodiments, the invention provides a peptidomimetic macrocycle comprising an amino acid sequence of formula:

X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17-X18-X19-X20- X21

wherein:

X1 is Ile, Arg, Ala, Lys, Pro, Leu, Asp, Glu, His, Ser, Gln, Phe, an analog thereof, or absent;

X2 is Trp, Arg, Ala, Asn, Phe, Pro, Leu, Ser, Lys, Tyr, His, Cou, Cou2, Cou4, Cou7, an analog thereof, a crosslinked amino acid, or absent;

X3 is Ile, Ala, Leu, Phe, Tyr, Val, Asp, Trp, Pro, Gln, Chg, Ac5c, Ac6c, Tba, Bip, Cha, Adm, hCha, an analog thereof, or absent;

X4 is Ala, Gln, Asp, Val, Gly, Ser, Leu, Phe, Cha, A4, an analog, thereof, a crosslinked amino acid, or absent;

X5 is Gln, Ala, Leu, Phe, Tyr, Gly, Ile, Val, Arg, Glu, Pro, Asp, MO, MO2, an analog thereof, a crosslinked amino acid, or absent;

X6 is Glu, Gln, His, Ala, Ser, Arg, Ile, Leu, Thr, Phe, Val, Tyr, Gly, Nle, St, an analog thereof, or absent;

X7 is Ala, Leu, Phe, Ile, 2Nal, 1Nal, 3cf, Chg, Cha, Adm, hCha, Igl, Bip, an analog thereof, or absent;

X8 is Arg, Ala, Asp, Glu, Thr, His, Gln, Gly, Asn, Phe, Cit, St, an analog thereof, a crosslinked amino acid, or absent;

X9 is Arg, Ala, Asp, Lys, Asn, Gly, Ser, Gln, Cys, Nle, St, an analog thereof, or a crosslinked amino acid;

X10 is Ile, Val, Ala, Asp, Asn, Phe, Tba, hL, hhL, Nle, Chg, Cha, an analog thereof, or a crosslinked amino acid;

X11 is Gly, Val, Ala, Leu, Ile, Asp, Glu, Cha, Aib, Abu, an analog thereof, or a crosslinked amino acid;

X12 is Asp, Ala, Asn, Gly, Arg, Glu, Lys, Leu, Nle, an analog thereof, or a crosslinked amino acid;

X13 is Ala, Glu, Gln, Leu, Lys, Asp, Tyr, Ile, Ser, Cys, St, Sta5, Aib, Nle, an analog thereof, or a crosslinked amino acid;

X14 is Phe, Ala, Leu, Val, Tyr, Glu, His, Ile, Nle, 1Nal, 2Nal, Chg, Cha, BiP, an analog thereof, or a crosslinked amino acid;

X15 is Asn, Gln, Ser, His, Glu, Asp, Ala, Leu, Ile, St, Nle, Aib, an analog thereof, a crosslinked amino acid, or absent;

X16 is Ala, Glu, Asp, Arg, Lys, Phe, Gly, Gln, Aib, Cha, St, an analog thereof, a crosslinked amino acid, or absent;

X17 is Phe, Tyr, Ala, Leu, Asn, Ser, Gln, Arg, His, Thr, Cou2, Cou3, Cou7, Dpr, Amf, Damf, Amye, an analog thereof, a crosslinked amino acid, or absent;

X18 is Tyr, Ala, Ile, Phe, His, Arg, Lys, Trp, Orn, Amf, Amye, Cha, 2Nal, an analog thereof, or absent;

X19 is Ala, Lys, Arg, His, Ser, Gln, Glu, Asp, Thr, Aib, Cha, an analog thereof, a crosslinked amino acid, or absent; and

X20 is Arg, His, Ala, Thr, Lys, Amr, an analog thereof, a crosslinked amino acid, or absent; and

X21 is Arg, His, Ala, Amr, an analog thereof, or absent, or

-   a pharmaceutically-acceptable salt thereof, -   wherein at least two of the amino acids of the amino acid sequence     are a crosslinked amino acid.

In some embodiments, the invention provides a peptidomimetic macrocycle comprising an amino acid sequence with C-terminal amino acid residues that are -His-His, wherein the peptidomimetic macrocycle comprises a crosslink connecting at least two amino acid residues, or a pharmaceutically-acceptable salt thereof.

In some embodiments, the invention provides a peptidomimetic macrocycle that comprises an amino acid sequence that has at least 60% identity to any one of SEQ ID NOs.: 1-1625.

INCORPORATION BY REFERENCE

All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference in their entirety for all purposes, to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates cell viability over time after treatment with a peptidomimetic macrocycle.

FIG. 2 illustrates cell viability over time after treatment with a peptidomimetic macrocycle.

FIG. 3 illustrates cell viability over time after treatment with a peptidomimetic macrocycle.

FIG. 4 illustrates cell viability over time after treatment with a peptidomimetic macrocycle.

FIG. 5 illustrates normalized fluorescence resonance energy transfer (FRET) signal after treatment with vehicle, a peptidomimetic macrocycle, or a BH3 mimetic.

FIG. 6 illustrates concentration of a peptidomimetic macrocycle in tissue over time after treatment.

FIG. 7 illustrates percentage remaining of a peptidomimetic macrocycle in plasma over time after treatment.

DETAILED DESCRIPTION OF THE INVENTION

The terminology used herein is for the purpose of describing particular cases only and is not intended to be limiting. As used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. Furthermore, to the extent that the terms “including”, “includes”, “having”, “has”, “with”, or variants thereof are used in either the detailed description or the claims, such terms are intended to be inclusive in a manner similar to the term “comprising”.

The term “about” or “approximately” can mean within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, “about” can mean within 1 or more than 1 standard deviation, per the practice in the art. Alternatively, “about” can mean a range of up to 20%, up to 10%, up to 5%, or up to 1% of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude, within 5-fold, and more preferably within 2-fold, of a value. Where particular values are described in the application and claims, unless otherwise stated the term “about” meaning within an acceptable error range for the particular value should be assumed. The term “about” has the meaning as commonly understood by one of ordinary skill in the art. In some embodiments, the term “about” refers to ±10%. In some embodiments, the term “about” refers to ±5%.

As used herein, the term “macrocycle” refers to a molecule having a chemical structure including a ring or cycle formed by at least 9 covalently bonded atoms.

As used herein, the term “peptidomimetic macrocycle” or “crosslinked polypeptide” refers to a compound comprising a plurality of amino acid residues joined by a plurality of peptide bonds and at least one macrocycle-forming linker which forms a macrocycle between a first naturally-occurring or non-naturally-occurring amino acid residue (or analog) and a second naturally-occurring or non-naturally-occurring amino acid residue (or analog) within the same molecule. Peptidomimetic macrocycles include embodiments where the macrocycle-forming linker connects the α carbon of the first amino acid residue (or analog) to the α carbon of the second amino acid residue (or analog). The peptidomimetic macrocycles optionally include one or more non-peptide bonds between one or more amino acid residues or amino acid analog residues, and optionally include one or more non-naturally-occurring amino acid residues or amino acid analog residues in addition to any which form the macrocycle. A “corresponding uncrosslinked polypeptide” when referred to in the context of a peptidomimetic macrocycle is understood to relate to a polypeptide of the same length as the macrocycle and comprising the equivalent natural amino acids of the wild-type sequence corresponding to the macrocycle.

As used herein, the term “stability” refers to the maintenance of a defined secondary structure in solution by a peptidomimetic macrocycle of the invention as measured by circular dichroism, NMR or another biophysical measure, or resistance to proteolytic degradation in vitro or in vivo. Non-limiting examples of secondary structures contemplated in this invention are α-helices, 3₁₀ helices, β-turns, and β-pleated sheets.

As used herein, the term “helical stability” refers to the maintenance of a helical structure by a peptidomimetic macrocycle of the invention as measured by circular dichroism or NMR. For example, in some embodiments, the peptidomimetic macrocycles of the invention exhibit at least a 1.25, 1.5, 1.75 or 2-fold increase in α-helicity as determined by circular dichroism compared to a corresponding uncrosslinked macrocycle.

The term “amino acid” refers to a molecule containing both an amino group and a carboxyl group. Suitable amino acids include, without limitation, both the D-and L-isomers of the naturally-occurring amino acids, as well as non-naturally occurring amino acids prepared by organic synthesis or other metabolic routes. The term amino acid, as used herein, includes without limitation, α-amino acids, natural amino acids, non-natural amino acids, and amino acid analogs.

The term “α-amino acid” refers to a molecule containing both an amino group and a carboxyl group bound to a carbon which is designated the α-carbon.

The term “β-amino acid” refers to a molecule containing both an amino group and a carboxyl group in a βconfiguration. The abbreviation “b-” prior to an amino acid represent a beta configuration for the amino acid.

The term “naturally occurring amino acid” refers to any one of the twenty amino acids commonly found in peptides synthesized in nature, and known by the one letter abbreviations A, R, N, C, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y and V.

The following Table shows a summary of the properties of natural amino acids:

Side- 3- 1- Side- chain Letter Letter chain charge Hydropathy Amino Acid Code Code Polarity (pH 7.4) Index Alanine Ala A nonpolar neutral 1.8 Arginine Arg R polar positive −4.5 Asparagine Asn N polar neutral −3.5 Aspartic acid Asp D polar negative −3.5 Cysteine Cys C polar neutral 2.5 Glutamic acid Glu E polar negative −3.5 Glutamine Gln Q polar neutral −3.5 Glycine Gly G nonpolar neutral −0.4 Histidine His H polar positive(10%) −3.2 neutral(90%) Isoleucine Ile I nonpolar neutral 4.5 Leucine Leu L nonpolar neutral 3.8 Lysine Lys K polar positive −3.9 Methionine Met M nonpolar neutral 1.9 Phenylalanine Phe F nonpolar neutral 2.8 Proline Pro P nonpolar neutral −1.6 Serine Ser S polar neutral −0.8 Threonine Thr T polar neutral −0.7 Tryptophan Trp W nonpolar neutral −0.9 Tyrosine Tyr Y polar neutral −1.3 Valine Val V nonpolar neutral 4.2

“Hydrophobic amino acids” include small hydrophobic amino acids and large hydrophobic amino acids. “Small hydrophobic amino acids” are glycine, alanine, proline, and analogs thereof. “Large hydrophobic amino acids” are valine, leucine, isoleucine, phenylalanine, methionine, tryptophan, tyrosine, and analogs thereof. “Polar amino acids” are serine, threonine, asparagine, glutamine, cysteine, and analogs thereof. “Charged amino acids” include positively charged amino acids and negatively charged amino acids. “Positively charged amino acids” include lysine, arginine, histidine, and analogs thereof. “Negatively charged amino acids” include aspartate, glutamate, and analogs thereof.

The term “amino acid analog” refers to a molecule which is structurally similar to an amino acid and which can be substituted for an amino acid in the formation of a peptidomimetic macrocycle. Amino acid analogs include, without limitation, β-amino acids and amino acids where the amino or carboxy group is substituted by a similarly reactive group (e.g., substitution of the primary amine with a secondary or tertiary amine, or substitution of the carboxy group with an ester).

The term “non-natural amino acid” refers to an amino acid which is not one of the the twenty amino acids commonly found in peptides synthesized in nature, and known by the one letter abbreviations A, R, N, C, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y and V. Non-natural amino acids or amino acid analogs include, without limitation, structures according to the following:

Amino acid analogs include β-amino acid analogs. Examples of β-amino acid analogs include, but are not limited to, the following: cyclic β-amino acid analogs; β-alanine; (R)-β-phenylalanine; (R)-1,2,3,4-tetrahydro-isoquinoline-3-acetic acid; (R)-3-amino-4-(1-naphthyl)-butyric acid; (R)-3-amino-4-(2,4-dichlorophenyl)butyric acid; (R)-3-amino-4-(2-chlorophenyl)-butyric acid; (R)-3-amino-4-(2-cyanophenyl)-butyric acid; (R)-3-amino-4-(2-fluorophenyl)-butyric acid; (R)-3-amino-4-(2-furyl)-butyric acid; (R)-3-amino-4-(2-methylphenyl)-butyric acid; (R)-3-amino-4-(2-naphthyl)-butyric acid; (R)-3-amino-4-(2-thienyl)-butyric acid; (R)-3-amino-4-(2-trifluoromethylphenyl)-butyric acid; (R)-3-amino-4-(3,4-dichlorophenyl)butyric acid; (R)-3-amino-4-(3,4-difluorophenyl)butyric acid; (R)-3-amino-4-(3-benzothienyl)-butyric acid; (R)-3-amino-4-(3-chlorophenyl)-butyric acid; (R)-3-amino-4-(3-cyanophenyl)-butyric acid; (R)-3-amino-4-(3-fluorophenyl)-butyric acid; (R)-3-amino-4-(3-methylphenyl)-butyric acid; (R)-3-amino-4-(3-pyridyl)-butyric acid; (R)-3-amino-4-(3-thienyl)-butyric acid; (R)-3-amino-4-(3-trifluoromethylphenyl)-butyric acid; (R)-3-amino-4-(4-bromophenyl)-butyric acid; (R)-3-amino-4-(4-chlorophenyl)-butyric acid; (R)-3-amino-4-(4-cyanophenyl)-butyric acid; (R)-3-amino-4-(4-fluorophenyl)-butyric acid; (R)-3-amino-4-(4-iodophenyl)-butyric acid; (R)-3-amino-4-(4-methylphenyl)-butyric acid; (R)-3-amino-4-(4-nitrophenyl)-butyric acid; (R)-3-amino-4-(4-pyridyl)-butyric acid; (R)-3-amino-4-(4-trifluoromethylphenyl)-butyric acid; (R)-3-amino-4-pentafluoro-phenylbutyric acid; (R)-3-amino-5-hexenoic acid; (R)-3-amino-5-hexynoic acid; (R)-3-amino-5-phenylpentanoic acid; (R)-3-amino-6-phenyl-5-hexenoic acid; (S)-1,2,3,4-tetrahydro-isoquinoline-3-acetic acid; (S)-3-amino-4-(1-naphthyl)-butyric acid; (S)-3-amino-4-(2,4-dichlorophenyl)butyric acid; (S)-3-amino-4-(2-chlorophenyl)-butyric acid; (S)-3-amino-4-(2-cyanophenyl)-butyric acid; (S)-3-amino-4-(2-fluorophenyl)-butyric acid; (S)-3-amino-4-(2-furyl)-butyric acid; (S)-3-amino-4-(2-methylphenyl)-butyric acid; (S)-3-amino-4-(2-naphthyl)-butyric acid; (S)-3-amino-4-(2-thienyl)-butyric acid; (S)-3-amino-4-(2-trifluoromethylphenyl)-butyric acid; (S)-3-amino-4-(3,4-dichlorophenyl)butyric acid; (S)-3-amino-4-(3,4-difluorophenyl)butyric acid; (S)-3-amino-4-(3-benzothienyl)-butyric acid; (S)-3-amino-4-(3-chlorophenyl)-butyric acid; (S)-3-amino-4-(3-cyanophenyl)-butyric acid; (S)-3-amino-4-(3-fluorophenyl)-butyric acid; (S)-3-amino-4-(3-methylphenyl)-butyric acid; (S)-3-amino-4-(3-pyridyl)-butyric acid; (S)-3-amino-4-(3-thienyl)-butyric acid; (S)-3-amino-4-(3-trifluoromethylphenyl)-butyric acid; (S)-3-amino-4-(4-bromophenyl)-butyric acid; (S)-3-amino-4-(4-chlorophenyl)-butyric acid; (S)-3-amino-4-(4-cyanophenyl)-butyric acid; (S)-3-amino-4-(4-fluorophenyl)-butyric acid; (S)-3-amino-4-(4-iodophenyl)-butyric acid; (S)-3-amino-4-(4-methylphenyl)-butyric acid; (S)-3-amino-4-(4-nitrophenyl)-butyric acid; (S)-3-amino-4-(4-pyridyl)-butyric acid; (S)-3-amino-4-(4-trifluoromethylphenyl)-butyric acid; (S)-3-amino-4-pentafluoro-phenylbutyric acid; (S)-3-amino-5-hexenoic acid; (S)-3-amino-5-hexynoic acid; (S)-3-amino-5-phenylpentanoic acid; (S)-3-amino-6-phenyl-5-hexenoic acid; 1,2,5,6-tetrahydropyridine-3-carboxylic acid; 1,2,5,6-tetrahydropyridine-4-carboxylic acid; 3-amino-3-(2-chlorophenyl)-propionic acid; 3-amino-3-(2-thienyl)-propionic acid; 3-amino-3-(3-bromophenyl)-propionic acid; 3-amino-3-(4-chlorophenyl)-propionic acid; 3-amino-3-(4-methoxyphenyl)-propionic acid; 3-amino-4,4,4-trifluoro-butyric acid; 3-aminoadipic acid; D-β-phenylalanine; β-leucine; L-β-homoalanine; L-β-homoaspartic acid γ-benzyl ester; L-β-homoglutamic acid δ-benzyl ester; L-β-homoisoleucine; L-β-homoleucine; L-β-homomethionine; L-β-homophenylalanine; L-β-homoproline; L-β-homotryptophan; L-β-homovaline; L-Nω-benzyloxycarbonyl-βhomolysine; Nω-L-β-homoarginine; O-benzyl-L-β-homohydroxyproline; O-benzyl-L-β-homoserine; O-benzyl-L-β-homothreonine; O-benzyl-L-β-homotyrosine; γ-trityl-L-β-homoasparagine; (R)-β-phenylalanine; L-β-homoaspartic acid γ-t-butyl ester; L-β-homoglutamic acid δ-t-butyl ester; L-Nω-β-homolysine; Nδ-trityl-L-β-homoglutamine; Nω-2,2,4,6,7-pentamethyl -dihydrobenzofuran-5-sulfonyl-L-β-homoarginine; O-t-butyl-L-β-homohydroxy-proline; O-t-butyl-L-β-homoserine; O-t-butyl-L-β-homothreonine; O-t-butyl-L-β-homotyrosine; 2-aminocyclopentane carboxylic acid; and 2-aminocyclohexane carboxylic acid.

Amino acid analogs include analogs of alanine, valine, glycine or leucine. Examples of amino acid analogs of alanine, valine, glycine, and leucine include, but are not limited to, the following: α-methoxyglycine; α-allyl-L-alanine; α-aminoisobutyric acid; α-methyl-leucine; β-(1-naphthyl)-D-alanine; β-(1-naphthyl)-L-alanine; β-(2-naphthyl)-D-alanine; β-(2-naphthyl)-L-alanine; β-(2-pyridyl)-D-alanine; β-(2-pyridyl)-L-alanine; β-(2-thienyl)-D-alanine; β-(2-thienyl)-L-alanine; β-(3-benzothienyl)-D-alanine; β-(3-benzothienyl)-L-alanine; β-(3-pyridyl)-D-alanine; β-(3-pyridyl)-L-alanine; β-(4-pyridyl)-D-alanine; β-(4-pyridyl)-L-alanine; β-chloro-L-alanine; β-cyano-L-alanin; β-cyclohexyl-D-alanine; β-cyclohexyl-L-alanine; β-cyclopenten-1-yl-alanine; β-cyclopentyl-alanine; β-cyclopropyl-L-Ala-OH•dicyclohexylammonium salt; β-t-butyl-D-alanine; β-t-butyl-L-alanine; γ-aminobutyric acid; L-α,β-diaminopropionic acid; 2,4-dinitro-phenylglycine; 2,5-dihydro-D-phenylglycine; 2-amino-4,4,4-trifluorobutyric acid; 2-fluoro-phenylglycine; 3-amino-4,4,4-trifluoro -butyric acid; 3-fluoro-valine; 4,4,4-trifluoro-valine; 4,5-dehydro-L-leu-OH•dicyclohexylammonium salt; 4-fluoro-D-phenylglycine; 4-fluoro-L-phenylglycine; 4-hydroxy-D-phenylglycine; 5,5,5-trifluoro-leucine; 6-aminohexanoic acid; cyclopentyl-D-Gly-OH•dicyclohexylammonium salt; cyclopentyl-Gly-OH•dicyclohexylammonium salt; D-α,β-diaminopropionic acid; D-α-aminobutyric acid; D-α-t-butylglycine; D-(2-thienyl)glycine; D-(3-thienyl)glycine; D-2-aminocaproic acid; D-2-indanylglycine; D-allylglycine•dicyclohexylammonium salt; D-cyclohexylglycine; D-norvaline; D-phenylglycine; β-aminobutyric acid; β-aminoisobutyric acid; (2-bromophenyl)glycine; (2-methoxyphenyl)glycine; (2-methylphenyl)glycine; (2-thiazoyl)glycine; (2-thienyl)glycine; 2-amino-3-(dimethylamino)-propionic acid; L-α,β-diaminopropionic acid; L-α-aminobutyric acid; L-α-t-butylglycine; L-(3-thienyl)glycine; L-2-amino-3-(dimethylamino)-propionic acid; L-2-aminocaproic acid dicyclohexyl-ammonium salt; L-2-indanylglycine; L-allylglycine•dicyclohexyl ammonium salt; L-cyclohexylglycine; L-phenylglycine; L-propargylglycine; L-norvaline; N-α-aminomethyl-L-alanine; D-α,γ-diaminobutyric acid; L-α,γ-diaminobutyric acid; β-cyclopropyl-L-alanine; (N-β-(2,4-dinitrophenyl))-L-α,β-diaminopropionic acid; (N-β-1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl)-D-α,β-diaminopropionic acid; (N-β-1-(4,4-dimethyl -2,6-dioxocyclohex-1-ylidene)ethyl)-L-α,β-diaminopropionic acid; (N-β-4-methyltrityl)-L-α,β-diaminopropionic acid; (N-β-allyloxycarbonyl)-L-α,β-diaminopropionic acid; (N-γ-1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl)-D-α,γ-diaminobutyric acid; (N-γ-1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl)-L-α,γ-diaminobutyric acid; (N-γ-4-methyltrityl)-D-α,γ-diaminobutyric acid; (N-γ-4-methyltrityl)-L-α,γ-diaminobutyric acid; (N-γ-allyloxycarbonyl)-L-α,γ-diaminobutyric acid; D-α,γ-diaminobutyric acid; 4,5-dehydro-L-leucine; cyclopentyl-D-Gly-OH; cyclopentyl-Gly-OH; D-allylglycine; D-homocyclohexylalanine; L-1-pyrenylalanine; L-2-aminocaproic acid; L-allylglycine; L-homocyclohexylalanine; and N-(2-hydroxy-4-methoxy-Bzl)-Gly-OH.

Amino acid analogs include analogs of arginine or lysine. Examples of amino acid analogs of arginine and lysine include, but are not limited to, the following: citrulline; L-2-amino-3-guanidinopropionic acid; L-2-amino-3-ureidopropionic acid; L-citrulline; Lys(Me)₂-OH; Lys(N₃)—OH; Nδ-benzyloxycarbonyl-L-ornithine; Nω-nitro-D-arginine; Nω-nitro-L-arginine; α-methyl-ornithine; 2,6-diaminoheptanedioic acid; L-ornithine; (Nδ-1-(4,4-dimethyl-2,6-dioxo-cyclohex-1-ylidene)ethyl)-D-ornithine; (Nδ-1-(4,4-dimethyl-2,6-dioxo-cyclohex-1-ylidene)ethyl)-L-ornithine; (Nδ-4-methyltrityl)-D-ornithine; (Nδ-4-methyltrityl)-L-ornithine; D-ornithine; L-ornithine; Arg(Me)(Pbf)-OH; Arg(Me)₂-OH (asymmetrical); Arg(Me)2-OH (symmetrical); Lys(ivDde)-OH; Lys(Me)2-OH•HCl; Lys(Me3)-OH chloride; Nω-nitro-D-arginine; and Nω-nitro-L-arginine.

Amino acid analogs include analogs of aspartic or glutamic acids. Examples of amino acid analogs of aspartic and glutamic acids include, but are not limited to, the following: α-methyl-D-aspartic acid; α-methyl-glutamic acid; α-methyl-L-aspartic acid; γ-methylene-glutamic acid; (N-γ-ethyl)-L-glutamine; [N-α-(4-aminobenzoyl)]-L-glutamic acid; 2,6-diaminopimelic acid; L-α-aminosuberic acid; D-2-aminoadipic acid; D-α-aminosuberic acid; α-aminopimelic acid; iminodiacetic acid; L-2-amino adipic acid; threo-β-methyl-aspartic acid; γ-carboxy-D-glutamic acid γ,γ-di-t-butyl ester; γ-carboxy-L-glutamic acid γ,γ-di-t-butyl ester; Glu(OAll)-OH; L-Asu(OtBu)-OH; and pyroglutamic acid.

Amino acid analogs include analogs of cysteine and methionine. Examples of amino acid analogs of cysteine and methionine include, but are not limited to, Cys(farnesyl)-OH, Cys(farnesyl)-OMe, α-methyl-methionine, Cys(2-hydroxyethyl)-OH, Cys(3-aminopropyl)-OH, 2-amino-4-(ethylthio)butyric acid, buthionine, buthioninesulfoximine, ethionine, methionine methylsulfonium chloride, selenomethionine, cysteic acid, [2-(4-pyridyl)ethyl]-DL-penicillamine, [2-(4-pyridyl)ethyl]-L-cysteine, 4-methoxybenzyl-D-penicillamine, 4-methoxybenzyl-L-penicillamine, 4-methylbenzyl-D-penicillamine, 4-methylbenzyl-L-penicillamine, benzyl-D-cysteine, benzyl-L-cysteine, benzyl-DL-homocysteine, carbamoyl-L-cysteine, carboxyethyl-L-cysteine, carboxymethyl-L-cysteine, diphenylmethyl-L-cysteine, ethyl-L-cysteine, methyl-L-cysteine, t-butyl-D-cysteine, trityl-L-homocysteine, trityl-D-penicillamine, cystathionine, homocystine, L-homocystine, (2-aminoethyl)-L-cysteine, seleno-L-cystine, cystathionine, Cys(StBu)-OH, and acetamidomethyl-D-penicillamine.

Amino acid analogs include analogs of phenylalanine and tyrosine. Examples of amino acid analogs of phenylalanine and tyrosine include β-methyl-phenylalanine, β-hydroxyphenylalanine, α-methyl-3-methoxy-DL-phenylalanine, α-methyl-D-phenylalanine, α-methyl-L-phenylalanine, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, 2,4-dichloro-phenylalanine, 2-(trifluoromethyl)-D-phenylalanine, 2-(trifluoromethyl)-L-phenylalanine, 2-bromo-D-phenylalanine, 2-bromo-L-phenylalanine, 2-chloro-D-phenylalanine, 2-chloro-L-phenylalanine, 2-cyano-D-phenylalanine, 2-cyano-L-phenylalanine, 2-fluoro-D-phenylalanine, 2-fluoro-L-phenylalanine, 2-methyl-D-phenylalanine, 2-methyl-L-phenylalanine, 2-nitro-D-phenylalanine, 2-nitro-L-phenylalanine, 2;4;5-trihydroxy-phenylalanine, 3,4,5-trifluoro-D-phenylalanine, 3,4,5-trifluoro-L-phenylalanine, 3,4-dichloro-D-phenylalanine, 3,4-dichloro-L-phenylalanine, 3,4-difluoro-D-phenylalanine, 3,4-difluoro-L-phenylalanine, 3,4-dihydroxy-L-phenylalanine, 3,4-dimethoxy-L-phenylalanine, 3,5,3′-triiodo-L-thyronine, 3,5-diiodo-D-tyrosine, 3,5-diiodo-L-tyrosine, 3,5-diiodo-L-thyronine, 3-(trifluoromethyl)-D-phenylalanine, 3-(trifluoromethyl)-L-phenylalanine, 3-amino-L-tyrosine, 3-bromo-D-phenylalanine, 3-bromo-L-phenylalanine, 3-chloro-D-phenylalanine, 3-chloro-L-phenylalanine, 3-chloro-L-tyrosine, 3-cyano-D-phenylalanine, 3-cyano-L-phenylalanine, 3-fluoro-D-phenylalanine, 3-fluoro-L-phenylalanine, 3-fluoro-tyrosine, 3-iodo-D-phenylalanine, 3-iodo-L-phenylalanine, 3-iodo-L-tyrosine, 3-methoxy-L-tyrosine, 3-methyl-D-phenylalanine, 3-methyl-L-phenylalanine, 3-nitro-D-phenylalanine, 3-nitro-L-phenylalanine, 3-nitro-L-tyrosine, 4-(trifluoromethyl)-D-phenylalanine, 4-(trifluoromethyl)-L-phenylalanine, 4-amino-D-phenylalanine, 4-amino-L-phenylalanine, 4-benzoyl-D-phenylalanine, 4-benzoyl-L-phenylalanine, 4-bis(2-chloroethyl)amino-L-phenylalanine, 4-bromo-D-phenylalanine, 4-bromo-L-phenylalanine, 4-chloro-D-phenylalanine, 4-chloro-L-phenylalanine, 4-cyano-D-phenylalanine, 4-cyano-L-phenylalanine, 4-fluoro-D-phenylalanine, 4-fluoro-L-phenylalanine, 4-iodo-D-phenylalanine, 4-iodo-L-phenylalanine, homophenylalanine, thyroxine, 3,3-diphenylalanine, thyronine, ethyl-tyrosine, and methyl-tyrosine.

Amino acid analogs include analogs of proline. Examples of amino acid analogs of proline include, but are not limited to, 3,4-dehydro-proline, 4-fluoro-proline, cis-4-hydroxy-proline, thiazolidine-2-carboxylic acid, and trans-4-fluoro-proline.

Amino acid analogs include analogs of serine and threonine. Examples of amino acid analogs of serine and threonine include, but are not limited to, 3-amino-2-hydroxy-5-methylhexanoic acid, 2-amino-3-hydroxy-4-methylpentanoic acid, 2-amino-3-ethoxybutanoic acid, 2-amino-3-methoxybutanoic acid, 4-amino-3-hydroxy-6-methylheptanoic acid, 2-amino-3-benzyloxypropionic acid, 2-amino-3-benzyloxypropionic acid, 2-amino-3-ethoxypropionic acid, 4-amino-3-hydroxybutanoic acid, and α-methylserine.

Amino acid analogs include analogs of tryptophan. Examples of amino acid analogs of tryptophan include, but are not limited to, the following: α-methyl-tryptophan; β-(3-benzothienyl)-D-alanine; β-(3-benzothienyl)-L-alanine; 1-methyl-tryptophan; 4-methyl-tryptophan; 5-benzyloxy-tryptophan; 5-bromo-tryptophan; 5-chloro-tryptophan; 5-fluoro-tryptophan; 5-hydroxy-tryptophan; 5-hydroxy-L-tryptophan; 5-methoxy-tryptophan; 5-methoxy-L-tryptophan; 5-methyl-tryptophan; 6-bromo-tryptophan; 6-chloro-D-tryptophan; 6-chloro-tryptophan; 6-fluoro-tryptophan; 6-methyl-tryptophan; 7-benzyloxy-tryptophan; 7-bromo-tryptophan; 7-methyl-tryptophan; D-1,2,3,4-tetrahydro-norharman-3-carboxylic acid; 6-methoxy-1,2,3,4-tetrahydronorharman-1-carboxylic acid; 7-azatryptophan; L-1,2,3,4-tetrahydro-norharman-3-carboxylic acid; 5-methoxy-2-methyl-tryptophan; and 6-chloro-L-tryptophan.

In some embodiments, amino acid analogs are racemic. In some embodiments, the D isomer of the amino acid analog is used. In some embodiments, the L isomer of the amino acid analog is used. In other embodiments, the amino acid analog comprises chiral centers that are in the R or S configuration. In still other embodiments, the amino group(s) of a β-amino acid analog is substituted with a protecting group, e.g., tert-butyloxycarbonyl (BOC group), 9-fluorenylmethyloxycarbonyl (FMOC), tosyl, and the like. In yet other embodiments, the carboxylic acid functional group of a β-amino acid analog is protected, e.g., as its ester derivative. In some embodiments the salt of the amino acid analog is used.

A “non-essential” amino acid residue is a residue that can be altered from the wild-type sequence of a polypeptide without abolishing or substantially abolishing its essential biological or biochemical activity (e.g., receptor binding or activation). An “essential” amino acid residue is a residue that, when altered from the wild-type sequence of the polypeptide, results in abolishing or substantially abolishing the polypeptide's essential biological or biochemical activity.

A “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., K, R, H), acidic side chains (e.g., D, E), uncharged polar side chains (e.g., G, N, Q, S, T, Y, C), nonpolar side chains (e.g., A, V, L, I, P, F, M, W), beta-branched side chains (e.g., T, V, I) and aromatic side chains (e.g., Y, F, W, H). Thus, a predicted nonessential amino acid residue in a polypeptide, for example, is replaced with another amino acid residue from the same side chain family. Other examples of acceptable substitutions are substitutions based on isosteric considerations (e.g. norleucine for methionine) or other properties (e.g. 2-thienylalanine for phenylalanine).

The term “capping group” refers to the chemical moiety occurring at either the carboxy or amino terminus of the polypeptide chain of the subject peptidomimetic macrocycle. The capping group of a carboxy terminus includes an unmodified carboxylic acid (ie —COOH) or a carboxylic acid with a substituent. For example, the carboxy terminus can be substituted with an amino group to yield a carboxamide at the C-terminus. Various substituents include but are not limited to primary and secondary amines, including pegylated secondary amines. Non-limiting representative secondary amine capping groups for the C-terminus include:

The capping group of an amino terminus includes an unmodified amine (ie —NH₂) or an amine with a substituent. For example, the amino terminus can be substituted with an acyl group to yield a carboxamide at the N-terminus. Various substituents include but are not limited to substituted acyl groups, including C₁-C₆ carbonyls, C₇-C₃₀ carbonyls, and pegylated carbamates. Non-limiting representative capping groups for the N-terminus include:

The term “member” as used herein in conjunction with macrocycles or macrocycle-forming linkers refers to the atoms that form or can form the macrocycle, and excludes substituent or side chain atoms. By analogy, cyclodecane, 1,2-difluoro-decane and 1,3-dimethyl cyclodecane are all considered ten-membered macrocycles as the hydrogen or fluoro substituents or methyl side chains do not participate in forming the macrocycle.

The symbol “

” when used as part of a molecular structure refers to a single bond or a trans or cis double bond.

The term “amino acid side chain” refers to a moiety attached to the α-carbon (or another backbone atom) in an amino acid. For example, the amino acid side chain for alanine is methyl, the amino acid side chain for phenylalanine is phenylmethyl, the amino acid side chain for cysteine is thiomethyl, the amino acid side chain for aspartate is carboxymethyl, the amino acid side chain for tyrosine is 4-hydroxyphenylmethyl, etc. Other non-naturally occurring amino acid side chains are also included, for example, those that occur in nature (e.g., an amino acid metabolite) or those that are made synthetically (e.g., an α,α di-substituted amino acid).

The term “α,α di-substituted amino” acid refers to a molecule or moiety containing both an amino group and a carboxyl group bound to a carbon (the α-carbon) that is attached to two natural or non-natural amino acid side chains.

The term “polypeptide” encompasses two or more naturally or non-naturally-occurring amino acids joined by a covalent bond (e.g., an amide bond). Polypeptides as described herein include full length proteins (e.g., fully processed proteins) as well as shorter amino acid sequences (e.g., fragments of naturally-occurring proteins or synthetic polypeptide fragments).

The term “macrocyclization reagent” or “macrocycle-forming reagent” as used herein refers to any reagent which may be used to prepare a peptidomimetic macrocycle of the invention by mediating the reaction between two reactive groups. Reactive groups may be, for example, an azide and alkyne, in which case macrocyclization reagents include, without limitation, Cu reagents such as reagents which provide a reactive Cu(I) species, such as CuBr, CuI or CuOTf, as well as Cu(II) salts such as Cu(CO₂CH₃)₂, CuSO₄, and CuCl₂ that can be converted in situ to an active Cu(I) reagent by the addition of a reducing agent such as ascorbic acid or sodium ascorbate. Macrocyclization reagents may additionally include, for example, Ru reagents known in the art such as Cp*RuCl(PPh₃)₂, [Cp*RuCl]₄ or other Ru reagents which may provide a reactive Ru(II) species. In other cases, the reactive groups are terminal olefins. In such embodiments, the macrocyclization reagents or macrocycle-forming reagents are metathesis catalysts including, but not limited to, stabilized, late transition metal carbene complex catalysts such as Group VIII transition metal carbene catalysts. For example, such catalysts are Ru and Os metal centers having a +2 oxidation state, an electron count of 16 and pentacoordinated. In other examples, catalysts have W or Mo centers. Various catalysts are disclosed in Grubbs et al., “Ring Closing Metathesis and Related Processes in Organic Synthesis” Acc. Chem. Res. 1995, 28, 446-452, and U.S. Pat. No. 5,811,515; U.S. Pat. No. 7,932,397; U.S. Application No. 2011/0065915; U.S. Application No. 2011/0245477; Yu et al., “Synthesis of Macrocyclic Natural Products by Catalyst-Controlled Stereoselective Ring-Closing Metathesis,” Nature 2011, 479, 88; and Peryshkov et al., “Z-Selective Olefin Metathesis Reactions Promoted by Tungsten Oxo Alkylidene Complexes,” J. Am. Chem. Soc. 2011, 133, 20754. In yet other cases, the reactive groups are thiol groups. In such embodiments, the macrocyclization reagent is, for example, a linker functionalized with two thiol-reactive groups such as halogen groups.

The term “halo” or “halogen” refers to fluorine, chlorine, bromine or iodine or a radical thereof.

The term “alkyl” refers to a hydrocarbon chain that is a straight chain or branched chain, containing the indicated number of carbon atoms. For example, C₁-C₁₀ indicates that the group has from 1 to 10 (inclusive) carbon atoms in it. In the absence of any numerical designation, “alkyl” is a chain (straight or branched) having 1 to 20 (inclusive) carbon atoms in it.

The term “alkylene” refers to a divalent alkyl (i.e., —R—).

The term “alkenyl” refers to a hydrocarbon chain that is a straight chain or branched chain having one or more carbon-carbon double bonds. The alkenyl moiety contains the indicated number of carbon atoms. For example, C₂-C₁₀ indicates that the group has from 2 to 10 (inclusive) carbon atoms in it. The term “lower alkenyl” refers to a C₂-C₆ alkenyl chain. In the absence of any numerical designation, “alkenyl” is a chain (straight or branched) having 2 to 20 (inclusive) carbon atoms in it.

The term “alkynyl” refers to a hydrocarbon chain that is a straight chain or branched chain having one or more carbon-carbon triple bonds. The alkynyl moiety contains the indicated number of carbon atoms. For example, C₂-C₁₀ indicates that the group has from 2 to 10 (inclusive) carbon atoms in it. The term “lower alkynyl” refers to a C₂-C₆ alkynyl chain. In the absence of any numerical designation, “alkynyl” is a chain (straight or branched) having 2 to 20 (inclusive) carbon atoms in it.

The term “aryl” refers to a monocyclic or bicyclic aromatic ring system wherein 0, 1, 2, 3, or 4 atoms of each ring are substituted by a substituent. Examples of aryl groups include phenyl, biphenyl, naphthyl and the like. The term “arylalkoxy” refers to an alkoxy substituted with aryl.

“Arylalkyl” refers to an aryl group, as defined above, wherein one of the aryl group's hydrogen atoms has been replaced with a C₁-C₅ alkyl group, as defined above. Representative examples of an arylalkyl group include, but are not limited to, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2-ethylphenyl, 3-ethylphenyl, 4-ethylphenyl, 2-propylphenyl, 3-propylphenyl, 4-propylphenyl, 2-butylphenyl, 3-butylphenyl, 4-butylphenyl, 2-pentylphenyl, 3-pentylphenyl, 4-pentylphenyl, 2-isopropylphenyl, 3-isopropylphenyl, 4-isopropylphenyl, 2-isobutylphenyl, 3-isobutylphenyl, 4-isobutylphenyl, 2-sec-butylphenyl, 3-sec-butylphenyl, 4-sec-butylphenyl, 2-t-butylphenyl, 3-t-butylphenyl and 4-t-butylphenyl.

“Arylamido” refers to an aryl group, as defined above, wherein one of the aryl group's hydrogen atoms has been replaced with one or more —C(O)NH₂ groups. Representative examples of an arylamido group include 2-C(O)NH2-phenyl, 3-C(O)NH₂-phenyl, 4-C(O)NH₂-phenyl, 2-C(O)NH₂-pyridyl, 3-C(O)NH₂-pyridyl, and 4-C(O)NH₂-pyridyl,

“Alkylheterocycle” refers to a C₁-C₅ alkyl group, as defined above, wherein one of the C₁-C₅ alkyl group's hydrogen atoms has been replaced with a heterocycle. Representative examples of an alkylheterocycle group include, but are not limited to, —CH₂CH₂-morpholine, —CH₂CH₂-piperidine, —CH₂CH₂CH₂-morpholine, and —CH₂CH₂CH₂-imidazole.

“Alkylamido” refers to a C₁-C₅ alkyl group, as defined above, wherein one of the C₁-C₅ alkyl group's hydrogen atoms has been replaced with a —C(O)NH₂ group. Representative examples of an alkylamido group include, but are not limited to, —CH₂—C(O)NH₂, —CH₂CH₂—C(O)NH₂, —CH₂CH₂CH₂C(O)NH₂, —CH₂CH₂CH₂CH₂C(O)NH₂, —CH₂CH₂CH₂CH₂CH₂C(O)NH₂, —CH₂CH(C(O)NH₂)CH₃, —CH₂CH(C(O)NH₂)CH₂CH₃, —CH(C(O)NH₂)CH₂CH₃, —C(CH₃)₂CH₂C(O)NH₂, —CH₂—CH₂—NH—C(O)—CH₃, —CH₂—CH₂—NH—C(O)—CH₃—CH3, and —CH₂—CH₂—NH—C(O)—CH═CH₂.

“Alkanol” refers to a C₁-C₅ alkyl group, as defined above, wherein one of the C₁-C₅ alkyl group's hydrogen atoms has been replaced with a hydroxyl group. Representative examples of an alkanol group include, but are not limited to, —CH₂OH, —CH₂CH₂OH, —CH₂CH₂CH₂OH, —CH₂CH₂CH₂CH₂OH, —CH₂CH₂CH₂ CH₂CH₂OH, —CH₂CH(OH)CH₃, —CH₂CH(OH)CH₂CH₃, —CH(OH)CH₃ and —C(CH₃)₂CH₂OH.

“Alkylcarboxy” refers to a C₁-C₅ alkyl group, as defined above, wherein one of the C₁-C₅ alkyl group's hydrogen atoms has been replaced with a —COOH group. Representative examples of an alkylcarboxy group include, but are not limited to, —CH₂COOH, —CH₂CH₂COOH, —CH₂CH₂CH₂COOH, —CH₂CH₂CH₂CH₂COOH, —CH₂CH(COOH)CH₃, —CH₂CH₂CH₂CH₂CH₂COOH, —CH₂CH(COOH)CH₂CH₃, —CH(COOH)CH₂CH₃ and —C(CH₃)₂CH₂COOH.

The term “cycloalkyl” as employed herein includes saturated and partially unsaturated cyclic hydrocarbon groups having 3 to 12 carbons, preferably 3 to 8 carbons, and more preferably 3 to 6 carbons, wherein the cycloalkyl group additionally is optionally substituted. Some cycloalkyl groups include, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl.

The term “heteroaryl” refers to an aromatic 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S (e.g., carbon atoms and 1-3, 1-6, or 1-9 heteroatoms of O, N, or S if monocyclic, bicyclic, or tricyclic, respectively), wherein 0, 1, 2, 3, or 4 atoms of each ring are substituted by a substituent. Examples of heteroaryl groups include pyridyl, furyl or furanyl, imidazolyl, benzimidazolyl, pyrimidinyl, thiophenyl or thienyl, quinolinyl, indolyl, thiazolyl, and the like.

The term “heteroarylalkyl” or the term “heteroaralkyl” refers to an alkyl substituted with a heteroaryl. The term “heteroarylalkoxy” refers to an alkoxy substituted with heteroaryl.

The term “heteroarylalkyl” or the term “heteroaralkyl” refers to an alkyl substituted with a heteroaryl. The term “heteroarylalkoxy” refers to an alkoxy substituted with heteroaryl.

The term “heterocyclyl” refers to a nonaromatic 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S (e.g., carbon atoms and 1-3, 1-6, or 1-9 heteroatoms of O, N, or S if monocyclic, bicyclic, or tricyclic, respectively), wherein 0, 1, 2 or 3 atoms of each ring are substituted by a substituent. Examples of heterocyclyl groups include piperazinyl, pyrrolidinyl, dioxanyl, morpholinyl, tetrahydrofuranyl, and the like.

The term “substituent” refers to a group replacing a second atom or group such as a hydrogen atom on any molecule, compound or moiety. Suitable substituents include, without limitation, halo, hydroxy, mercapto, oxo, nitro, haloalkyl, alkyl, alkaryl, aryl, aralkyl, alkoxy, thioalkoxy, aryloxy, amino, alkoxycarbonyl, amido, carboxy, alkanesulfonyl, alkylcarbonyl, and cyano groups.

In some embodiments, the compounds of this invention contain one or more asymmetric centers and thus occur as racemates and racemic mixtures, single enantiomers, individual diastereomers and diastereomeric mixtures. All such isomeric forms of these compounds are included in the present invention unless expressly provided otherwise. In some embodiments, the compounds of this invention are also represented in multiple tautomeric forms, in such instances, the invention includes all tautomeric forms of the compounds described herein (e.g., if alkylation of a ring system results in alkylation at multiple sites, the invention includes all such reaction products). All such isomeric forms of such compounds are included in the present invention unless expressly provided otherwise. All crystal forms of the compounds described herein are included in the present invention unless expressly provided otherwise.

As used herein, the terms “increase” and “decrease” mean, respectively, to cause a statistically significantly (i.e., p<0.1) increase or decrease of at least 5%.

As used herein, the recitation of a numerical range for a variable is intended to convey that the variable is equal to any of the values within that range. Thus, for a variable which is inherently discrete, the variable is equal to any integer value within the numerical range, including the end-points of the range Similarly, for a variable which is inherently continuous, the variable is equal to any real value within the numerical range, including the end-points of the range. As an example, and without limitation, a variable which is described as having values between 0 and 2 takes the values 0, 1 or 2 if the variable is inherently discrete, and takes the values 0.0, 0.1, 0.01, 0.001, or any other real values ≥0 and ≤2 if the variable is inherently continuous.

As used herein, unless specifically indicated otherwise, the word “or” is used in the inclusive sense of “or” and not the exclusive sense of “either/or.”

The term “on average” represents the mean value derived from performing at least three independent replicates for each data point.

The term “biological activity” encompasses structural and functional properties of a macrocycle of the invention. Biological activity is, for example, structural stability, alpha-helicity, affinity for a target, resistance to proteolytic degradation, cell penetrability, intracellular stability, in vivo stability, or any combination thereof.

The details of one or more particular embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.

Peptidomimetic Macrocycles of the Invention

The present invention provides pharmaceutical formulations comprising an effective amount of peptidomimetic macrocycles or pharmaceutically acceptable salts thereof. The peptidomimetic macrocycles of the invention are cross-linked (e.g., stapled or stitched) and possess improved pharmaceutical properties relative to their corresponding uncross-linked peptidomimetic macrocycles. These improved properties include improved bioavailability, enhanced chemical and in vivo stability, increased potency, and reduced immunogenicity (i.e., fewer or less severe injection site reactions).

In some embodiments, the peptide sequences are derived from BIM.

In some embodiments, a peptidomimetic macrocycle peptide derived from a human BIM peptide can be a peptide comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 amino acids from a BIM peptide sequence.

In some embodiments, a peptidomimetic macrocycle peptide derived from a human BIM peptide sequence can be a peptide comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 amino acids that are different from the selected sequences from which the peptide is derived. In some embodiments, a peptidomimetic macrocycle peptide derived from a human BIM peptide sequence can be a peptide comprising a mutation at amino acid position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22. In some embodiments, mutations are mutations of non-essential amino acids. In some embodiments, mutations are mutations of essential amino acids. In some embodiments, mutations are mutations of hydrophobic amino acids. In some embodiments, mutations are mutations of naturally occurring amino acids. In some embodiments, mutations are mutations to a conservative amino acid. In some embodiments, a peptidomimetic macrocycle peptide derived from a human BIM peptide sequence can be a peptide comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 amino acid analogues. In some embodiments, a peptidomimetic macrocycle peptide derived from a human BIM peptide sequence can be a peptide comprising 1 or 2 capping groups.

In some embodiments, the peptidomimetic macrocycle comprises a C-terminal truncation of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 amino acids from an amino acid sequence in Table 1. In some embodiments, the peptidomimetic macrocycle comprises a N-terminal truncation of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 amino acids from the sequence of BIM.

A non-limiting list of suitable BIM macrocycles for use in the present disclosure are given in Table 1. In Table 1, at the C-terminus, some peptides possess a carboxamide terminus (shown as —NH₂); some peptides possess a hydroxyl terminus (shown as -OH); some peptides possess a 5-carboxyfluorescein terminus (shown as -5-FAM); some peptides possess a isobutylamide terminus (shown as -NHiBu); some peptides possess a cyclohexylamide terminus (shown as -NHChx); some peptides possess a cyclohexylmethylamide terminus (shown as -NHMeChx); some peptides possess a phenethylamide terminus (shown as -NHPe); some peptides possess a n-butylamide terminus (shown as -NHBu); some peptides possess a sec-butylamide terminus (shown as -NHsBu); and some peptides possess an uncapped terminus (shown as no terminal modification).

In Table 1, at the N-terminus, some peptides possess an acetyl terminus (shown as Ac-); some peptides possess a fluorescein isothiocyanate terminus (shown as FITC-); some peptides possess a single-unit polyethylene glycol terminus (shown as dPEG1-); some peptides possess a five-unit polyethylene glycol terminus (shown as dPEG5-); some peptides possess an eleven-unit polyethylene glycol terminus (shown as dPEG11-); some peptides possess a propyl terminus (shown as Pr-); some peptides possess a biotin terminus (shown as Biotin-); some peptides possess a KLH terminus (shown as KLH-); some peptides possess an ovalbumin terminus (shown as OVA-); some peptides possess an uncapped terminus (shown as H-); some peptides possess a isobutyl terminus (shown as iBu-); some peptides possess a decanoyl terminus (shown as Decac-); some peptides possess a benzyl terminus (shown as Bz-); some peptides possess a cyclohexyl terminus (shown as Chx-); some peptides possess a benzyl terminus (shown as Bz-); some peptides possess a Vrl terminus (shown as Vrl-); some peptides possess a HBS terminus (shown as HBS-); some peptides possess a Melm terminus (shown as MeImC-); some peptides possess a tert-butyl terminus (shown as t-Bu-U-); some peptides possess a nonanoyl terminus (shown as non-U-); some peptides possess a ethyl terminus (shown as Et-U-); some peptides possess a cyclohexyl terminus (shown as Chx-U-); some peptides possess a isopropyl terminus (shown as iPr-U-); some peptides possess a phenyl terminus (shown as Ph-U-); some peptides possess a uric terminus (shown as NH2CO-); some peptides possess a palmitoyl terminus (shown as Pam-); some peptides possess a heptenoic terminus (shown as Hep-); and some peptides possess a 5-carboxytetramethylrhodamine terminus (shown as 5-TAMRA-).

TABLE 1 SEQ ID NO Peptide seguence 1 Ac-IWIAQELRRIGDEFNAYYARR-NH2 2 Ac-IWIAQELR$IGD$FNAYYARR-NH2 3 Ac-IWIAQELR$IED$FNAYYARR-NH2 4 FITC-IWIAQELRRIGDEFNAYYARR-NH2 5 FITC-IWIAQELR$IGD$FNAYYARR-NH2 6 FITC-IWIAQELR$IED$FNAYYARR-NH2 7 Ac-IWIAQQLR$IGD$FNAYYARR-NH2 8 Ac-RWIAQQLR$IGD$FNAYYARR-NH2 9 Ac-IRIAQQLR$IGD$FNAYYARR-NH2 10 Ac-RRIAQQLR$IGD$FNAYYARR-NH2 11 Ac-EIWIAQQLR$IGD$FNAYYARR-NH2 12 Ac-ERRIAQQLR$IGD$FNAYYARR-NH2 13 Ac-IRIAQELR$IGD$FNAYYARR-NH2 14 Ac-RWIAQELR$IGD$FNAYYARR-NH2 15 Ac-RRIAQELR$IGD$FNAYYARR-NH2 16 Ac-EIWIAQELR$IGD$FNAYYARR-NH2 17 Ac-ERWIAQELR$IGD$FNAYYARR-NH2 18 Ac-EIRIAQELR$IGD$FNAYYARR-NH2 19 Ac-ERRIAQELR$IGD$FNAYYARR-NH2 20 PEG1-IWIAQELR$IGD$FNAYYARR-NH2 21 PEGS-IWIAQELR$IGD$FNAYYARR-NH2 22 PEG11-IWIAQELR$IGD$FNAYYARR-NH2 23 Ac-IWIAQELR$IGD$FNASYARR-NH2 24 Ac-RRIAQELR$IGD$FNASYARR-NH2 25 Ac-ERRIAQELR$IGD$FNASYARR-NH2 26 Ac-RRIAQELR$IGD$FNAYYAR-NH2 27 Ac-RRIAQELR$IGD$FNAYYA-NH2 28 Ac-RRIAQELR$IGD$FNAYYAib-NH2 29 Ac-RRIAQELR$IGD$FNASYAib-NH2 30 Ac-IWIAQELR$IAibD$FNAYYAR-NH2 31 Ac-IWIAQELR%IAibD%FNAYYAR-NH2 32 Ac-IRIAQELRRIGDEFNETYTRR-NH2 33 Ac-IRIAQELR$IGD$FNETYTRR-NH2 34 Ac-IRIAQELR$IED$FNETYTRR-NH2 35 Ac-IWIAQELR$/IGD$/FNAYYARR-NH2 36 Pr-IWIAQELR$IGD$FNAYYARR-NH2 37 Ac-IWIAQELR$IAibD$FNAYYARR-NH2 38 Ac-IWIAQELR%IAibD%FNAYYARR-NH2 39 Ac-IWIAQELR$IGD$ANAYYARR-NH2 40 Ac-IWIAQELR$IGD$FAAYYARR-NH2 41 Ac-IWIAQELR$IGD$AAAYYARR-NH2 42 Ac-IWIAQELR%IGD%FNAYYARR-NH2 43 Ac-AWIAQELR$IGD$FNAYYARR-NH2 44 Ac-IWAAQELR$IGD$FNAYYARR-NH2 45 Ac-AWAAQELR$IGD$FNAYYARR-NH2 46 Ac-IWIAibQELR$IGD$FNAYYARR-NH2 47 Ac-IWIAQELR$IGD$FNAAYARR-NH2 48 Ac-IWIAQELR$IGD$FNAYAARR-NH2 49 Ac-IWIAQELR$IGD$FNAAAARR-NH2 50 Ac-IWIAQELR$IGD$FNAYYAibRR-NH2 51 Ac-IAIAQELR%IAibD%FNAYYARR-NH2 52 Ac-IAIAQELR$IAibD$FNAYYARR-NH2 53 Ac-DIIRNIAibRHLA$VGD$NleDRSI-NH2 54 Ac-DIIRNIARHLA$VGD$NleDKSI-NH2 55 Ac-DIIKNIARHLA$VGD$NleDRSI-NH2 56 Ac-DIIRNIARHLACVGDCNleDRSI-NH2 57 Ac-DIIRNIARHLACVAibDCNleDRSI-NH2 58 Ac-IWIAQELR$IGD$FNA-NH2 59 Ac-IWIAQELR$IGD$FNRSI-NH2 60 Ac-IWIAQELR$IGD$FNRSIARR-NH2 61 Ac-IWIAQELR$IGD$NleDRSI-NH2 62 Ac-IWIAQELR$VGD$NleDRSI-NH2 63 Ac-IWIAQEAR$IGA$FNAYYARR-NH2 64 Ac-WIAQELR$IGD$FNAYYARR-NH2 65 Ac-IAQELR$IGD$FNAYYARR-NH2 66 Ac-AQELR$IGD$FNAYYARR-NH2 67 Ac-QELR$IGD$FNAYYARR-NH2 68 Ac-ELR$IGD$FNAYYARR-NH2 69 Ac-IWIAQELR$IGD$FNAYYAR-NH2 70 Ac-IWIAQELR$IGD$FNAYYA-NH2 71 Ac-IWIAQELR$IGD$FNAYY-NH2 72 Ac-IWIAQELR$IGD$FNAY-NH2 73 Ac-IAIAQELR$IGD$FNAYYARR-NH2 74 Ac-IWIAAELR$IGD$FNAYYARR-NH2 75 Ac-IWIAQALR$IGD$FNAYYARR-NH2 76 Ac-IWIAQEAR$IGD$FNAYYARR-NH2 77 Ac-IWIAQELA$IGD$FNAYYARR-NH2 78 Ac-IWIAQELR$AGD$FNAYYARR-NH2 79 Ac-IWIAQELR$IAD$FNAYYARR-NH2 80 Ac-IWIAQELR$IGA$FNAYYARR-NH2 81 Ac-IWIAQELR$IGD$FNAYYAAR-NH2 82 Ac-IWIAQELR$IGD$FNAYYARA-NH2 83 Pr-RNIARHLA$VGD$FNAYYARR-NH2 84 Pr-RNIARHLAib$VGD$FNAYYARR-NH2 85 Pr-RNIAibRHLAib$VGD$FNAYYARR-NH2 86 Pr-RNChgARHLA$VAibD$FNAYYARR-NH2 87 Pr-RNChaARHLA$VAibD$FNAYYARR-NH2 88 FITC-BaIWIAQELRRIGDEFNAYYARR-NH2 89 Biotin-AhxIWIAQELRRIGDEFNAYYARR-NH2 90 KLH-CBaIWIAQELRRIGDEFNAYYARR-NH2 91 OVA-CBaIWIAQELRRIGDEFNAYYARR-NH2 92 FITC-BaIWIAQELR$IGD$FNAYYARR-NH2 93 Biotin-AhxIWIAQELR$IGD$FNAYYARR-NH2 94 KLH-CBaIWIAQELR$IGD$FNAYYARR-NH2 95 OVA-CBaIWIAQELR$IGD$FNAYYARR-NH2 96 FITC-BaIWIAQELR$IED$FNAYYARR-NH2 97 Biotin-AhxIWIAQELR$IED$FNAYYARR-NH2 98 FITC-BaIWIAQELR$/IGD$/FNAYYARR-NH2 99 Ac-BaIWIAQELR$IGD$FNAYYAR-NH2 100 Ac-IWIAQELR%IGD%FNAYYARR-NH2 101 H-CBaIWIAQELR$IGD$FNAYYARR-NH2 102 Ac-IWIAQALR$IGD$FAAYYARR-NH2 103 Ac-IWIAQALR$IAibD$FNAYYARR-NH2 104 Ac-IWIAQ$LRR$GDEFNAYYARR-NH2 105 Ac-IWIAQ$LRR$GDAFNAYYARR-NH2 106 Ac-IWIAQ$LRA$GDAFNAYYARR-NH2 107 Ac-IWI$QEL$RIGDEFNAYYARR-NH2 108 Ac-IWI$QAL$RIGDEFNAYYARR-NH2 109 Ac-IWI$QEL$RIGDAFNAYYARR-NH2 110 Ac-IWI$QAL$RIGDAFNAYYARR-NH2 111 Ac-IWIAQALR$IGD$ANAYYARR-NH2 112 Ac-RWIAQALR$IGD$FNAYYARR-NH2 113 Ac-RNIAQELR$IGD$FNAYYARR-NH2 114 Ac-RNIAQALR$IGD$FNAYYARR-NH2 115 Ac-RRIAQALR$IGD$FNAYYARR-NH2 116 Ac-RNIAQALR$IGD$ANAYYARR-NH2 117 Ac-RRIAQALR$IGD$ANAYYARR-NH2 118 H-IWIAQELR$IGD$FNAYYARR-NH2 119 Ac-IWIAQEChaR$IGD$FNAYYARR-NH2 120 Ac-IWChgAQELR$IGD$FNAYYARR-NH2 121 Ac-IRIAQALR$IGD$FNAYYARR-NH2 122 Ac-IWIAQAibLR$IGD$FNAYYARR-NH2 123 Ac-IWIAibQALR$IGD$FNAYYARR-NH2 124 Ac-IWIAQALR$IGD$FNAibYYARR-NH2 125 Ac-IWIAQALR$IGD$FNAYYAibRR-NH2 126 Ac-IWIAQALR$IGD$FNASIARR-NH2 127 Ac-IWIAQALR$IGD$FNAFYARR-NH2 128 Ac-IWIAQALR$IGD$FNAFFARR-NH2 129 Ac-IWIAQALR$IGD$FNARRA-NH2 130 Ac-IWIAQALR$IGD$FNAYKA-NH2 131 Ac-IWIAQALR$IGD$FNAYK-NH2 132 Ac-IWIAQALR$IGD$FNASKARR-NH2 133 Ac-RRIAQQLR$IGD$ANAYYARR-NH2 134 Ac-WIAQQLR$IGD$FNAYYARR-NH2 135 Pr-WIAQQLR$IGD$FNAYYARR-NH2 136 Ac-RWIAQQLR$IGN$FNAYYARR-NH2 137 H-NMeRWIAQQLR$IGD$FNAYYARR-NH2 138 Ac-NMeRWIAQQLR$IGD$FNAYYARR-NH2 139 Ac-IWIAQHLR$IGD$FNAYYARR-NH2 140 Ac-RWIAQHLR$IGD$FNAYYARR-NH2 141 Ac-RWIAQELR$ChgGD$FNAYYARR-NH2 142 Ac-RWIAQELR$ChaGD$FNAYYARR-NH2 143 Ac-IWIAQQLR$IGD$FNAFFARR-NH2 144 Ac-RWIAQQLR$IGD$FNAFYARR-NH2 145 Ac-RWIAQQLR$IGD$FNAYFARR-NH2 146 Ac-RWIAQQLR$IGD$FNATIARR-NH2 147 Ac-RWIAQQLR$IGD$FNAYYAR-NH2 148 Ac-RWIAQQLR$IGD$FNAYYA-NH2 149 Ac-RWIAQQLR$IGD$FNAYY-NH2 150 Ac-IWIAQ$LRR$GDQFNAYYARR-NH2 151 Ac-IWIAQ$LRQ$GDQFNAYYARR-NH2 152 Ac-RWIAQ$LRA$GDQFNAYYARR-NH2 153 H-CBaIWIAQELRRIGDEFNAYYARR-NH2 154 H-CBaIWIAQELRRIGDEFNAYYARR-NH2 155 H-CBaIWIAQELR$IGD$FNAYYARR-NH2 156 H-CBaIWIAQELR$IGD$FNAYYARR-NH2 157 Ac-RRIAQQLR$IGD$FNAYYAR-NH2 158 Ac-RRIAQALR$IGD$FNAYYAR-NH2 159 Ac-RRIAQQLR$IGD$FNAYYA-NH2 160 Ac-IWIAQQLR$IGD$FNARRA-NH2 161 Ac-RWIAQQLR$IGD$FNARRA-NH2 162 Ac-RRIAQQLR$IGD$FNARRA-NH2 163 Ac-RRIAQQLR$IGD$FNARRA-NH2 164 Ac-RWIAQQLR$IGD$FNARYA-NH2 165 Ac-RWIAQQLR$IGD$FNAYRA-NH2 166 Ac-RWIAQQLR$IGD$FNARYA-NH2 167 Ac-RWIAQQLR$IGD$FNAYRA-NH2 168 Ac-RRIAQQLR$IGD$FNASIA-NH2 169 Ac-RRIAQALR$IGD$FNASIA-NH2 170 Ac-RRIAQALR$IGD$FNASI-NH2 171 Ac-RWIAQQLR$IGD$FNARR-NH2 172 Ac-RWIAQQLR$IGD$FNAR-NH2 173 Ac-RRIAQQLR$IGD$FNAR-NH2 174 Ac-RRIAQQLR$IGD$FNAib-NH2 175 Ac-RRIAQQLR$IGD$FNA-NH2 176 Ac-RRIAQQLR$IGD$FNARRA-NH2 177 Ac-RRIAQQLR$IGD$FNAYYA-NH2 178 Ac-RRIAQQLR$IGD$FNAYYAib-NH2 179 Ac-RWIAQQLR$IGD$FNAibRRA-NH2 180 Ac-RWIAibQQLR$IGD$FNARRA-NH2 181 Ac-RWAibAQQLR$IGD$FNARRA-NH2 182 Ac-RAibIAQQLR$IGD$FNARRA-NH2 183 Ac-RFIAQQLR$IGD$FNAYYARR-NH2 184 Ac-RFIAQQLR$IGD$FNARRA-NH2 185 Ac-RAibIAQQLR$IGD$FNAYYARR-NH2 186 Ac-RWIAQQhFR$IGD$FNAYYARR-NH2 187 Ac-RWIAQQ3cfR$IGD$FNAYYARR-NH2 188 Ac-RWIAQQ1NalR$IGD$FNAYYARR-NH2 189 Ac-RWIAQQ2NalR$IGD$FNAYYARR-NH2 190 Ac-IWIAQEAR$IGD$ANAYYARR-NH2 191 Ac-RRI$QAL$RIGDAibFNARRA-NH2 192 Ac-RRIAQ$LRR$GDAibFNARRA-NH2 193 iBu-RWIAQQLR$IGD$FNAYYARR-NH2 194 Dec-RWIAQQLR$IGD$FNAYYARR-NH2 195 Bz-RWIAQQLR$IGD$FNAYYARR-NH2 196 H-RWIAQQLR$IGD$FNAYYARR-NH2 197 Chx-RWIAQQLR$IGD$FNAYYARR-NH2 198 Vrl-RWIAQQLR$IGD$FNAYYARR-NH2 199 PhAc-RWIAQQLR$IGD$FNAYYARR-NH2 200 MeImC-RWIAQQLR$IGD$FNAYYARR-NH2 201 Pr-RWIAQQLR$IGD$FNAYYARR-NH2 202 Ac-RWIAQALR$IGD$FNASIARR-NH2 203 Ac-RWIAQQLR$IGD$FNASIARR-NH2 204 Ac-RWIAQALR$IGD$FNAFYARR-NH2 205 Ac-RRIAQALR$IGD$FNAFYA-NH2 206 Ac-RRIAQQLR$IGD$FNAFYA-NH2 207 Ac-RWIAQALR$IGD$FNAYYARR-NHPr 208 Ac-RWIAQALR$IGD$FNAYYARR-NHiBu 209 Ac-RWIAQALR$IGD$FNAYYARR-NHChx 210 Ac-RWIAQALR$IGD$FNAYYARR-NHBn 211 Ac-RWIAQALR$IGD$FNAYYARR-NHMeChx 212 Ac-RWIAQALR$IGD$FNAYYARR-NHEtPh 213 Ac-RWIAQALR$IGD$FNAYYARR-NHsBu 214 Ac-RWIAQALR$IGD$FNARR-NHPr 215 Ac-RWIAQALR$IGD$FNARR-NHiBu 216 Ac-RWIAQALR$IGD$FNARR-NHChx 217 Ac-RWIAQALR$IGD$FNARR-NHBn 218 Ac-RWIAQALR$IGD$FNARR-NHMeChx 219 Ac-RWIAQALR$IGD$FNARR-NHEtPh 220 Ac-RWIAQALR$IGD$FNARR-NHsBu 221 Ac-RWIAQALR$IGA$FNAYYARR-NH2 222 Ac-RWIAQALR$IGN$FNAYYARR-NH2 223 Ac-IWIAQALR$IGA$FNARRA-NH2 224 Ac-IWIAQALR$IGN$FNARRA-NH2 225 Ac-RWIAQAFR$IGD$FNAYYARR-NH2 226 H-CAhxIWIAQELRRIGDEFNAYYARR-NH2 227 H-CAhxIWIAQELR$IGD$FNAYYARR-NH2 228 Pr-IPIAQALR$IGD$FNARRA-NH2 229 Pr-PWIAQALR$IGD$FNARRA-NH2 230 KLH-CAhxIWIAQELRRIGDEFNAYYARR-NH2 231 OVA-CAhxIWIAQELRRIGDEFNAYYARR-NH2 232 KLH-CAhxIWIAQELR$IGD$FNAYYARR-NH2 233 OVA-CAhxIWIAQELR$IGD$FNAYYARR-NH2 234 Ac-IWIAEELA$IGD$FDAYYA-NH2 235 FITC-BaIWIAEELA$IGD$FDAYYA-NH2 236 Ac-IWIAEELA$IGD$FDAYYAAA-NH2 237 FITC-BaIWIAEELA$IGD$FDAYYAAA-NH2 238 Ac-RWIAQALR$IGD$FNAYKARR-NH2 239 Ac-RWIAQQLR$IGD$FNAYKARR-NH2 240 Ac-RWIAQALR$IGD$FNAYK-NH2 241 Ac-RWIAQALR$IGD$FNAFK-NH2 242 Ac-RWIAQALR$IGD$hFNAYYARR-NH2 243 Ac-RWIAQALR$IGD$1NalNAYYARR-NH2 244 Ac-RWIAQALR$IGD$2NalNAYYARR-NH2 245 Ac-R2NalIAQALR$IGD$FNAYYARR-NH2 246 Ac-RhFIAQALR$IGD$FNAYYARR-NH2 247 Ac-RWIAQALR$IGNle$FNAYYARR-NH2 248 Ac-RWNleAQALR$IGD$FNAYYARR-NH2 249 Ac-RWIAQNleLR$IGD$FNAYYARR-NH2 250 Ac-RWIAQQLR$IGD$FNAYK-NH2 251 H-CAhxIWIAQELR$IED$FNAYYARR-NH2 252 Ac-IWIAQALR$IGD$FNAYOrnARR-NH2 253 Ac-IWIAQALR$IGD$FNAYOrn-NH2 254 Ac-IWIAQALR$IGD$FNAYR-NH2 255 Ac-IWIAQALR$IGD$FNAYRA-NH2 256 Ac-IWIAQALR$IFD$FNARRA-NH2 257 Ac-RWIAQALR$IGD$FNARRA-NH2 258 Ac-IWIAQELR$ChgGD$FNAYYARR-NH2 259 Ac-IWIAQQLR$IGD$FNAYY-NH2 260 Ac-IWIAQ$LRA$GDQFNAYYARR-NH2 261 Ac-IWIAQALR$IGD$FAibAYK-NH2 262 Ac-IWIAQALR$IGD$FAibAYYARR-NH2 263 Ac-IWIAQALR$IGN$FNAFYARR-NH2 264 Ac-RWIAQALR$IGN$FNAFYARR-NH2 265 Ac-IWIAQAibLR$IGN$FNAFYARR-NH2 266 Ac-IWIAQALR$IGN$FNAibFYARR-NH2 267 Ac-IWIAQAibLR$IGN$FNAibFYARR-NH2 268 Pr-RNChgARHLA$VAibD$FNAFYARR-NH2 269 Ac-IWIAQAAR$IGD$FNAYYARR-NH2 270 Ac-IWIAQAAR$IGD$ANAYYARR-NH2 271 Ac-IWIAQAAR$IGA$ANAYYARR-NH2 272 Ac-IWIAQAAR$IEA$ANAYYARR-NH2 273 Ac-IWIAQALR$DIG$FNAYYARR-NH2 274 Ac-IWIAQAAR$DIG$ANAYYARR-NH2 275 Ac-IWIAQALR$IED$FNAYYARR-NH2 276 Ac-IWIAQALD$IGR$FNAYYARR-NH2 277 Ac-IWIAQAAD$IGR$ANAYYARR-NH2 278 Ac-IWIAQAAD$IER$ANAYYARR-NH2 279 Ac-IWIAQAibLR$IGD$FNAibYYARR-NH2 280 Ac-IWIAQQLR$IGD$FNAYRA-NH2 281 Ac-IWI$QAL$RIGDAibFNAYYARR-NH2 282 t-Bu-U-IWIAQELR$IGD$FNAYYARR-NH2 283 non-U-IWIAQELR$IGD$FNAYYARR-NH2 284 Et-U-IWIAQELR$IGD$FNAYYARR-NH2 285 Chx-U-IWIAQELR$IGD$FNAYYARR-NH2 286 iPr-U-IWIAQELR$IGD$FNAYYARR-NH2 287 Ph-U-IWIAQELR$IGD$FNAYYARR-NH2 288 NH2CO-IWIAQELR$IGD$FNAYYARR-NH2 289 Ac-IWIAQAAR$IGR$ANAYYARR-NH2 290 Ac-IWIAQAAD$IGD$ANAYYARR-NH2 291 Ac-IWIAQALD$IGD$FNAYYARR-NH2 292 Ac-IWIAQALR$IGR$FNAYYARR-NH2 293 Ac-IWIAQAAR$IGD$ANAYYARR-NH2 294 Ac-IWIAQAAD$IGR$ANAYYARR-NH2 295 Ac-IWIAQALD$IGR$FNAYYARR-NH2 296 Ac-IWIAQALRRIGDEFNAYYARR-NH2 297 Ac-IWIAQALR$IGN$FNAYYARR-NH2 298 Ac-IWIAQALR$IGNle$FNAYYARR-NH2 299 Ac-IWIAQALR$IGA$FNAFYARR-NH2 300 Ac-IWIAQALR$IGN$FNAFYARR-NH2 301 Ac-IWIAQALR$IGNle$FNAFYARR-NH2 302 Ac-RWIAQAFR$IGD$FNAFYARR-NH2 303 Ac-IWIAQAFR$IGD$FNAFYARR-NH2 304 Ac-IWIAQAFR$IGN$FNAYYARR-NH2 305 Ac-IWIAQAFR$IGN$FNAFYARR-NH2 306 Ac-IWIAQALR$IG$EFNAYYARR-NH2 307 Ac-IWIAQALRR$GD$FNAYYARR-NH2 308 Ac-IWIAQALRAibIGAmDEFNAYYARR-NH2 309 Ac-IWIAQELR#IGD#FNAYYARR-NH2 310 Ac-IWIAQELR$IGD#FNAYYARR-NH2 311 Ac-IWIAQELR#IGD$FNAYYARR-NH2 312 Ac-IWIAQALR$IGD$FNAYYARR-NHiBu 313 Chx-IWIAQALR$IGD$FNAYYARR-NHiBu 314 Chx-U-IWIAQALR$IGD$FNAYYARR-NHiBu 315 FITC-AhxIWIAQALR$IGD$FNAibYYARR-NH2 316 FITC-AhxIWIAQALR$IGD$FNAFYARR-NH2 317 FITC-AhxRWIAQALR$IGD$FNAFYARR-NH2 318 FITC-AhxRWIAQALR$IGN$FNAYYARR-NH2 319 FITC-AhxRWIAQALR$IGNle$FNAYYARR-NH2 320 FITC-AhxIWIAQALR$IGN$FNAYYARR-NH2 321 FITC-AhxIWIAQALR$IGNle$FNAYYARR-NH2 322 Ac-IWIAQELRbKIGDbEFNAYYARR-NH2 323 Ac-IWIAQELRbEIGDbKFNAYYARR-NH2 324 Ac-IWIAQELRbKIAibDbEFNAYYARR-NH2 325 Ac-IWIAQELRbEIAibDbKFNAYYARR-NH2 326 Ac-IWIAQELR#sIGD#sFNAYYARR-NH2 327 Ac-IWIAQELR#sIAibD#sFNAYYARR-NH2 328 Ac-IWIAQELR$sIGD$sFNAYYARR-NH2 329 Ac-IAmWIAQELR$IGD$FNAYYARR-NH2 330 Ac-IWIAQELR$r5IGD$r5FNAYYARR-NH2 331 Ac-IWIA$r5ELR$r5IGDEFNAYYARR-NH2 332 Ac-IWIA$ELR$IGDEFNAYYARR-NH2 333 Ac-IWIAQ$r8LRRIGD$FNAYYARR-NH2 334 Ac-I$r8IAQELR$IGDEFNAYYARR-NH2 335 HepIAQ$LRRIGDEFNAYYARR-NH2 336 HepIAQ$LR$IGD$FNAYYARR-NH2 337 HepWIA$ELRRIGDEFNAYYARR-NH2 338 HepWIA$ELR$IGD$FNAYYARR-NH2 339 Ac-I$IAQ$LRRIGDEFNAYYARR-NH2 340 Ac-I$IAQ$LR$IGD$FNAYYARR-NH2 341 Ac-IWIAQALE$IGD$FNAYYARR-NH2 342 Ac-IWIAQALR$IGR$ANAYYARR-NH2 343 Ac-IWIAQAAESIGR$ANAYYARR-NH2 344 Ac-IWIAQAAE$IGE$ANAYYARR-NH2 345 Ac-RWIAQALR$IGR$FNAFYARR-NH2 346 Ac-RWIAQALE$IGD$FNAFYARR-NH2 347 Ac-RWIAQAAR$IGR$ANAFYARR-NH2 348 Ac-RWIAQAAE$IGD$ANAFYARR-NH2 349 Ac-RWIAQAAD$IGD$ANAFYARR-NH2 350 Ac-RWIAQAAESIGR$ANAFYARR-NH2 351 Ac-RWIAQAAR$IGD$ANAFYARR-NH2 352 Ac-RWIAQALR$DIG$FNAFYARR-NH2 353 Ac-RWIAQALR$IGN$ANAYYARR-NH2 354 Ac-RWIAQAAR$IGN$ANAYYARR-NH2 355 Ac-RWIAQAAESIGN$ANAYYARR-NH2 356 Ac-RWIAQAAESIGN$ANAYYARR-NH2 357 Ac-RWIAQAAE$NIG$ANAYYARR-NH2 358 Ac-RWIAQAAR$NIG$ANAYYARR-NH2 359 Ac-IWIAQALR$IGN$ANAYYARR-NH2 360 Ac-IWIAQAAR$IGN$ANAYYARR-NH2 361 Ac-IWIAQAAE$IGN$ANAYYARR-NH2 362 Ac-IWIAQAAE$IGN$ANAYYARR-NH2 363 Ac-IWIAQAAE$NIG$ANAYYARR-NH2 364 Ac-IWIAQAAR$NIG$ANAYYARR-NH2 365 Ac-RWIAQALRRIGNEFNAYYARR-NH2 366 Ac-IWIAQALRRIGNEFNAYYARR-NH2 367 Ac-RWIAQALR$IEN$FNAYYARR-NH2 368 Ac-RWIAQALR$IED$FNAFYARR-NH2 369 Ac-IWIAQALR$IED$FNAFYARR-NH2 370 Ac-IWIAQELR$IGR$FNAYYARR-NH2 371 Ac-IWIAQELRbKIGDbDFNAYYARR-NH2 372 Ac-IWIAQELRbDIGDbKFNAYYARR-NH2 373 FITC-AhxRWIAQALRRIGDEFNAFYARR-NH2 374 FITC-AhxRWIAQALRRIGNEFNAYYARR-NH2 375 FITC-AhxIWIAQALRRIGNEFNAYYARR-NH2 376 FITC-AhxIWIAQELRRIGDEFNAYYARR-NH2 377 Ac-RWIAQALR$/IGN$/FNAYYARR-NH2 378 Ac-IWIAQELR#cIGR#cFNAYYARR-NH2 379 Ac-IWIAQELRCIGRCFNAYYARR-NH2 380 FITC-AhxIWIAQAAR$DIG$ANAYYARR-NH2 381 Ac-IWIAQQLR%IGD%FNAYYARR-NH2 382 FITC-AhxRNIARHLA$VGD$NleAibRSI-NH2 383 FITC-AhxIWIAQALR$IGD$FNAYYARR-NH2 384 Ac-IWIAQELR#c4IGD#c4FNAYYARR-NH2 385 Ac-IWIAQELR$c4IGD$c4FNAYYARR-NH2 386 Ac-IWIAQELR#cIGD#cFNAYYARR-NH2 387 Ac-IWIAQELR$cIGD$cFNAYYARR-NH2 388 FITC-AhxIWIAQELR#IGD#FNAYYARR-NH2 389 5-FAM-AhxIWIAQELR#c4IGD#c4FNAYYARR-NH2 390 5-FAM-AhxIWIAQELR$c4IGD$c4INAYYARR-NH2 391 FITC-AhxIWIAQELR#cIGD#cFNAYYARR-NH2 392 FITC-AhxIWIAQELR#sIGD#sFNAYYARR-NH2 393 FITC-AhxIWIAQELR$cIGD$cFNAYYARR-NH2 394 Ac-IWIAQELR$4n4IGD$4a5FNAYYARR-NH2 395 Ac-IWIAQELR$4a5IGD$4n4FNAYYARR-NH2 396 Ac-IWIAQELR$5n3IGD$5a5FNAYYARR-NH2 397 Ac-IWIAQELR$5a5IGD$5n3FNAYYARR-NH2 398 Ac-IWIAQELR#5n3IGD#5a5FNAYYARR-NH2 399 Ac-IWIAQELR#5a5IGD#5n3FNAYYARR-NH2 400 FITC-AhxIWIAQELR$4n4IGD$4a5FNAYYARR-NH2 401 FITC-AhxIWIAQELR$4a5IGD$4n4FNAYYARR-NH2 402 FITC-AhxIWIAQELR$5n3IGD$5a5FNAYYARR-NH2 403 FITC-AhxIWIAQELR$5a5IGD$5n3FNAYYARR-NH2 404 FITC-AhxIWIAQELR#5n3IGD#5a5FNAYYARR-NH2 405 FITC-AhxIWIAQELR#5a5IGD#5n3FNAYYARR-NH2 406 Ac-IWIAQALR$IEN$FNAYYARR-NH2 407 Ac-RWIAQALR$/IGD$/FNAFYARR-NH2 408 Ac-IWIAQALR$/IGN$/FNAYYARR-NH2 409 Ac-IWIAQALR$/IGD$/FNAYYARR-NH2 410 Ac-RWIChaQALR$IGD$FNAFYARR-NH2 411 Ac-RWIAQALR$IChaD$FNAFYARR-NH2 412 Ac-RWIAQALR$IGD$FNAFYARR-NH2 413 Ac-RWIAQALR$IGD$FNChaFYARR-NH2 414 Ac-RWIAQALR$IGD$FNAFYChaRR-NH2 415 Ac-IWIChaQALR$IGN$FNAYYARR-NH2 416 Ac-IWIAQALR$IChaN$FNAYYARR-NH2 417 Ac-IWIAQALR$IGN$FNAYYARR-NH2 418 Ac-IWIAQALR$IGN$FNChaYYARR-NH2 419 Ac-IWIAQALR$IGN$FNAYYChaRR-NH2 420 HepIAQ$LR$IGD$FNAFYARR-NH2 421 Ac-YGRKKRRQRRRIWIAQELRRIGDEFNAYYARR-NH2 422 FITC-AhxYGRKKRRQRRRIWIAQELRRIGDEFNAYYARR- NH2 423 Ac-RWIAQALR$IGD$FNAFYAHR-NH2 424 Ac-RWIAQALR$IGD$FNAFYARH-NH2 425 Ac-RWIAQSLR$IGD$FNAFYARR-NH2 426 Ac-IWIAQELR#4n4IGD#4a5FNAYYARR-NH2 427 FITC-AhxRWIAQALR$/IGN$/FNAYYARR-NH2 428 FITC-AhxRWIAQALR$/IGD$/FNAFYARR-NH2 429 FITC-AhxIWIAQALR$/IGN$/FNAYYARR-NH2 430 FITC-AhxIWIAQALR$/IGD$/FNAYYARR-NH2 431 FITC-AhxIWIAQELR$sIGD$sFNAYYARR-NH2 432 Biotin-AhxRWIAQALRRIGDEFNAFYARR-NH2 433 Biotin-AhxRWIAQALRRIGNEFNAYYARR-NH2 434 Biotin-AhxIWIAQALRRIGNEFNAYYARR-NH2 435 Biotin-AhxIWIAQALRRIGDEFNAYYARR-NH2 436 FITC-AhxIWIAQALRRIGDEFNAYYARR-NH2 437 Biotin-AhxRWIAQALR$IGD$FNAFYARR-NH2 438 Biotin-AhxRWIAQALR$IGN$FNAYYARR-NH2 439 Biotin-AhxIWIAQALR$IGN$FNAYYARR-NH2 440 Biotin-AhxIWIAQALR$IGD$FNAYYARR-NH2 441 Biotin-AhxIWIAQALR$IGD$FNAFYARR-NH2 442 5-FAM-AhxIWIAQELR$IGD$FNAYYARR-NH2 443 DuIAQDprLRRIGDEFNAYYARR-NH2 444 DuIAQDprLRRIGDQFNAYYARR-NH2 445 DuWIADprALRRIGDEFNAYYARR-NH2 446 DuWIADprALRRIGDQFNAYYARR-NH2 447 5-FAM-AhxIWIAQALRRIGDEFNAYYARR-NH2 448 5-FAM-AhxIWIAQALR$IGD$FNAYYARR-NH2 449 5-FAM-AhxIWIAQAARRDIGEANAYYARR-NH2 450 5-FAM-AhxRWIAQALR$IGD$FNAFYARR-NH2 451 5-FAM-AhxIWIAQALRRIGDEFNAFYARR-NH2 452 Ac-IWIAQEAmLR$IGD$FNAYYARR-NH2 453 Ac-IWIAQELR$IGD$FNAibYYARR-NH2 454 Ac-IWIAQELR$IGD$FNAAmfYARR-NH2 455 Ac-IWIAQELR$IGD$FNAYAmfARR-NH2 456 Ac-IWIAQELR$IGD$FNAAmyeYARR-NH2 457 Ac-IWIAQELR$IGD$FNAYAmyeARR-NH2 458 Ac-IWIAQELR$IGD$FNAYYAAmrR-NH2 459 Ac-IWIAQELR$IGD$FNAYFARR-NH2 460 Ac-IWIAQELR$IGD$FNAFYARR-NH2 461 Ac-RWIAQELR$IGD$FNAFYARR-NH2 462 Ac-RWIAQALR$IGD$FNAAmfYARR-NH2 463 Ac-RWIAQALR$IGD$FNAFYAAmrR-NH2 464 Ac-IWIA$r5ALRStIGD$FNAYYARR-NH2 465 Ac-IWIA$ALRStIGDEFN$s8YYARR-NH2 466 Ac-IWIAQALR$r5IGDStFNA$YARR-NH2 467 5-FAM-AhxIWIAQELRbKIGDbDFNAYYARR-NH2 468 5-FAM-AhxIWIAQELRbDIGDbKFNAYYARR-NH2 469 5-FAM-AhxIWIAQELR#IGD#FNAYYARR-NH2 470 5-FAM-AhxIWIAQELR#cmlIGD#cmlFNAYYARR-NH2 471 5-FAM-AhxRWIAQALR$IGD$FNAFYAHR-NH2 472 5-FAM-AhxRWIAQALRRIGDEFNAFYAHR-NH2 473 5-FAM-AhxRWIAQALR$IGD$FNAFYARH-NH2 474 5-FAM-AhxRWIAQALRRIGDEFNAFYARH-NH2 475 Ac-RWIAQALR$IGD$FNAFYAAR-NH2 476 Ac-RWIAQALR$IGD$FNAFYARA-NH2 477 Ac-RWIAQAAR$DIG$ANAFYARR-NH2 478 Ac-IWIAQAAR$DIG$ANAFYARR-NH2 479 5-FAM-AhxIWIAQELR$IED$FNAYYARR-NH2 480 5-FAM-AhxIWIAQELRRIEDEFNAYYARR-NH2 481 Ac-IWIAQELRNleIGDNleFNAYYARR-NH2 482 Ac-IWIAQELRAibIGDAibFNAYYARR-NH2 483 5-FAM-AhxRWIAQALR$IGD$FNAFYARR-NH2 484 5-FAM-AhxRWIAQALRRIGDEFNAFYARR-NH2 485 H-CAhxIWIAQALR$IGD$FNAFYARR-NH2 486 H-CAhxRWIAQALR$IGD$FNAFYARR-NH2 487 5-FAM-AhxIWIAQALR$IGD$FNAFYARR-NH2 488 OVA-CAhxIWIAQELR$IGD$FNAYYARR-NH2 489 OVA-CAhxRWIAQQLR$IGD$FNAYYARR-NH2 490 H-CAhxRWIAQAAR$IGR$ANAFYARR-NH2 491 H-CAhxRWIAQALR$IGD$FNAYYARR-NH2 492 H-CAhxIWIAQALRRIGDEFNAYYARR-NH2 493 OVA-CAhxRWIAQAAR$IGD$ANAYYARR-NH2 494 OVA-CAhxRWIAQALR$IGD$FNAYYARR-NH2 495 OVA-CAhxIWIAQALRRIGDEFNAYYARR-NH2 496 Ac-6xhAhxIWIAQAAR$DIG$ANAYYARR-NH2 497 Ac-FlagAhxIWIAQAAR$DIG$ANAYYARR-NH2 498 5-FAM-6xhAhxIWIAQAAR$DIG$ANAYYARR-NH2 499 5-FAM-FlagAhxIWIAQAAR$DIG$ANAYYARR-NH2 500 Ac-6xhAhxRWIAQALR$IGD$FNAFYARR-NH2 501 Ac-FlagAhxRWIAQALR$IGD$FNAFYARR-NH2 502 5-FAM-6xhAhxRWIAQALR$IGD$FNAFYARR-NH2 503 5-FAM-FlagAhxRWIAQALR$IGD$FNAFYARR-NH2 504 5-FAM-IWIAQELR$IGD$FNAYYARR-NH2 505 5-FAM-BaIWIAQELR$IGD$FNAYYARR-NH2 506 Ac-IWIAQELR%OcoIGD%OcoFNAYYARR-NH2 507 Ac-AhxIWIAQELR$IGD$FNAYYARR-NH2 508 Ac-BaIWIAQELR$IGD$FNAYYARR-NH2 509 H-CAhxIWIAQALR$IGD$FNAYYARR-NH2 510 5-FAM-AhxIWIAQELR$/IGD$/FNAYYARR-NH2 511 Ac-RWIAQALRRIGDEFNAFYAHH-NH2 512 5-FAM-AhxRWIAQALR$IGD$FNAFYAHH-NH2 513 5-FAM-AhxIWIAQELRRIGDEFNAYYARR-NH2 514 Ac-TatAhxIWIAQELRRIGDEFNAYYARR-NH2 515 5-FAM-TatAhxIWIAQELRRIGDEFNAYYARR-NH2 516 Ac-TatAhxIWIAQELR$IGD$FNAYYARR-NH2 517 5-FAM-TatAhxIWIAQELR$IGD$FNAYYARR-NH2 518 Ac-TatAhxRWIAQALR$IGD$FNAFYARR-NH2 519 5-FAM-TatAhxRWIAQALR$IGD$FNAFYARR-NH2 520 Ac-TatAhxRWIAQALRRIGDEFNAFYARR-NH2 521 5-FAM-TatAhxRWIAQALRRIGDEFNAFYARR-NH2 522 5-FAM-AhxRWIAQALR$/IGD$/FNAFYARR-NH2 523 5-FAM-AhxIWIAQALR$/IGD$/FNAFYARR-NH2 524 Ac-TatAhxIWIAQELR$IED$FNAYYARR-NH2 525 5-FAM-TatAhxIWIAQELR$IED$FNAYYARR-NH2 526 Ac-IWIAQELRRIEDDFNAYYARR-NH2 527 Ac-TatAhxIWIAQELRRIEDDFNAYYARR-NH2 528 5-FAM-TatAhxIWIAQELRRIEDDFNAYYARR-NH2 529 Ac-IWIAQELR$/iED$/FNAYYARR-NH2 530 5-FAM-AhxIWIAQELR$/IED$/FNAYYARR-NH2 531 5-FAM-AhxIWIAQAAR$DIG$ANAYYARR-NH2 532 Ac-TatAhxIWIAQAAR$DIG$ANAYYARR-NH2 533 5-FAM-TatAhxIWIAQAAR$DIG$ANAYYARR-NH2 534 Ac-IWIAQAARRDIGEANAYYARR-NH2 535 Ac-TatAhxIWIAQAARRDIGEANAYYARR-NH2 536 5-FAM-TatAhxIWIAQAARRDIGEANAYYARR-NH2 537 Ac-IWIAQAAR$DIG$ANAYYARR-NH2 538 5-FAM-AhxIWIAQAAR$/DIG$/ANAYYARR-NH2 539 Ac-IWIAQELRRIEDEFNAYYARR-NH2 540 Ac-IWIAQALR$/IGD$/FNAFYARR-NH2 541 Ac-RWIAQALR$IGD$FNAFYAHH-NH2 542 TatAhxIWIAQELRRIGDEFNAYYARR-NH2 543 5-FAM-TatAhxIWIAQELRRIEDEFNAYYARR-NH2 544 Ac-IWIAQALRRI$DEF$AYYARR-NH2 545 Ac-IWIAQALR$r8IGDEFN$YYARR-NH2 546 Ac-IWIAQELRRIEDEFNAYYARR-NH2 547 Ac-IWIAQELR$/IED$/FNAYYARR-NH2 548 Ac-IWIAQAARRDIGEANAYYARR-NH2 549 Ac-IWIAQAAR$/DIG$/ANAYYARR-NH2 550 Ac-IWIAQALR$/IGD$/FNAFYARR-NH2 551 Ac-RWIAQALR$IGD$FNAFYAHH-NH2 552 Ac-IWIAQALRRIGDEFNAFYARR-NH2 553 5-FAM-AhxIWIAQALR$r8IGDEFN$YYARR-NH2 554 Ac-RWIAQALR$IGD$FNA-OH 555 Ac-RWIAQALR$IGD$FNAFYA-OH 556 Ac-RWIAQALR$IGD$FNAF-OH 557 Ac-RWIAQALR$IGD$FNAFYARAmr-NH2 558 5-FAM-AhxIWIAQALR$/r8IGDEFN$/YYARR-NH2 559 Ac-IWIAQALR$/r8IGDEFN$/YYARR-NH2 560 OVA-CAhxIWIAQALR$IGD$FNAYYARR-NH2 561 Ac-IWIA$ALR$IGDEFNAYYARR-NH2 562 Ac-IWIA$/ALR$/IGDEFNAYYARR-NH2 563 5-FAM-AhxIWIA$/r5ALRSt//IGD$/FNAYYARR-NH2 564 5-FAM-AhxIWIA$ALRStIGDEFN$s8YYARR-NH2 565 HepIAQ$LR$IGD$FNAYYARRTag5-FAM 566 5-FAM-AhxIWIA$/ALRSt//IGDEFN$/s8YYARR-NH2 567 5-FAM-AhxIWIA$r5ALRStIGD$FNAYYARR-NH2 568 Ac-AAARAAARAAA$AAA$AAAAA-NH2 569 Ac-AAAAAAAR$AAA$AAAAAARA-NH2 570 Ac-AAARAAARAAAKAAAEAAAAA-NH2 571 Ac-AAAAAAARKAAAEAAAAAARA-NH2 572 Ac-AAARAAAAAARAAAAA-NH2 573 Ac-IWIAQELR%OIGD%OFNAYYARR-NH2 574 Ac-IWIA$/r5ALRSt//IGD$/FNAYYARR-NH2 575 Ac-IWIA$/ALRSt//IGDEFN$/s8YYARR-NH2 576 Ac-I$r8IAQALR$IGDEFNAYYARR-NH2 577 Ac-IWIAQALRRIG$r8EFNAYY$RR-NH2 578 Ac-I$/r8IAQALRVIGDEFNAYYARR-NH2 579 Ac-IWIAQALRRIG$/r8EFNAYY$/RR-NH2 580 Ac-RWIAQALR$IGD$FNAFYAibRR-NH2 581 Ac-RWIAQALR$IGD$FNASYARR-NH2 582 Ac-RWIAQALR$r5IGD$r5FNAFYARR-NH2 583 Ac-IWIAQALRRIGDEF$AYY$RR-NH2 584 Ac-RWIAEALR$IGD$FNAFYARR-NH2 585 Ac-RWIAEALR$IGD$FDAFYARR-NH2 586 Ac-RWIAQALR$/r5IGD$/FNAFYARR-NH2 587 Ac-RWIAQALR$/IGD$/r5FNAFYARR-NH2 588 Ac-IWIAQALRRIG$EFN$YYARR-NH2 589 Ac-IWIAQALRRIGD$FNA$YARR-NH2 590 Ac-IWIAQALRRIGDE$NAY$ARR-NH2 591 Ac-IWIAQALRRIGD$r8FNAYYA$R-NH2 592 %HepIAQ%LR%IGD%FNAYYARR-NH2 593 Ac-SYDDALLMLRSIGDSL-NH2 594 Ac-TEMMLAIMLRGIGDSL-NH2 595 Ac-WVSEFLAIGDYVDFHY-NH2 596 Ac-DLPVFILRNIGDSLIG-NH2 597 Ac-VSDFDDFLTSVLDIYL-NH2 598 5-FAM-AhxIWIA$ALR$IGDEFNAYYARR-NH2 599 5-FAM-AhxIWIAQALRRIGDEF$AYY$RR-NH2 600 5-FAM-AhxI$IAQ$LRRIGDEFNAYYARR-NH2 601 5-FAM-AhxI$IAQ$LR$IGD$FNAYYARR-NH2 602 5-FAM-AhxIWIAQALRRIG$EFN$YYARR-NH2 603 5-FAM-AhxIWIAQALRRIGD$FNA$YARR-NH2 604 5-FAM-AhxIWIAQALRRIGDE$NAY$ARR-NH2 605 5-FAM-AhxI$r8IAQALR$IGDEFNAYYARR-NH2 606 5-FAM-AhxIWIAQALRRIGD$r8FNAYYA$R-NH2 607 5-FAM-AhxIWIAQALRRIGD$r8FNAYYA$R-NH2 608 Ac-RWIAQALR$IGD$FDAFYARR-NH2 609 Ac-IWIA$ALRStIGD$r5FNAYYARR-NH2 610 Ac-IWIAQALR$IGDStFNA$r5YARR-NH2 611 Ac-RWIA$ALRStIGD$r5FNAFYARR-NH2 612 Ac-RWIAQALR$IGDStFNA$r5YARR-NH2 613 Ac-TENleNleLAINleLR$IGD$L-NH2 614 Ac-WVSEFL$IGD$VDFHY-NH2 615 Ac-DLPVFILR$IGD$LIG-NH2 616 Ac-VSDFDDFLT$VLD$YL-NH2 617 Ac-RWIAQALR$trIGD$trFNAFYARR-NH2 618 Ac-RWIAQALR$r5IGDStFNA$YARR-NH2 619 Ac-RWIAQALR$IGD$FNAibFYARR-NH2 620 Ac-RWIAQALR$IGD$FNAibFYAibRR-NH2 621 Ac-PEG3RWIAQALR$IGD$FNAFYARR-NH2 622 Ac-RWIAQALR$IGD$FNAFYAibHH-NH2 623 Ac-RWIAQALR$IGD$FNAibFYAHH-NH2 624 Ac-RWIAQALR$IGD$FNAibFYAibHH-NH2 625 Ac-RWIAQALR$IGD$FNAAmfYAHH-NH2 626 Ac-RWIAQALR$r5IGD$FNAFYARR-NH2 627 Ac-RWIAQALR$IGD$r5FNAFYARR-NH2 628 Ac-RWIAQALR$IGD$FNAFYARRPEG3-NH2 629 Ac-RWIAQ$r8LRRIGDStFNAFYA$s8R-NH2 630 Ac-R$r8IAQALRStIGDEFN$s8FYARR-NH2 631 Ac-RWIAQALR$IGD$FNADamfYARR-NH2 632 Ac-RWIAQALRbDIGDbKFNAFYARR-NH2 633 Ac-RWIAQALRbKIGDbDFNAFYARR-NH2 634 Ac-RWIAQALR$IAibD$FNAFYARR-NH2 635 Ac-R$r5IGDStFNA$YARR-NH2 636 Ac-RWIA$ALRStIGD$r5FNAAmfYARR-NH2 637 Ac-RWIA$r5ALRStIGD$FNAAmfYARR-NH2 638 Ac-IWIA$ALRStIGD$r5FNAAmfYARR-NH2 639 Ac-IWIA$r5ALRStIGD$FNAAmfYARR-NH2 640 Ac-RWIAQQLR$IGD$FNAFYAHH-NH2 641 Ac-RWIAQALR#c4IGD#c4FNAFYARR-NH2 642 Ac-RWIAQALR#c4eIGD#c4eFNAFYARR-NH2 643 Ac-RWIAQLLR$IGD$FNAFYARR-NH2 644 Ac-RWIAQALR$IGD$FNAhFYARR-NH2 645 Ac-RWIAQALR$IGD$FNAAmfYAAmrR-NH2 646 Biotin-IWIAQELR$IGD$FNAYYARR-NH2 647 5-FAM-AhxIWIA$/ALR$/IGDEFNAYYARR-NH2 648 5-FAM-AhxRWIAQALR$DIG$FNAFYARR-NH2 649 Ac-RWIAQALR$IGD$FNAFYARR-OH 650 Ac-IWIAQALR$5a5IGD$5n3FNAYYARR-NH2 651 Ac-RWIAQQFR$IGD$FNAYYARR-NH2 652 Ac-RWIAQQLR$IGD$FNAFYAHR-NH2 653 Ac-RWIAQQLR$IGD$FNAFYARH-NH2 654 Ac-RWIAQQLRRIGDEFNAFYAHH-NH2 655 Pr-WIAQQLR$IGD$FNAFYARR-NH2 656 Ac-WIAQQLR$IGD$FNAYYAR-NH2 657 Ac-WIAQQLR$IGD$FNAFYAR-NH2 658 Ac-IWIAQELD$IGD$FNAYYARR-NH2 659 Ac-RWIAQALD$IGD$FNAFYARR-NH2 660 Ac-IWIAQLLR$IGD$FNAFYARR-NH2 661 Ac-RWIAQQLR$IGD$INalNAYYARR-NH2 662 Ac-RWIAQLLR$IGD$INalNAYYARR-NH2 663 Ac-RWIAQALR$IGD$INalNAFYARR-NH2 664 Ac-RWIAQALR$5n3IGD$5a5FNAFYARR-NH2 665 Ac-RWIAQALR$5a5IGD$5n3FNAFYARR-NH2 666 Ac-RWIAQALR$/n3IGD$/a5FNAFYARR-NH2 667 Ac-RWIAQALR$/a5IGD$/n3FNAFYARR-NH2 668 Pr-WIAQQLR$IGD$FNASYARR-NH2 669 Pr-NIAQQLR$IGD$FNASYARR-NH2 670 Pr-SIAQQLR$IGD$FNASYARR-NH2 671 Pr-WIAQQLR$IGD$FNASYAR-NH2 672 Ac-RWIAQNLR$IGD$FNAYYARR-NH2 673 Ac-RWIAQRLR$IGD$FNAYYARR-NH2 674 Pr-WIAQ$LRR$GDAFNASYARR-NH2 675 Ac-RWIAQQLR$IGD$FNAYYAHR-NH2 676 Ac-RWIAQQLR$IGD$FNAYYARH-NH2 677 Ac-RWIAQQLR$IGD$FNAYYAHH-NH2 678 Pr-WIAQQLR$IGD$FNASIARR-NH2 679 Ac-IWIAQQLR$IED$FNAYYARR-NH2 680 FITC-BaIWIAQELR$IGD$FNAYYARR-NH2 681 FITC-BaIWIAQELD$IGD$FNAYYARR-NH2 682 FITC-BaRWIAQALR$IGD$FNAFYARR-NH2 683 FITC-BaRWIAQALD$IGD$FNAFYARR-NH2 684 HBS-IWAarAQELRRIGDEFNAYYARR-NH2 685 FITC-BaBaRWIAQALR$IGD$FNAFYARR-NH2 686 5-TAMRA-BaIWIAQELR$IGD$FNAYYARR-NH2 687 5-TAMRA-BaRWIAQALR$IGD$FNAFYARR-NH2 688 5-TAMRA-BaIWIAQELR$IED$FNAYYARR-NH2 689 Ac-RWIAQQLR$IGD$FNASYARR-NH2 690 Ac-RWIAQQLR$r5IGDStFNA$YARR-NH2 691 Ac-RWIAQALR$IGD$FNAC13FYARR-NH2 692 Ac-WIAQQLR$r5IGDStFNA$YARR-NH2 693 Ac-RIAQELR$IGD$FNAYYAR-NH2 694 Ac-RIAQQLR$IGD$FNAYYAR-NH2 695 Ac-RWIA4QAL7R$IGD$FNAFYARR-NH2 696 Ac-IWIAQELR#cIGR#cFNAYYARR-NH2 697 Ac-IWIAQELR#cIGD#cFNAYYARR-NH2 698 Ac-IWIAQELR#5n3IGD#5a5FNAYYARR-NH2 699 FITC-AhxIWIAQELR#5n3IGD#5a5FNAYYARR-NH2 700 HepIAQ$LR$IGD$FNAFYARR-NH2 701 IAQDprLRRIGDEFNAYYARR-NH2 702 IAQDprLRRIGDQFNAYYARR-NH2 703 WIADprALRRIGDEFNAYYARR-NH2 704 WIADprALRRIGDQFNAYYARR-NH2 705 HepIAQ$LR$IGD$FNAYYARRTag5-FAM- 706 Ac-TENleNleLAINleLR$IGD$L-NH2 707 5-TAMRA-BaIWIAQELR$IGD$FNAYYARR-NH2 708 Ac-RWIAQALR$IGD$FNAFYARR-NH2 709 Ac-IWIAQELR#sIGD#sFNAYYARR-NH2 710 Ac-IWIAQELR#sIAibD#sFNAYYARR-NH2 711 Ac-IWIAQELR$sIGD$sFNAYYARR-NH2 712 HepIAQ$LR$IGD$FNAYYARR-NH2 713 Ac-RWIAQALR$IGD$VNAFYARR-NH2 714 Pr-WIAQQLR$IGD$VNAFYARR-NH2 715 Ac-RWIAQALR$IGD$VNASYARR-NH2 716 Ac-RWIAQQLR$IGD$VNAFYARR-NH2 717 Ac-RWIAQQLR$IGD$VNASYARR-NH2 718 Ac-RWIAQALR$IGD$LNAFYARR-NH2 719 Ac-RWIAQQLR$IGD$LNAFYARR-NH2 720 Ac-KALETLRRVGDGV$RNH$TA-NH2 721 Pr-WIAQQLR$IGD$VNAFYARR-NH2 722 Pr-WIAQQLR$IGD$VNASYARR-NH2 723 Ac-RWIAQQLR$IGD$VNAFYAHH-NH2 724 Pr-WIAQQLR$IGD$VNAFYAR-NH2 725 Pr-WIAQQLR$IGD$FNAFYAHH-NH2 726 Pr-WIAQQLR$IGD$FNAFYARH-NH2 727 Pr-WIAQQLR$IGD$FNAFYAHR-NH2 728 Ac-RWIA4QAL7R$IGD$FNAFYARR-NH2 729 Pr-WIAQQLR$IGD$LNAYYARR-NH2 730 Pr-WIAQQLR$IGD$LNASYARR-NH2 731 Pr-WIAQQLR$IGD$LNAYYARH-NH2 732 Pr-WIAQQLR$IGD$LNAYYAHR-NH2 733 Pr-RIAQQLR$IGD$LNAYYARH-NH2 734 Pr-RIAQQLR$IGD$LNAYYAHR-NH2 735 Pr-RIAQQLR$IGD$LNAYYAHH-NH2 736 Pr-SIAQQLR$IGD$LNAYYARR-NH2 737 Pr-AibIAQQLR$IGD$LNAYYARR-NH2 738 Pr-YIAQQLR$IGD$LNAYYARR-NH2 739 Pr-RIAQQLR$IGD$LNAYYAR-NH2 740 Ac-RSIAQQLR$IGD$LNAYYARR-NH2 741 Ac-IWIAQELR$r5IGDStFNA$YARR-NH2 742 Pr-SIAQQLR$r5IGDStFNA$YARR-NH2 743 Ac-RWIA$r5ALRStDIL$FNAFYARR-NH2 744 Ac-RWIAQALR$5a5DIL$5n3FNAFYARR-NH2 745 Ac-RWIAQQLR$IGD$FNAYYAH-NH2 746 Ac-RWIA$r5ALRStIDL$FNAFYARR-NH2 747 Ac-RWIAQALR$5a5ILL$5n3FNAFYARR-NH2 748 Pr-RIAQQLR$IGD$FNAYYAHH-NH2 749 Pr-WIAQQLR$IGD$VNAYYAHR-NH2 750 Pr-WIAQQLR$IGD$VNAFYAHR-NH2 751 Pr-RIAQQLR$IGD$VNAYYAHR-NH2 752 Ac-RWIAQALR$5n3DIL$5a5FNAFYARR-NH2 753 Ac-R$r8IAQALRStIGDLFN$s8FYARR-NH2 754 Pr-RIAQQLR$IGD$FNAYYAH-NH2 755 Ac-RWIAQALR$5n3ILL$5a5FNAFYARR-NH2 756 Ac-RAIAQQLR$IGD$FNAYYAH-NH2 757 Pr-WIAQQLR$IGD$LNAYYAHH-NH2 758 Pr-SIAQQLR$IGD$LNAYYAHR-NH2 759 Ac-RWIAQQLR$IGD$VNAFYAHR-NH2 760 Ac-IWIA$QLRStIGD$r5FNAYYARR-NH2 761 Ac-RWIA$QLRStIGD$r5FNAYYARR-NH2 762 Ac-RWIAQQLR$IGD$FNAibFYAHH-NH2 763 Ac-RWIAQALR$IGD$LNAibFYAHH-NH2 764 Ac-IWIA$ALRStIGD$r5LNAYYARR-NH2 765 Ac-IWIAQALR$IGDStFNA$r5YAHH-NH2 766 Ac-RWIA$ALRStIGD$r5FNAYYARR-NH2 767 Pr-WIAQQLR$IGD$FNAYYAHH-NH2 768 Pr-SIAQQLR$IGD$FNAFYARR-NH2 769 Ac-WIAQQLR$IGD$FNAibFYAHH-NH2 770 Ac-RWIAQALR$IGD$VNAibFYAHH-NH2 771 Ac-IWIAQQLR$IGD$FNAibFYAHH-NH2 772 Ac-IWIAQALR$IGD$VNAibFYAHH-NH2 773 Ac-IWIAQALR$IGD$LNAibFYAHH-NH2 774 Ac-ELR$r5IGDStFNA$YARR-NH2 775 Ac-QELR$r5IGDStFNA$YARR-NH2 776 Ac-AQELR$r5IGDStFNA$YARR-NH2 777 Ac-IAQELR$r5IGDStFNA$YARR-NH2 778 Ac-RWIAQALR$r5IGDStFNA$YAHH-NH2 779 Ac-RWIAQQLR$r5IGDStFNA$YAHH-NH2 780 Ac-RWIAQALR$IGDStFNA$r5YAHH-NH2 781 Ac-RWIAQQLR$IGDStFNA$r5YAHH-NH2 782 Ac-IWIAQQFR$IGD$FNAYYARR-NH2 783 Ac-RWIAQQFR$IGD$FNAFYAHH-NH2 784 Ac-IWIAQALR$IGD$FNAibFYAHH-NH2 785 Ac-RWIAQQLR$IGD$FNAibYYAHH-NH2 786 Ac-IWIAQALR$IGD$FNAibYYAHH-NH2 787 Ac-RWIAQALR$IGD$FNAibYYAHH-NH2 788 Ac-RWIAQALR$IGD$LNAibYYAHH-NH2 789 Ac-RIAQQLR$IGD$FNAibFYAHH-NH2 790 Pr-WIAQQLR$IGD$FNAibYYAHH-NH2 791 Pr-RIAQQLR$IGD$FNAibYYAHH-NH2 792 Pr-NIAQQLR$IGD$FNAibFYAHH-NH2 793 Pr-SIAQQLR$IGD$FNAibFYAHH-NH2 794 Pr-NIAQQLR$IGD$FNAibYYARR-NH2 795 Pr-SIAQQLR$IGD$FNAibYYARR-NH2 796 Ac-IWIA$r5QLRStIGD$FNAYYARR-NH2 797 Ac-IWIA$ALDStIGD$r5FNAYYARR-NH2 798 Ac-RWIAQALD$IGD$FNAibFYAHH-NH2 799 Ac-RWIAQQLR$IGD$LNAibFYAHH-NH2 800 Ac-IWIAQQLR$IGD$LNAibFYAHH-NH2 801 Ac-RAIAQQLR$IGD$LNAibFYAHH-NH2 802 Ac-IRIAQQLR$IGD$LNAibFYAHH-NH2 803 Ac-RAIAQQLR$IGD$FNAibFYAHH-NH2 804 Ac-IRIAQQLR$IGD$FNAibFYAHH-NH2 805 Ac-RWIAQALR$IGA$FNAibFYAHH-NH2 806 Ac-RWIAQQLR$IGA$FNAFYAHH-NH2 807 Pr-RIAQQLR$IGD$FNAibFYAHH-NH2 808 Pr-WIAQQLR$IGD$FNAibFYAHH-NH2 809 Ac-RWIAQALR$IGD$INAibFYAHH-NH2 810 Ac-RWIAQALR$IGD$ChgNAibFYAHH-NH2 811 Ac-IWIAQQLR$IGD$VNAibFYAHH-NH2 812 Ac-IWIAQQLR$IGD$INAibFYAHH-NH2 813 Ac-RWIAQQLR$IGD$VNAibFYAHH-NH2 814 Ac-RWIAQQLR$IGD$INAibFYAHH-NH2 815 Pr-WIAQQLR$IGD$VNAibFYAHH-NH2 816 Ac-RWIAQAFR$IGD$VNAibFYAHH-NH2 817 Ac-RWIAQANleR$IGD$VNAibFYAHH-NH2 818 Ac-RWIAQAChgR$IGD$VNAibFYAHH-NH2 819 Ac-RWIAQALR$IGD$LNAFYAibHH-NH2 820 Ac-RWIAQALR$IGD$VNAFYAibHH-NH2 821 Ac-RWIAQALD$IGD$FNAibYYAHH-NH2 822 Ac-RWIA$r5ALRStIGD$FNAYYARR-NH2 823 Ac-IWIA$r5ALDStIGD$FNAYYARR-NH2 824 Ac-IWIA$r5ALRStIGD$FNAYYAibRR-NH2 825 Ac-IWIA$r5ALRStIGD$VNAYYARR-NH2 826 Ac-IRIAQALR$IGD$FNAibFYAHH-NH2 827 Ac-INIAQALR$IGD$FNAibFYAHH-NH2 828 Ac-IFIAQALR$IGD$FNAibFYAHH-NH2 829 Ac-ISIAQALR$IGD$FNAibFYAHH-NH2 830 Ac-IAibIAQALR$IGD$FNAibFYAHH-NH2 831 Ac-IWNleAQALR$IGD$FNAibFYAHH-NH2 832 Ac-IWIAQANleR$IGD$FNAibFYAHH-NH2 833 Ac-IWIAibQALR$IGD$FNAibFYAHH-NH2 834 Pr-IAQALR$IGD$FNAibFYAHH-NH2 835 Ac-IWIAQAibLR$IGD$FNAibFYAHH-NH2 836 Ac-IWIAQLLR$IGD$FNAibFYAHH-NH2 837 Ac-IWIAQFLR$IGD$FNAibFYAHH-NH2 838 Ac-IAIAAFLR$IGD$FNAibFYA-NH2 839 Ac-IWIAQALR$IGD$FNAibYYAibHH-NH2 840 Ac-IWIAQALR$IGD$FAAibFYAHH-NH2 841 Ac-RWIAQALR$r8IGDAibFN$FYAHH-NH2 842 Ac-RWIAQALR$r8IGDAFN$FYAHH-NH2 843 Ac-RWIA$r8ALRAibIG$AFNAibYYAHH-NH2 844 Ac-RWIA$r8ALRAIG$AFNAibYYAHH-NH2 845 Ac-IWIAQALR$IGD$ChaNAibFYAHH-NH2 846 5-FAM-BaIWIAQALR$IGD$FNAibFYAHH-NH2 847 5-FAM-BaRWIAQALR$IGD$LNAibFYAHH-NH2 848 Ac-IWILQALR$IAibD$FNAibFYAHH-NH2 849 Ac-IAIAQFLR$IGD$FNAibFYAHH-NH2 850 Ac-IWIAQALR$r8IGDAFN$FYAHH-NH2 851 Ac-IWIAQALR$r8IGDAibFN$FYAHH-NH2 852 Ac-IWIAQNLR$IGD$FNAibFYAHH-NH2 853 Ac-IWIAQHLR$IGD$FNAibFYAHH-NH2 854 Ac-RWIAAQLR$IGD$FNAibFYA-NH2 855 Ac-RNIAQALR$IGD$FNAibFYAHH-NH2 856 Ac-RFIAQALR$IGD$FNAibFYAHH-NH2 857 Ac-RAibIAQALR$IGD$FNAibFYAHH-NH2 858 Ac-RAIAQFLR$IGD$FNAibFYAHH-NH2 859 Ac-RWIAQLLR$IGD$FNAibFYAHH-NH2 860 Ac-RWIAQFLR$IGD$FNAibFYAHH-NH2 861 Ac-RWIAQAibLR$IGD$FNAibFYAHH-NH2 862 Ac-RWIAQALR$IGD$FNAibFYQHH-NH2 863 Ac-RWIAQHLR$IGD$FNAibFYAHH-NH2 864 Ac-RWIAQALR$NleGD$FNAibFYAHH-NH2 865 Pr-IAQLLR$IGD$FNAibFYAHH-NH2 866 Ac-RWIALALR$IGD$FNAibFYAHH-NH2 867 Pr-WIALALR$IGD$FNAibFYAHH-NH2 868 Ac-RAIAFALR$IGD$FNAibFYAHH-NH2 869 Ac-WIAQALR$IGD$FNAibFYQHH-NH2 870 Ac-CCPGCCBaIWIAQALR$IGD$FNAibFYAHH-NH2 871 Ac-CCPGCCBaRWIAQALR$IGD$VNAibFYAHH-NH2 872 Ac-CCPGCCBaRWIAQALR$IGD$LNAibFYAHH-NH2 873 Ac-IWIAQALR$IGD$FNAibFYQHH-NH2 874 Ac-RWIAQAibLR$r5IGDStFNA$YAHH-NH2 875 Ac-IWIAQLLR$IGD$FNAibFYQHH-NH2 876 Ac-RWIAQALR$IGD$FNRFYAHH-NH2 877 Ac-RWIAQALR$IGD$FNAFYRHH-NH2 878 Ac-RWIAQRLR$IGD$FNAFYAHH-NH2 879 Ac-RWIAQALR$IGD$FNARYAHH-NH2 880 Ac-RWIAERLR$IGD$FNAFYAHH-NH2 881 Ac-RWIAQALR$IGD$FNQFYAHH-NH2 882 Ac-RWIAQALR$IGD$FNAFYQHH-NH2 883 Ac-RWIAQELR$IGD$FNARYAHH-NH2 884 Ac-RWIAQALR$IGD$FNAQYAHH-NH2 885 Ac-RWIAQQLR$IGD$QNQQYQHH-NH2 886 Ac-IWIAAFLR$IGD$FNAibFYAHH-NH2 887 Ac-IWIAQALR$IGD$FNleAibFYAHH-NH2 888 Ac-IWIAQALR$IGD$FNleAibFYQHH-NH2 889 Ac-IWIAQAibLR$IGD$VNAibFYAHH-NH2 890 Ac-IWIAQLLR$IGD$VNAibFYAHH-NH2 891 Ac-IWIAQAAR$IGD$VNAibFYAHH-NH2 892 Ac-IAIAFALR$IGD$VNAibFYAHH-NH2 893 Ac-IWIALALR$IGD$VNAibFYAHH-NH2 894 Ac-IWIAQALR$IGD$VNAibFYQHH-NH2 895 Ac-IWIAQELR$4n4IGD$4a3FNAYYARR-NH2 896 Ac-IWIAQELR$4a3IGD$4n4FNAYYARR-NH2 897 Ac-IWIAQELR$4n3IGD$4a5FNAYYARR-NH2 898 Ac-IWIAQELR$4a5IGD$4n3FNAYYARR-NH2 899 Ac-IWIAQELR$4n5IGD$4a5FNAYYARR-NH2 900 Ac-IWIAQELR$4a5IGD$4n5FNAYYARR-NH2 901 Ac-RCouIAQALR$IGD$LNAibFYAHH-NH2 902 Ac-RCouIAQALR$r5IGDStFNA$YAHH-NH2 903 Ac-ICouIAQALRRIGDELNAibFYAHH-NH2 904 Ac-RCouIAQALRRIGDEFNAFYAHH-NH2 905 Ac-IWIAQALR$IGD$FNAFYAibHH-NH2 906 Ac-IWIALALR$IGD$FNAibFYAHH-NH2 907 Ac-IAIAFALR$IGD$FNAibFYAHH-NH2 908 Ac-RWIAQHLR$IGD$VNAibFYAHH-NH2 909 Ac-IWIAQHLR$IGD$VNAibFYAHH-NH2 910 Ac-RWIAQLLR$IGD$VNAibFYAHH-NH2 911 Ac-IWIAQLLR$IGD$VNAibFYAHH-NH2 912 Ac-IWIAQFLR$IGD$VNAibFYAHH-NH2 913 Ac-IWIAQALR$IGD$HNAibFYAHH-NH2 914 Ac-IWIAHLLR$IGD$VNAibFYAHH-NH2 915 Ac-IWIAQALR$IGD$INAibFYAHH-NH2 916 Ac-IWIAQLLR$IGD$INAibFYAHH-NH2 917 Ac-IHIAQLLR$IGD$FNAibFYAHH-NH2 918 Ac-IHIAQLLR$IGD$VNAibFYAHH-NH2 919 Ac-IWIAQLLR$IGD$VNAibFYAHA-NH2 920 Ac-IWIAQLLR$IGD$VNAibFYAAH-NH2 921 Ac-RWIAQALD$IGR$VNAibFYAHH-NH2 922 Ac-RWIAQALD$IGD$VNAibFYAHH-NH2 923 Ac-IWIAQALD$IGR$VNAibFYAHH-NH2 924 Ac-RWIAQAAR$IAibD$VNAibFYAHH-NH2 925 Ac-IWIAQALD$IGR$FNAibFYAHH-NH2 926 Ac-IWIAQALD$IGD$FNAibFYAHH-NH2 927 Ac-IWIAQAAR$IAibD$FNAibFYAHH-NH2 928 Ac-RWIAQALD$r5IGRStFNA$YAHH-NH2 929 Ac-IWIAQALR$r5IGDStFNA$YAHH-NH2 930 Ac-RWIAAQLR$IGD$VNAibFYAHH-NH2 931 Ac-IWIAAQLR$IGD$FNAibFYAHH-NH2 932 Ac-IWNleAQLLR$IGD$FNAibFYAHH-NH2 933 Ac-RWNleAQLLR$IGD$VNAibFYAHH-NH2 934 Ac-IWNleAibQLLR$IGD$FNAibFYAHH-NH2 935 Ac-RWNleAibQLLR$IGD$VNAibFYAHH-NH2 936 Ac-IRIAQLLR$IGD$FNAibFYAHH-NH2 937 Ac-ISIAQLLR$IGD$FNAibFYAHH-NH2 938 Ac-IRIAibQLLR$IGD$FNAibFYAHH-NH2 939 Ac-ISIAibQLLR$IGD$FNAibFYAHH-NH2 940 Ac-IWIA$r5ALDStIGR$FNAYYARR-NH2 941 Pr-WIAibQLLR$IGD$FNAibFYAibHH-NH2 942 Ac-IWIAibQLLR$IGD$VNAibFYAibHH-NH2 943 Pr-WIAQLLR$IGD$VNAibFYAibHH-NH2 944 Pr-WIAibQALR$IGD$FNAibFYAibHH-NH2 945 Ac-IWIAibQALR$IGD$VNAibFYAibHH-NH2 946 Ac-RWIAibQALR$IGD$VNAibFYAibHH-NH2 947 Ac-IWIAQAibLR$IGD$FNAibFYAibHH-NH2 948 Ac-IWIAQAibLR$IGD$VNAibFYAibHH-NH2 949 Ac-RWIAQAibLR$IGD$VNAibFYAibHH-NH2 950 Ac-IWIAQALR$IGD$VNAibFYAibHH-NH2 951 FITC-BaIWIAQELR$IGD$F 952 Ac-I$IAQ$LRRIGDEF$AYY$R-NH2 953 Ac-I$IAQ$LRNleIGDNleF$AYY$R-NH2 954 Ac-I$IAQ$LRRIGDEF$AYY$HH-NH2 955 Ac-I$IAQ$LRNleIGDNleF$AYY$HH-NH2 956 Ac-IWIA$ALR$IGD$FNA$YARR-NH2 957 Ac-IWIA$ALR$IGD$FNA$YAHH-NH2 958 Ac-IWIA$ALR$IGD$FNA$YAR-NH2 959 Ac-IWIAQ$LRA$GDAFNAYYAR-NH2 960 Ac-IWIAQ$LRA$GDAFNAYYAHH-NH2 961 Ac-IWIAQALR$r8IGDAFN$YYARR-NH2 962 Ac-IWIAQALR$r8IGDNleFN$YYARR-NH2 963 Ac-IWIAQALR$r8IGDAibFN$YYARR-NH2 964 Ac-IWIAQALR$r8IGDAFN$YYAHH-NH2 965 Ac-IWIAQALR$r8IGDNleFN$YYAHH-NH2 966 Ac-IWIAQALR$r8IGDAibFN$YYAHH-NH2 967 Ac-IWIAQALR$r8IGDAFN$YYAR-NH2 968 Ac-ICouIAQQLR$IGD$FNAibFYAHH-NH2 969 Ac-ICouIAQALR$IGD$FNAibFYAHH-NH2 970 Ac-ICouIAQELR$IGD$FNAibFYAHH-NH2 971 Ac-ICouIAQALD$IGR$FNAibFYAHH-NH2 972 Ac-ICouIAQALR$IGD$FNAibFYAAA-NH2 973 Ac-ICouIAQALR$IGD$FNAibFYA-NH2 974 Ac-RCou2IAQALR$r5IGDStFNA$YAHH-NH2 975 Ac-RCou2IAQQLR$r5IGDStFNA$YAHH-NH2 976 Ac-RCou2IAQALR$IGD$LNAibFYAHH-NH2 977 Ac-ICou2IAQALR$IGD$FNAibFYAHH-NH2 978 Ac-ICou2IAQQLR$IGD$FNAibFYAHH-NH2 979 Ac-RWIAQALR$5rn3IGDSta5FNA$5n3YAHH-NH2 980 Ac-RCou3IAQALR$r5IGDStFNA$YAHH-NH2 981 Ac-RCou3IAQQLR$r5IGDStFNA$YAHH-NH2 982 Ac-RCou3IAQALR$IGD$LNAibFYAHH-NH2 983 Ac-ICou3IAQALR$IGD$FNAibFYAHH-NH2 984 Ac-ICou3IAQQLR$IGD$FNAibFYAHH-NH2 985 Ac-IWIAQALR$IGD$FNAibFYAAA-NH2 986 Ac-IWIAQELR$IGD$FNAibFYAHH-NH2 987 Ac-IWIAQALR$r8IGAAibFN$FYAHH-NH2 988 Ac-IWIAQALR$IGD$FNAibFYA-NH2 989 Ac-ICou2IA$ALRStIGD$r5FNAYYARR-NH2 990 Ac-IDprIA$ALRStIGD$r5FNAYYARR-NH2 991 Ac-ICou2IA$QLRStIGD$r5FNAYYARR-NH2 992 Ac-IDprIA$QLRStIGD$r5FNAYYARR-NH2 993 Ac-IWIAQQLR$r5IGDStFNA$YAHH-NH2 994 Ac-ICou2IAQQLR$r5IGDStFNA$YAHH-NH2 995 Ac-IDprIAQQLR$r5IGDStFNA$YAHH-NH2 996 Ac-RDprIAQQLR$r5IGDStFNA$YAHH-NH2 997 Ac-IWIAQALR$IGD$FNAibCou2YAHH-NH2 998 Ac-IWIAQALR$IGD$FNAibCou3YAHH-NH2 999 Ac-IWIAQALR$IGD$FNAibDprYAHH-NH2 1000 Ac-IRIAQALR$IGD$FNAibCou2YAHH-NH2 1001 Ac-IRIAQALR$IGD$FNAibCou3YAHH-NH2 1002 Ac-IRIAQALR$IGD$FNAibDprYAHH-NH2 1003 Ac-IAibIAQALR$IGD$FNAibCou2YAHH-NH2 1004 Ac-IAibIAQALR$IGD$FNAibCou3YAHH-NH2 1005 Ac-IAibIAQALR$IGD$FNAibDprYAHH-NH2 1006 Ac-ICou2IAQALR$IGD$FAAibFYAHH-NH2 1007 Ac-ICou3IAQALR$IGD$FAAibFYAHH-NH2 1008 Ac-IDprIAQALR$IGD$FAAibFYAHH-NH2 1009 Pam-IWIAQALR$IGD$FNAibFYAHH-NH2 1010 Pam-ICou2IAQALR$IGD$FNAibFYAHH-NH2 1011 Pam-ICou3IAQALR$IGD$FNAibFYAHH-NH2 1012 Pam-IDprIAQALR$IGD$FNAibFYAHH-NH2 1013 Ac-IWIAQALR$5n3IGD$5a5FNAibFYAHH-NH2 1014 Ac-IWIAQALR$5a5IGD$5n3FNAibFYAHH-NH2 1015 Ac-IWIAQALR$r8IGDAFN$YYARR-NH2 1016 Ac-ICou2IAQELR$IGD$FNAibFYAHH-NH2 1017 Ac-ICou2IAQALD$IGR$FNAibFYAHH-NH2 1018 Ac-ICou2IAQALR$IGD$FNAibFYAAA-NH2 1019 Ac-ICou2IAQALR$IGD$FNAibFYA-NH2 1020 Ac-RCou2IAQQLR$IGD$FNAibFYAHH-NH2 1021 Ac-RCou2IAQALR$IGD$FNAibFYAHH-NH2 1022 Ac-RCou2IAQELR$IGD$FNAibFYAHH-NH2 1023 Ac-RCou2IAQALD$IGR$FNAibFYAHH-NH2 1024 Ac-RCou2IAQALR$IGD$FNAibFYAAA-NH2 1025 Ac-RCou2IAQALR$IGD$FNAibFYA-NH2 1026 Ac-IWIAQALR$r8IGAAibFN$FYAHH-NH2 1027 Ac-IWIA$ALRStIGD$r5FNAYYARR-NH2 1028 Pr-Cou2IAQALR$IGD$FNAibFYAHH-NH2 1029 Pr-Cou2IAQALR$IGD$FNAibFYQHH-NH2 1030 Ac-RWIAQELR$IGD$FNAibFYAHH-NH2 1031 Ac-RWIAQALD$IGR$FNAibFYAHH-NH2 1032 Ac-RWIAQALR$IGD$FNAibFYAAA-NH2 1033 Ac-RWIAQALR$IGD$FNAibFYA-NH2 1034 Ac-ICou2IAQALRRIGDEFNAYYAHH-NH2 1035 Ac-ICou2IAQELR$IGD$FNAibFYAHH-NH2 1036 Ac-ICou2IAQALD$IGR$FNAibFYAHH-NH2 1037 Ac-ICou4IAQALR$r5IGDStFNA$YAHH-NH2 1038 Ac-RCou4IAQALR$r5IGDStFNA$YAHH-NH2 1039 Ac-ICou4IAQALR$IGD$FNAibFYAHH-NH2 1040 Ac-ICou4IAQQLR$IGD$FNAibFYAHH-NH2 1041 Ac-RCou4IAQALR$IGD$LNAibFYAHH-NH2 1042 Ac-IWIAQALR$5a5IGD$5n3FNAibFYAHH-NH2 1043 Ac-RWIAQALR$/rn3IGDSta/FNA$/n3YAHH-NH2 1044 Ac-ICou2IA$r5ALRStIGD$FNAYYARR-NH2 1045 Ac-ICou2IA$r5QLRStIGD$FNAYYARR-NH2 1046 Ac-ICou4IA$r5ALRStIGD$FNAYYARR-NH2 1047 Ac-ICou4IA$r5QLRStIGD$FNAYYARR-NH2 1048 Ac-RCou2IAQALR$IGDStFNA$r5YAHH-NH2 1049 Ac-RCou4IAQALR$IGDStFNA$r5YAHH-NH2 1050 Ac-ICou7IAQQLR$r5IGDStFNA$YAHH-NH2 1051 Ac-RCou7IAQQLR$r5IGDStFNA$YAHH-NH2 1052 Ac-IWIAQALR$IGD$FNAibCou7YAHH-NH2 1053 Ac-IRIAQALR$IGD$FNAibCou7YAHH-NH2 1054 Ac-ICou2IAQQLR$r5IGDStFNA$YAHH-NH2 1055 Ac-AAIAQALR$IGD$FNAibFYAHH-NH2 1056 Ac-AAIAQALR$IGD$FNAibFYA-NH2 1057 Ac-IWIAQALR$IGD$FNAibFYAAAAa-NH2 1058 Ac-IWIAQALR$IGD$FNAibAAAAAa-NH2 1059 Ac-IWIAQALR$IGD$FNAibFYAHHAAAAa-NH2 1060 Ac-IWIAQALA$IGD$FNAibFYAHH-NH2 1061 Ac-IWIAQALR$IGD$FAAibFYA-NH2 1062 Ac-IWIALALR$IGD$FAAibFYA-NH2 1063 Ac-IWIALALR$IGD$FNAibFYA-NH2 1064 Ac-IWIALALR$IGD$FAAibFYAHH-NH2 1065 Ac-IWIALALR$IGD$FAAAAA-NH2 1066 Ac-IWIALALR$IGD$FNAAAA-NH2 1067 Ac-IWIALLLR$IGD$FAAibFYAHH-NH2 1068 Ac-IWIALLLR$IGD$FNAibFYAHH-NH2 1069 Ac-IWIALLLR$IGD$FNAibFYA-NH2 1070 Ac-IWIALLLR$IGD$FNAibFYAAAAAa-NH2 1071 Ac-RWIALQLR$r5IGDStFNA$YAHH-NH2 1072 Ac-RWIAQQLR$r5IGDStFNA$YA-NH2 1073 Ac-RWIAQQLR$r5IGDStFNA$YAAa-NH2 1074 Ac-RWIALQLR$r5IGDStFNA$YAAa-NH2 1075 Ac-RCou2IALQLR$r5IGDStFNA$YAHH-NH2 1076 Ac-RCou2IAQQLR$r5IGDStFNA$YA-NH2 1077 Ac-RCou2IAQQLR$r5IGDStFNA$YAAa-NH2 1078 Ac-RCou2IALQLR$r5IGDStFNA$YAAa-NH2 1079 Ac-RCou2IAQALR$5rn3IGDSta5FNA$5n3YAHH-NH2 1080 RCou4IAQALR$5rn3IGDSta5FNA$5n3YAHH-NH2 1081 5-FAM-BaRWIAQALR$r5IGDStFNA$YAHH-NH2 1082 Ac-RCou2IAQQLRAibIGDAibFNAAibYAHH-NH2 1083 Ac-RWIAQQLRAibIGDAibFNAAibYAHH-NH2 1084 Ac-RCou2IAQELR$r5IGDStFNA$YAHH-NH2 1085 Ac-RWIAQELR$r5IGDStFNA$YAHH-NH2 1086 Ac-ICou2IAQELR$IGD$FNAYYARR-NH2 1087 Ac-IWIAQALR4Me$5a5IGD$5n3FNAibFYAHH-NH2 1088 Ac-IWIAQALR4Ph$5a5IGD$5n3FNAibFYAHH-NH2 1089 Ac-NleWIAQALR$r5IGDStFNA$YAHH-NH2 1090 Ac-KWIAQALR$r5IGDStFNA$YAHH-NH2 1091 Ac-RWIAQALR$r5IGDStFNA$YQHH-NH2 1092 Ac-IWIAQALR$r5IGDStFNA$YQHH-NH2 1093 Ac-NleCou2IAQALR$r5IGDStFNA$YAHH-NH2 1094 Ac-KCou2IAQALR$r5IGDStFNA$YAHH-NH2 1095 Ac-IWIAQELRRIGDEF$AYY$RR-NH2 1096 Ac-IWIAQELRRIGDEFN$YYA$R-NH2 1097 Ac-IWIAQEL$r8RIGDEF$AYYARR-NH2 1098 Ac-IWIAQELR$r8IGDEFN$YYARR-NH2 1099 Ac-IWIAQELRRIGD$r8FNAYYA$R-NH2 1100 Ac-I$IAQStLRRIGD$s8FNAYYARR-NH2 1101 Ac-I$r8IAQELRStIGD$r5FNAYYARR-NH2 1102 Ac-I$r8IAQELRStIGDEFN$s8YYARR-NH2 1103 Ac-IWI$QELStRIGDEF$s8AYYARR-NH2 1104 Ac-IWIA$ELRStIGD$r5FNAYYARR-NH2 1105 Ac-IWIA$r5ELRStIGD$FNAYYARR-NH2 1106 Ac-IWIA$ELRStIGDEFN$s8YYARR-NH2 1107 Ac-IWIAQ$r8LRRIGDStFNAYYA$s8R-NH2 1108 Ac-IWIAQEL$r8RIGDEFStAYY$r5RR-NH2 1109 Ac-IWIAQELR$IGDStFNAYYA$s8R-NH2 1110 Ac-IWIAQELR$r8IGDEFNStYYA$r5R-NH2 1111 Ac-I$IAQ$LRRIGDEF$AYY$RR-NH2 1112 Ac-I$IAQ$LRRIGDEFN$YYA$R-NH2 1113 Ac-IWI$QEL$RIGDEF$AYY$RR-NH2 1114 Ac-IWI$QEL$RIGDEFN$YYA$R-NH2 1115 Ac-IWIA$ELR$IGDEF$AYY$RR-NH2 1116 Ac-IWIA$ELR$IGDEFN$YYA$R-NH2 1117 Ac-I$r8IAQELR$IGDEF$AYY$RR-NH2 1118 Ac-I$r8IAQELR$IGDEFN$YYA$R-NH2 1119 Ac-IWIAQ$r8LRRIGD$F$AYY$RR-NH2 1120 Ac-IWIAQ$r8LRRIGD$FN$YYA$R-NH2 1121 Ac-I$IAQ$L$r8RIGDEF$AYYARR-NH2 1122 Ac-I$IAQ$LR$r8IGDEFN$YYARR-NH2 1123 Ac-I$IAQ$LRRIGD$r8FNAYYA$R-NH2 1124 Ac-IWI$QEL$RIGD$r8FNAYYA$R-NH2 1125 Ac-IWIA$ELR$IGD$r8FNAYYA$R-NH2 1126 5-FAM-BaIWIAQELRRIGDEFNAYYARR-NH2 1127 5-FAM-BaIWIAQELR$IGD$FNAYYARR-NH2 1128 5-FAM-BaNLWAAQRYGRELR$NleSD$FVDSFKK-NH2 1129 5-FAM-BaKALETLR$VGD$VQRNHETAF-NH2 1130 Ac-RCou2IAQALR$IGD$FNAFYARR-NH2 1131 Ac-RCou2IAQALR$5rn3IGDSta5FNA$5n3YAHH-NH2 1132 Ac-IWI$QEL$RIGDEF$AYY$RR-NH2 1133 Ac-IWIAQ$r8LRRIGD$F$AYY$RR-NH2 1134 Ac-IWIAQ$r8LRRIGD$FN$YYA$R-NH2 1135 Ac-IWI$QEL$RIGD$r8FNAYYA$R-NH2 1136 Ac-IWIA$ELR$IGD$r8FNAYYA$R-NH2 1137 Ac-IWI$QELStRIGDEF$s8AYYARR-NH2 1138 Ac-IWIAQ$r8LRRIGDStFNAYYA$s8R-NH2 1139 Ac-IWIAQEL$r8RIGDEFStAYY$r5RR-NH2 1140 Ac-I$r8IAQELR$IGDEF$AYY$RR-NH2 1141 Ac-IWIAQ$r8LRRIGD$FNAYYARR-NH2 1142 Ac-IWIAQELRRIGDEF$AYY$RR-NH2 1143 Ac-IWIAQALR$r8IGDAFN$YYA-NH2 1144 Ac-WIAQALR$r8IGDAFN$YYA-NH2 1145 Ac-IAQALR$r8IGDAFN$YYA-NH2 1146 Ac-IAAALR$r8IGDAFN$YYA-NH2 1147 Ac-IAQALA$r8IGDAFN$YYA-NH2 1148 Ac-IAQALR$r8IADAFN$YYA-NH2 1149 Ac-IAQALR$r8IGDAAN$YYA-NH2 1150 Ac-IAQALR$r8IGDAFA$YYA-NH2 1151 Ac-IAQALR$r8IGDAFN$AYA-NH2 1152 Ac-IAQALR$r8IGDAFN$YAA-NH2 1153 Ac-IAQALRRIGDEFNAYYAHH-NH2 1154 Ac-IAQALR$IGD$FNAYYAHH-NH2 1155 Ac-IWIAQALRRIGDEFNAYYAHH-NH2 1156 Ac-IWIAQALR$IGD$FNAYYAHH-NH2 1157 Ac-I$IAQ$LR$IGD$FNAYYAHH-NH2 1158 HepIAQ$LRRIGDEFNAYYAHH-NH2 1159 HepIAQ$LR$IGD$FNAYYAHH-NH2 1160 HepIA$ALRRIGDEFNAYYAHH-NH2 1161 HepIA$ALR$IGD$FNAYYAHH-NH2 1162 Ac-I$IAQ$LRRIGDEF$AYY$AA-NH2 1163 Ac-I$IAQ$LRRIGDEF$AYY$A-NH2 1164 Ac-I$IAA$LRRIGDEF$AYY$A-NH2 1165 Ac-I$IAV$LRRIGDEF$AYY$A-NH2 1166 Ac-I$IAL$LRRIGDEF$AYY$A-NH2 1167 Ac-I$IAI$LRRIGDEF$AYY$A-NH2 1168 Ac-I$IAF$LRRIGDEF$AYY$A-NH2 1169 Ac-I$IAY$LRRIGDEF$AYY$A-NH2 1170 Ac-I$IAG$LRRIGDEF$AYY$A-NH2 1171 Ac-I$IAQ$LRAIGDAF$AYY$A-NH2 1172 Ac-I$IAQ$LRAIGDAibF$AYY$A-NH2 1173 Ac-I$IAQ$LRAibIGDAF$AYY$A-NH2 1174 Ac-I$IAQ$LRAibIGDAibF$AYY$A-NH2 1175 Ac-I$IAQ$LRNleIGDNleF$AYY$A-NH2 1176 Ac-I$IAQ$LRNleIGDAibF$AYY$A-NH2 1177 Ac-I$IAQ$LRAibIGDNleF$AYY$A-NH2 1178 Ac-I$IAQ$LR$r8IGDEFN$YYA-NH2 1179 Ac-I$IAA$LR$r8IGDEFN$YYA-NH2 1180 Ac-I$IAV$LR$r8IGDEFN$YYA-NH2 1181 Ac-I$IAL$LR$r8IGDEFN$YYA-NH2 1182 Ac-I$IAI$LR$r8IGDEFN$YYA-NH2 1183 Ac-I$IAF$LR$r8IGDEFN$YYA-NH2 1184 Ac-I$IAY$LR$r8IGDEFN$YYA-NH2 1185 Ac-I$IAG$LR$r8IGDEFN$YYA-NH2 1186 Ac-I$IAQ$LR$r8IGDAFN$YYA-NH2 1187 Ac-I$IAQ$LR$r8IGDNleFN$YYA-NH2 1188 Ac-I$IAQ$LR$r8IGDAibFN$YYA-NH2 1189 Ac-IWIA$ELR$IGD$r8FNAYYA$A-NH2 1190 Ac-IWIA$ALR$IGD$r8FNAYYA$A-NH2 1191 Ac-IWIA$VLR$IGD$r8FNAYYA$A-NH2 1192 Ac-IWIA$LLR$IGD$r8FNAYYA$A-NH2 1193 Ac-IWIA$ILR$IGD$r8FNAYYA$A-NH2 1194 Ac-IWIA$FLR$IGD$r8FNAYYA$A-NH2 1195 Ac-IWIA$YLR$IGD$r8FNAYYA$A-NH2 1196 Ac-IWIA$GLR$IGD$r8FNAYYA$A-NH2 1197 Ac-IWIA$SLR$IGD$r8FNAYYA$A-NH2 1198 Ac-I$IAQ$LRRIGDEF$AYY$-NH2 1199 Ac-IWIA$ELR$IGD$r8FNAYYA$-NH2 1200 Ac-WIAQALR$r8IGDAFN$YYA-NH2 1201 Ac-IAQALR$r8IGDAFN$YYA-NH2 1202 Ac-IAAALR$r8IGDAFN$YYA-NH2 1203 Ac-IAQALA$r8IGDAFN$YYA-NH2 1204 Ac-IAQALR$r8IADAFN$YYA-NH2 1205 Ac-IAQALR$r8IGDAAN$YYA-NH2 1206 Ac-IAQALR$r8IGDAFA$YYA-NH2 1207 Ac-IAQALR$r8IGDAFN$AYA-NH2 1208 Ac-IAQALR$r8IGDAFN$YAA-NH2 1209 Ac-I$IAL$LR$r8IGDAFN$YYA-NH2 1210 Ac-I$IALALR$IGDAFN$YYA$A-NH2 1211 Ac-IWIA$ALR$IGDAFN$YYA$A-NH2 1212 Ac-IWIA$ALRStIGDAFN$s8YYA-NH2 1213 Ac-IWIA$ALRStIGDNleFN$s8YYA-NH2 1214 Ac-I$r8IALALRStIGDAFN$s8YYA-NH2 1215 Ac-I$r8IALALRStIGD$r5FNAYYA-NH2 1216 Ac-IWIALALR$IGD$FNAYYA-NH2 1217 Ac-IWIAQALR$IGD$FNAYYA-NH2 1218 Ac-I$IAA$LRAibIGDAibF$AYY$A-NH2 1219 Ac-I$IAL$LRAibIGDAibF$AYY$A-NH2 1220 Ac-I$r8IALALR$IGDAF$AYY$A-NH2 1221 Ac-I$r8IAQELRStIGDAFN$s8YYARR-NH2 1222 Ac-I$r8IAQALRStIGDAFN$s8YYA-NH2 1223 HBS-IAAarALRRIGDEFNAYYAHH-NH2 1224 HBS-IAAarALR$IGD$FNAYYAHH-NH2 1225 HBS-IWAarAQALRRIGDEFNAYYAHH-NH2 1226 HBS-IWAarAQALR$IGD$FNAYYAHH-NH2 1227 HepIAQ$LRRIGDEFNAYYAHH-NH2 1228 HepIAQ$LR$IGD$FNAYYAHH-NH2 1229 HepIA$ALR$IGD$FNAYYAHH-NH2 1230 Ac-I$IAQ$LR$r8IGDEFN$YYA-NH2 1231 Ac-I$IAA$LR$r8IGDEFN$YYA-NH2 1232 Ac-I$IAV$LR$r8IGDEFN$YYA-NH2 1233 Ac-I$IAV$LR$r8IGDEFN$YYA-NH2 1234 Ac-I$IAI$LR$r8IGDEFN$YYA-NH2 1235 Ac-I$IAI$LR$r8IGDEFN$YYA-NH2 1236 Ac-I$IAY$LR$r8IGDEFN$YYA-NH2 1237 Ac-I$IAL$LR$r8IGDEFN$YYA-NH2 1238 Ac-I$IAL$LR$r8IGDEFN$YYA-NH2 1239 Ac-I$IAF$LR$r8IGDEFN$YYA-NH2 1240 Ac-I$IAF$LR$r8IGDEFN$YYA-NH2 1241 Ac-I$IAQ$LR$r8IGDAFN$YYA-NH2 1242 Ac-I$IAQ$LR$r8IGDNleFN$YYA-NH2 1243 Ac-I$IAQ$LR$r8IGDAibFN$YYA-NH2 1244 Ac-I$IAQ$LRRIGDEF$AYY$-NH2 1245 Ac-I$IAA$LRRIGDEF$AYY$-NH2 1246 Ac-I$IAV$LRRIGDEF$AYY$-NH2 1247 Ac-I$IAL$LRRIGDEF$AYY$-NH2 1248 Ac-I$IAI$LRRIGDEF$AYY$-NH2 1249 Ac-I$IAF$LRRIGDEF$AYY$-NH2 1250 Ac-I$IAY$LRRIGDEF$AYY$-NH2 1251 Ac-I$IAG$LRRIGDEF$AYY$-NH2 1252 Ac-I$IAQ$LRAIGDAF$AYY$-NH2 1253 Ac-I$IAQ$LRAIGDAibF$AYY$-NH2 1254 Ac-I$IAQ$LRAibIGDAF$AYY$-NH2 1255 Ac-I$IAQ$LRAibIGDAibF$AYY$-NH2 1256 Ac-I$IAQ$LRNleIGDNleF$AYY$-NH2 1257 Ac-I$IAQ$LRNleIGDAibF$AYY$-NH2 1258 Ac-I$IAQ$LRAibIGDNleF$AYY$-NH2 1259 Ac-IWIA$ALR$IGD$r8FNAYYA$-NH2 1260 Ac-IWIA$VLR$IGD$r8FNAYYA$-NH2 1261 Ac-IWIA$LLR$IGD$r8FNAYYA$-NH2 1262 Ac-IWIA$ILR$IGD$r8FNAYYA$-NH2 1263 Ac-IWIA$FLR$IGD$r8FNAYYA$-NH2 1264 Ac-IWIA$YLR$IGD$r8FNAYYA$-NH2 1265 Ac-IWIA$GLR$IGD$r8FNAYYA$-NH2 1266 Ac-IWIA$SLR$IGD$r8FNAYYA$-NH2 1267 Ac-I$r8IALALR$IGDAFN$YYA$A-NH2 1268 Ac-IWIA$r5ALRStIGDNleFN$r8YYA-NH2 1269 Ac-I$IAL$LR$r8IGDAFN$YYA-NH2 1270 Ac-ICou2IAQALR$r5IGDStFNA$YAHH-NH2 1271 Ac-I$IAQ$LRAIGDAF$AYY$-NH2 1272 Ac-I$IAQ$LRAIGDAibF$AYY$-NH2 1273 Ac-I$IAQ$LRAIGDAibF$AYY$-NH2 1274 Ac-I$IAQ$LRAibIGDAF$AYY$-NH2 1275 Ac-I$IAQ$LRAibIGDAF$AYY$-NH2 1276 Ac-I$IAQ$LRAibIGDAibF$AYY$-NH2 1277 Ac-I$IAQ$LRAibIGDAibF$AYY$-NH2 1278 Ac-I$IAQ$LRNleIGDNleF$AYY$-NH2 1279 Ac-I$IAQ$LRNleIGDNleF$AYY$-NH2 1280 Ac-I$IAQ$LRNleIGDAibF$AYY$-NH2 1281 Ac-I$IAQ$LRNleIGDAibF$AYY$-NH2 1282 Ac-IWIA$VLR$IGD$r8FNAYYA$-NH2 1283 Ac-IWIA$LLR$IGD$r8FNAYYA$-NH2 1284 Ac-IWIA$FLR$IGD$r8FNAYYA$-NH2 1285 Ac-IWIA$SLR$IGD$r8FNAYYA$-NH2 1286 Ac-IWIA$ELR$IGD$r8FNAYYA$-NH2 1287 Ac-IWIA$ALR$IGD$r8FNAYYA$-NH2 1288 Ac-I$IAA$LRRIGDEF$AYY$-NH2 1289 Ac-I$IAA$LRRIGDEF$AYY$-NH2 1290 Ac-I$IAL$LRRIGDEF$AYY$RR-NH2 1291 Ac-I$IAQ$LRAibIGDAF$AYY$RR-NH2 1292 Ac-I$IAL$LRAibIGDAF$AYY$RR-NH2 1293 Ac-I$IAL$LRRIGDEF$AYY$R-NH2 1294 Ac-I$IAQ$LRAibIGDAF$AYY$R-NH2 1295 Ac-I$IAL$LRAibIGDAF$AYY$R-NH2 1296 Ac-I$IAY$LR$r8IGDEFN$YYARR-NH2 1297 Ac-I$IAL$LR$r8IGDEFN$YYARR-NH2 1298 Ac-I$IAF$LR$r8IGDEFN$YYARR-NH2 1299 Ac-I$IAQ$LR$r8IGDEFN$YYAR-NH2 1300 Ac-I$IAY$LR$r8IGDEFN$YYAR-NH2 1301 Ac-I$IAL$LR$r8IGDEFN$YYAR-NH2 1302 Ac-I$IAF$LR$r8IGDEFN$YYAR-NH2 1303 Ac-IWIA$ALR$IGD$r8FNAYYA$R-NH2 1304 Ac-IWIALALR$r8IGDEFN$YYARR-NH2 1305 Ac-IWIAYALR$r8IGDEFN$YYARR-NH2 1306 Ac-IWIAQALR$r8IGDEFN$YYAR-NH2 1307 Ac-IWIALALR$r8IGDEFN$YYAR-NH2 1308 Ac-IWIAYALR$r8IGDEFN$YYAR-NH2 1309 Ac-IWIALALR$IGD$FNAYYARR-NH2 1310 Ac-IWIAYALR$IGD$FNAYYARR-NH2 1311 Ac-IWIALALR$IGD$FNAYYAR-NH2 1312 Ac-IWIAYALR$IGD$FNAYYAR-NH2 1313 Ac-IWIALALR$IGD$FNAYYAH-NH2 1314 Ac-IWIAQALR%r8IGDAFN%YYA-NH2 1315 Ac-I$IAL$LRRIGDEF$AYY$RR-NH2 1316 Ac-I$IAL$LRRIGDEF$AYY$R-NH2 1317 Ac-I$IAQ$LRAibIGDAF$AYY$R-NH2 1318 Ac-I$IAL$LRAibIGDAF$AYY$R-NH2 1319 Ac-I$IAY$LR$r8IGDEFN$YYARR-NH2 1320 Ac-I$IAL$LR$r8IGDEFN$YYARR-NH2 1321 Ac-IWIA$ALR$IGD$r8FNAYYA$R-NH2 1322 Ac-I$IAY$LR$r8IGDEFN$YYAR-NH2 1323 Ac-I$IAL$LR$r8IGDEFN$YYAR-NH2 1324 Ac-I$IAF$LR$r8IGDEFN$YYAR-NH2 1325 Ac-I$IAQ$LR$r8IGDAFN$YYARR-NH2 1326 Ac-I$IAY$LR$r8IGDAFN$YYARR-NH2 1327 Ac-I$IAL$LR$r8IGDAFN$YYARR-NH2 1328 Ac-I$IAF$LR$r8IGDAFN$YYARR-NH2 1329 Ac-I$IAQ$LR$r8IGDAFN$YYAR-NH2 1330 Ac-I$IAY$LR$r8IGDAFN$YYAR-NH2 1331 Ac-I$IAL$LR$r8IGDAFN$YYAR-NH2 1332 Ac-I$IAF$LR$r8IGDAFN$YYAR-NH2 1333 Ac-IWIAQALR$r8IGDEFN$YYA-NH2 1334 Ac-IWIAQALR$r8IGDQFN$YYA-NH2 1335 Ac-IWIAAALR$r8IGDEFN$YYA-NH2 1336 Ac-IWIAAALR$r8IGDQFN$YYA-NH2 1337 Ac-IWIAAALR$r8IGDAFN$YYA-NH2 1338 Ac-IWIAQALR$r8IGDEFA$YYA-NH2 1339 Ac-IWIAQALR$r8IGDQFA$YYA-NH2 1340 Ac-IWIAQALR$r8IGDAFA$YYA-NH2 1341 Ac-IWIAQALCit$r8IGDAFN$YYA-NH2 1342 Ac-IWIAQALCit$r8IGDQFN$YYA-NH2 1343 Ac-IWIAQALH$r8IGDAFN$YYA-NH2 1344 Ac-IWIAQALH$r8IGDQFN$YYA-NH2 1345 Ac-IWIAQALQ$r8IGDAFN$YYA-NH2 1346 Ac-IWIAQALQ$r8IGDQFN$YYA-NH2 1347 Ac-IWIAQALR$r8IGDAAN$YYA-NH2 1348 Ac-IWIAQALR$r8IGDQAN$YYA-NH2 1349 Ac-IWIAQALR$r8IGDAIN$YYA-NH2 1350 Ac-IWIAQALR$r8IGDQIN$YYA-NH2 1351 Ac-IWIAQAAR$r8IGDAAN$YYA-NH2 1352 Ac-IWIAQALR$r8IADAFN$YYA-NH2 1353 Ac-IWIAQALR$r8IADQFN$YYA-NH2 1354 Ac-IWIAQALR$r8AGDAFN$YYA-NH2 1355 Ac-IWIAQALR$r8AGDQFN$YYA-NH2 1356 Ac-IWIAQALR$r8FGDAFN$YYA-NH2 1357 Ac-IWIAQALR$r8FGDQFN$YYA-NH2 1358 Ac-IWFAQALR$r8IGDAFN$YYA-NH2 1359 Ac-IWFAQALR$r8IGDQFN$YYA-NH2 1360 Ac-IAIAQALR$r8IGDAFN$YYA-NH2 1361 Ac-IWIAQALA$r8IGDAFN$YYA-NH2 1362 Ac-IWIAQALR$r8IGNAFN$YYA-NH2 1363 Ac-IWIAQAAR$r8IGDAFN$YYA-NH2 1364 FITC-BaIWIAQALR$r8IGDAFN$YYA-NH2 1365 5-FAM-BaIWIAQALR$r8IGDAFN$YYA-NH2 1366 5-FAM-BaIWIAQALR$r8IGDEFN$YYA-NH2 1367 Ac-WLAQLLR$IGD$IN-NH2 1368 Ac-ICou2IALALR$IGD$FNAYYA-NH2 1369 Ac-ICou2IALALR$IGD$FNAibFYA-NH2 1370 Ac-I$IAY$LR$r8IGDAFN$YYARR-NH2 1371 Ac-I$IAL$LR$r8IGDAFN$YYARR-NH2 1372 Ac-I$IAF$LR$r8IGDAFN$YYARR-NH2 1373 Ac-I$IAQ$LR$r8IGDAFN$YYAR-NH2 1374 Ac-I$IAY$LR$r8IGDAFN$YYAR-NH2 1375 Ac-I$IAL$LR$r8IGDAFN$YYAR-NH2 1376 Ac-I$IAF$LR$r8IGDAFN$YYAR-NH2 1377 Ac-IAIAQALR$r8IGDAFN$YYA-NH2 1378 Ac-IWIAQALR$r8IGDEFN$YYA-NH2 1379 Ac-IWIAQALR$r8IGDQFN$YYA-NH2 1380 Ac-IWIAAALR$r8IGDEFN$YYA-NH2 1381 Ac-IWIAAALR$r8IGDQFN$YYA-NH2 1382 Ac-IWIAAALR$r8IGDAFN$YYA-NH2 1383 Ac-IWIAQALR$r8IGDAFA$YYA-NH2 1384 Ac-IWIAQALCit$r8IGDAFN$YYA-NH2 1385 Ac-IWIAQALCit$r8IGDQFN$YYA-NH2 1386 Ac-IWIAQALH$r8IGDAFN$YYA-NH2 1387 Ac-IWIAQALH$r8IGDQFN$YYA-NH2 1388 Ac-IWIAQALQ$r8IGDAFN$YYA-NH2 1389 Ac-IWIAQALQ$r8IGDQFN$YYA-NH2 1390 Ac-IWIAQALR$r8IGDAAN$YYA-NH2 1391 Ac-IWIAQALR$r8IGDAIN$YYA-NH2 1392 Ac-IWIAQALR$r8IGDQIN$YYA-NH2 1393 Ac-IWIAQAAR$r8IGDAAN$YYA-NH2 1394 Ac-IWIAQALR$r8IADAFN$YYA-NH2 1395 Ac-IWIAQALR$r8IADQFN$YYA-NH2 1396 Ac-IWIAQALR$r8AGDAFN$YYA-NH2 1397 Ac-IWIAQALR$r8AGDQFN$YYA-NH2 1398 Ac-IWIAQALR$r8FGDAFN$YYA-NH2 1399 Ac-IWIAQALR$r8FGDQFN$YYA-NH2 1400 Ac-IWFAQALR$r8IGDAFN$YYA-NH2 1401 Ac-IWFAQALR$r8IGDQFN$YYA-NH2 1402 Ac-IWIAQALA$r8IGDAFN$YYA-NH2 1403 Ac-IWIAQALR$r8IGNAFN$YYA-NH2 1404 Ac-IWIAQAAR$r8IGDAFN$YYA-NH2 1405 Ac-IWIALALG$IGD$VNAYYA-NH2 1406 Ac-IWIALALG$IGD$INAYYA-NH2 1407 Ac-IWIALALG$IGN$VNAYYA-NH2 1408 Ac-IWIALALG$IGN$INAYYA-NH2 1409 Ac-IWIALALN$IGD$VNAYYA-NH2 1410 Ac-IWIALALN$IGD$INAYYA-NH2 1411 Ac-IWIALALN$IGN$VNAYYA-NH2 1412 Ac-IWIALALN$IGN$INAYYA-NH2 1413 Ac-IWIALALR$IGD$VNAFYA-NH2 1414 Ac-IWIALALR$IGD$VNAYYA-NH2 1415 Ac-IWIALALR$IGD$VNAibFYA-NH2 1416 Ac-IWIALALR$IGD$VNAibYYA-NH2 1417 Ac-IWFALALR$IGD$FNAYYA-NH2 1418 Ac-IWYALALR$IGD$FNAYYA-NH2 1419 Ac-IWVALALR$IGD$FNAYYA-NH2 1420 Ac-IWLALALR$IGD$FNAYYA-NH2 1421 Ac-IWIAQALR$IGD$VNAYYA-NH2 1422 Ac-IWIAQALR$IGD$INAYYA-NH2 1423 Ac-IWIALALR$IGD$INAYYA-NH2 1424 Ac-IWIALLLR$IGD$VNAYYA-NH2 1425 Ac-IWIALLLR$IGD$INAYYA-NH2 1426 Ac-IWIALALG$IGD$FNAYYA-NH2 1427 Ac-IWIALALS$IGD$FNAYYA-NH2 1428 Ac-IWIALALH$IGD$FNAYYA-NH2 1429 Ac-IWIALALN$IGD$FNAYYA-NH2 1430 Ac-IWIALAIG$IGD$VNAYYA-NH2 1431 Ac-IWIALAIG$IGD$INAYYA-NH2 1432 Ac-IWIALAIN$IGD$VNAYYA-NH2 1433 Ac-IWIALAIN$IGD$INAYYA-NH2 1434 Ac-IWIALALN$IGD$VNAYYAHH-NH2 1435 Ac-IWIALALN$IGD$INAYYAHH-NH2 1436 Ac-IWIALALN$IGN$VNAYYAHH-NH2 1437 Ac-IWIALALN$IGN$INAYYAHH-NH2 1438 Ac-IWIA$r5ALGStIGD$VNAYYA-NH2 1439 Ac-IWIA$r5ALGStIGD$INAYYA-NH2 1440 Ac-IWIA$r5ALGStIGN$VNAYYA-NH2 1441 Ac-IWIA$r5ALGStIGN$INAYYA-NH2 1442 Ac-IWIALALR$IGD$VNAAAA-NH2 1443 Ac-IWIALALG$IGD$VNAAAA-NH2 1444 Ac-IWIALALD$IGD$VNAAAA-NH2 1445 Ac-IWIALALN$IGD$VNAAAA-NH2 1446 Ac-IWIALALR$IGD$VN-NH2 1447 Ac-IWIALALG$IGD$VN-NH2 1448 Ac-IWIALALD$IGD$VN-NH2 1449 Ac-IWIALALN$IGD$VN-NH2 1450 5-FAM-BaIWIA$r5ALGStIGD$VNAYYA-NH2 1451 5-FAM-BaIWIALALR$IGD$FNAibFYA-NH2 1452 5-FAM-BaIWIA$r5ALGStIGN$INAYYA-NH2 1453 5-FAM-BaIWIALALG$IGN$INAYYA-NH2 1454 FITC-BaIWIA$r5ALGStIGD$VNAYYA-NH2 1455 FITC-BaIWIALALR$IGD$FNAibFYA-NH2 1456 5-FAM-BaIWIA$r5ALGStIGD$INAYYA-NH2 1457 Ac-IWIAQALR$r8IGDQFA$YYA-NH2 1458 Ac-RWIAQALR$IGD$LNAFYAHH-NH2 1459 Ac-RWIAQELR$IGD$LNAibFYAHH-NH2 1460 Ac-RWIAQALR$IGD$LNAibFYA-NH2 1461 Ac-RWIAQAAR$IGD$LNAibFYAHH-NH2 1462 Ac-RWIAQALA$IGD$LNAibFYAHH-NH2 1463 Ac-RWIAQALR$IGN$LNAibFYAHH-NH2 1464 Ac-RWIAQALCit$IGD$LNAibFYAHH-NH2 1465 Ac-RWIAQALR$IGD$ANAibFYAHH-NH2 1466 Ac-RCou2IAQAAR$IGD$LNAibFYAHH-NH2 1467 Ac-RCou2IAQALA$IGD$LNAibFYAHH-NH2 1468 Ac-RCou2IAQALR$IGN$LNAibFYAHH-NH2 1469 Ac-RCou2IAQALCit$IGD$LNAibFYAHH-NH2 1470 Ac-IWIAMOALCit$r8IGDAFN$YYA-NH2 1471 Ac-IWIAMO2ALCit$r8IGDAFN$YYA-NH2 1472 Ac-RWIAMOALR$IGD$LNAibFYAHH-NH2 1473 Ac-RWIAMO2ALR$IGD$LNAibFYAHH-NH2 1474 Ac-RWIAQALR$IGN$VNAibFYAHH-NH2 1475 Ac-RWIAQAAR$IGD$VNAibFYAHH-NH2 1476 Ac-RWIAQALA$IGD$VNAibFYAHH-NH2 1477 Ac-RWIAQALCit$IGD$VNAibFYAHH-NH2 1478 Ac-RCou2IAQALR$IGD$VNAibFYAHH-NH2 1479 Ac-RCou2IAQALR$IGN$VNAibFYAHH-NH2 1480 Ac-RCou2IAQAAR$IGD$VNAibFYAHH-NH2 1481 Ac-RCou2IAQALA$IGD$VNAibFYAHH-NH2 1482 Ac-RCou2IAQALCit$IGD$VNAibFYAHH-NH2 1483 Ac-IWChaAQALR$r8IGDAFN$YYA-NH2 1484 Ac-IWhhLAQALR$r8IGDAFN$YYA-NH2 1485 Ac-IWAdmAQALR$r8IGDAFN$YYA-NH2 1486 Ac-IWhChaAQALR$r8IGDAFN$YYA-NH2 1487 Ac-IWhFAQALR$r8IGDAFN$YYA-NH2 1488 Ac-IWIglAQALR$r8IGDAFN$YYA-NH2 1489 Ac-IWF4CF3AQALR$r8IGDAFN$YYA-NH2 1490 Ac-IWF4tBuAQALR$r8IGDAFN$YYA-NH2 1491 Ac-IW2NalAQALR$r8IGDAFN$YYA-NH2 1492 Ac-IWBipAQALR$r8IGDAFN$YYA-NH2 1493 Ac-IWIAQAChaR$r8IGDAFN$YYA-NH2 1494 Ac-IWIAQAhhLR$r8IGDAFN$YYA-NH2 1495 Ac-IWIAQAAdmR$r8IGDAFN$YYA-NH2 1496 Ac-IWIAQAhChaR$r8IGDAFN$YYA-NH2 1497 Ac-IWIAQAhAdmR$r8IGDAFN$YYA-NH2 1498 Ac-IWIAQAhFR$r8IGDAFN$YYA-NH2 1499 Ac-IWIAQAIglR$r8IGDAFN$YYA-NH2 1500 Ac-IWIAQAF4CF3R$r8IGDAFN$YYA-NH2 1501 Ac-IWIAQAF4tBuR$r8IGDAFN$YYA-NH2 1502 Ac-IWIAQA2NalR$r8IGDAFN$YYA-NH2 1503 Ac-IWIAQABipR$r8IGDAFN$YYA-NH2 1504 Ac-IWIAQALR$r8CbaGDAFN$YYA-NH2 1505 Ac-IWIAQALR$r8hLGDAFN$YYA-NH2 1506 Ac-IWIAQALR$r8ChaGDAFN$YYA-NH2 1507 Ac-IWIAQALR$r8TbaGDAFN$YYA-NH2 1508 Ac-IWIAQALR$r8hhLGDAFN$YYA-NH2 1509 Ac-IAmWIAQALR$r8IGDAFN$YYA-NH2 1510 Ac-IAibIAQALR$r8IGDAFN$YYA-NH2 1511 Ac-AmLWIAQALR$r8IGDAFN$YYA-NH2 1512 Ac-IWAmLAQALR$r8IGDAFN$YYA-NH2 1513 Ac-IWIAibQALR$r8IGAmDAFN$YYA-NH2 1514 Ac-IWIAAibALR$r8IGDAFN$YYA-NH2 1515 Ac-IWIAQAAmLR$r8IGDAFN$YYA-NH2 1516 Ac-IWIAQALR$r8IGAmDAFN$YYA-NH2 1517 Ac-IWIAQALR$r8IGDAFN$F4FYA-NH2 1518 Ac-IWIAQALR$r8IGDAFN$AYA-NH2 1519 Ac-IWIAQALR$r8IGDAFN$YF4FA-NH2 1520 Ac-IWIAQALR$r8IGDAFN$YYAib-NH2 1521 Ac-I$r8IAQALRStIGDEFN$s8YYA-NH2 1522 Ac-IWIA$ALRStIGDEFN$s8YYA-NH2 1523 Ac-IWIAQALR$r8IGDEFNStYYA$r5A-NH2 1524 Ac-IWIAQAACit$r8IGDAFN$YYA-NH2 1525 Ac-IWIAQALCit$r8IGNAFN$YYA-NH2 1526 Ac-IWIAQALCit$r8IGDAAN$YYA-NH2 1527 Ac-IWIAQALCit$r8IGDAVN$YYA-NH2 1528 Ac-RWIAQAChaR$IGD$LNAibFYAHH-NH2 1529 Ac-RWIAQAhhLR$IGD$LNAibFYAHH-NH2 1530 Ac-RWIAQAAdmR$IGD$LNAibFYAHH-NH2 1531 Ac-RWIAQAhChaR$IGD$LNAibFYAHH-NH2 1532 Ac-RWIAQAhFR$IGD$LNAibFYAHH-NH2 1533 Ac-RWIAQAIglR$IGD$LNAibFYAHH-NH2 1534 Ac-RWIAQAF4CF3R$IGD$LNAibFYAHH-NH2 1535 Ac-RWIAQAF4tBuR$IGD$LNAibFYAHH-NH2 1536 Ac-RWIAQA2NalR$IGD$LNAibFYAHH-NH2 1537 Ac-RWIAQABipR$IGD$LNAibFYAHH-NH2 1538 Ac-IWIAQ$r8LRRIGD$FNAYYA-NH2 1539 Ac-IWIAQ$r8LRAIGD$FNAYYA-NH2 1540 Ac-IWIAQ$r8LCitRIGD$FNAYYA-NH2 1541 Ac-IWIAQ$r8LCitAIGD$FNAYYA-NH2 1542 Ac-IWIAMOALCit$r8IGDAFN$YYA-NH2 1543 Ac-IWIAMO2ALCit$r8IGDAFN$YYA-NH2 1544 Ac-IWIAQALD$r8IGRAFN$YYA-NH2 1545 Ac-RWIAQALD$IGR$LNAibFYAHH-NH2 1546 Ac-RPEIWIAQAID$r8IGDAVN$YYAR-NH2 1547 Ac-RPEIWIAQAID$IGD$VNAYYAR-NH2 1548 Ac-DWIAQALR$r8IGDAFN$YYR-NH2 1549 Ac-IWAAQALR$r8IGDAFN$YYA-NH2 1550 Ac-IWTbaAQALR$r8IGDAFN$YYA-NH2 1551 Ac-IWhLAQALR$r8IGDAFN$YYA-NH2 1552 Ac-IWChgAQALR$r8IGDAFN$YYA-NH2 1553 Ac-IWAc6cAQALR$r8IGDAFN$YYA-NH2 1554 Ac-IWAc5cAQALR$r8IGDAFN$YYA-NH2 1555 Ac-EWIAAALR$r8IGDAFN$YYA-NH2 1556 Ac-RWIAAALR$r8IGDAFN$YYA-NH2 1557 Ac-KWIAAALR$r8IGDAFN$YYA-NH2 1558 Ac-HWIAAALR$r8IGDAFN$YYA-NH2 1559 Ac-SWIAAALR$r8IGDAFN$YYA-NH2 1560 Ac-QWIAAALR$r8IGDAFN$YYA-NH2 1561 Ac-AWIAAALR$r8IGDAFN$YYA-NH2 1562 Ac-AibWIAAALR$r8IGDAFN$YYA-NH2 1563 Ac-FWIAAALR$r8IGDAFN$YYA-NH2 1564 Ac-IDIAAALR$r8IGDAFN$YYA-NH2 1565 Ac-IRIAAALR$r8IGDAFN$YYA-NH2 1566 Ac-IHIAAALR$r8IGDAFN$YYA-NH2 1567 Ac-ISIAAALR$r8IGDAFN$YYA-NH2 1568 Ac-INIAAALR$r8IGDAFN$YYA-NH2 1569 Ac-ILIAAALR$r8IGDAFN$YYA-NH2 1570 Ac-IFIAAALR$r8IGDAFN$YYA-NH2 1571 Ac-I2NalIAAALR$r8IGDAFN$YYA-NH2 1572 Ac-IWISAALR$r8IGDAFN$YYA-NH2 1573 Ac-IWILAALR$r8IGDAFN$YYA-NH2 1574 Ac-IWIFAALR$r8IGDAFN$YYA-NH2 1575 Ac-IWIALALR$r8IGDAFN$YYA-NH2 1576 Ac-IWIAAALF4g$r8IGDAFN$YYA-NH2 1577 Ac-IWIAAALK$r8IGDAFN$YYA-NH2 1578 Ac-IWIAAALR$r8IAbuDAFN$YYA-NH2 1579 Ac-IWIAAALR$r8IVDAFN$YYA-NH2 1580 Ac-IWIAAALR$r8IGEAFN$YYA-NH2 1581 Ac-IWIAAALR$r8IGDAGN$YYA-NH2 1582 Ac-IWIAQALR$r8IGDAWN$YYA-NH2 1583 Ac-IWIAQALR$r8IGDAhFN$YYA-NH2 1584 Ac-IWIAQALR$r8IGDAF4CF3N$YYA-NH2 1585 Ac-IWIAQALR$r8IGDAF4tBuN$YYA-NH2 1586 Ac-IWIAQALR$r8IGDA2NalN$YYA-NH2 1587 Ac-IWIAQALR$r8IGDABipN$YYA-NH2 1588 Ac-IWIAAALR$r8IGDAFD$YYA-NH2 1589 Ac-IWIAAALR$r8IGDAFE$YYA-NH2 1590 Ac-IWIAAALR$r8IGDAFQ$YYA-NH2 1591 Ac-IWIAAALR$r8IGDAFS$YYA-NH2 1592 Ac-IWIAAALR$r8IGDAFH$YYA-NH2 1593 Ac-IWIAAALR$r8IGDAFN$LYA-NH2 1594 Ac-IWIAQALR$r8IGDAFN$YAA-NH2 1595 Ac-IWIAQALR$r8IGDAFN$YLA-NH2 1596 Ac-IWIAQALR$r8IGDAFN$YChaA-NH2 1597 Ac-IWIAQALR$r8IGDAFN$YhFA-NH2 1598 Ac-IWIAQALR$r8IGDAFN$YWA-NH2 1599 Ac-IWIAQALR$r8IGDAFN$Y2NalA-NH2 1600 Ac-IWIAAALR$r8IGDAFN$YYD-NH2 1601 Ac-IWIAAALR$r8IGDAFN$YYE-NH2 1602 Ac-IWIAAALR$r8IGDAFN$YYQ-NH2 1603 Ac-IWIAAALR$r8IGDAFN$YYS-NH2 1604 Ac-IWIAAALR$r8IGDAFN$YYH-NH2 1605 Ac-IWIAAALR$r8IGDAFN$YYR-NH2 1606 Ac-IWIAAALR$r8IGDAFN$YYK-NH2 1607 Ac-IWIAQALR$rda6IGDAFN$da5YYA-NH2 1608 Ac-IWIAQAAmLR$r8IGDAFN$YYA-NH2 1609 Ac-IWIAQALR$r8IGAmDAFN$YYA-NH2 1610 Ac-IWIAQALR$r8IGDAFN$F4FYA-NH2 1611 Ac-IWIAQALR$r8IGDAFN$YYAib-NH2 1612 Ac-IWIAQAACit$r8IGDAFN$YYA-NH2 1613 Ac-IWIAQALCit$r8IGNAFN$YYA-NH2 1614 Ac-IWIAQALCit$r8IGDAAN$YYA-NH2 1615 Ac-IWIAQALCit$r8IGDAVN$YYA-NH2 1616 Ac-IWIAQ$r8LRAIGD$FNAYYA-NH2 1617 Ac-IWIAQ$r8LCitAIGD$FNAYYA-NH2 1618 Ac-IWIAQALR$r8IGDAFN$AYA-NH2 1619 Ac-IWIAQ$r8LRRIGD$FNAYYA-NH2 1620 Ac-IWIAQALR$r8hLGDAFN$F4FYA-NH2 1621 Ac-IWIAQALR$r8hLGDAFN$YF4FA-NH2 1622 Ac-IWIAQALR$r8hLGDAFN$F4FF4FA-NH2 1623 Ac-AWIAAALR$r8hLGDAFN$YF4FA-NH2 1624 Ac-AWIAAALR$r8hLGDAFN$AF4FA-NH2 1625 Ac-IWIAQAAR$r8hLGDAFN$F4FF4FA-NH2

In the sequences shown above and elsewhere, the following abbreviations are used: “Nle” represents norleucine, “Aib” represents 2-aminoisobutyric acid, “Ac” represents acetyl, and “Pr” represents propionyl. Amino acids represented as “$” are alpha-Me S5-pentenyl-alanine olefin amino acids connected by an all-carbon crosslinker comprising one double bond. Amino acids represented as “$r5” are alpha-Me R5-pentenyl-alanine olefin amino acids connected by an all-carbon comprising one double bond. Amino acids represented as “$s8” are alpha-Me S8-octenyl-alanine olefin amino acids connected by an all-carbon crosslinker comprising one double bond. Amino acids represented as “$r8” are alpha-Me R8-octenyl-alanine olefin amino acids connected by an all-carbon crosslinker comprising one double bond. “Ahx” represents an aminocyclohexyl linker. The crosslinkers are linear all-carbon crosslinker comprising eight or eleven carbon atoms between the alpha carbons of each amino acid. Amino acids represented as “$/” are alpha-Me S5-pentenyl-alanine olefin amino acids that are not connected by any crosslinker. Amino acids represented as “$/r5” are alpha-Me R5-pentenyl-alanine olefin amino acids that are not connected by any crosslinker. Amino acids represented as “$/s8” are alpha-Me S8-octenyl-alanine olefin amino acids that are not connected by any crosslinker. Amino acids represented as “$/r8” are alpha-Me R8-octenyl-alanine olefin amino acids that are not connected by any crosslinker. Amino acids represented as “Amw” are alpha-Me tryptophan amino acids. Amino acids represented as “Aml” are alpha-Me leucine amino acids. Amino acids represented as “Amf” are alpha-Me phenylalanine amino acids. Amino acids represented as “2ff” are 2-fluoro-phenylalanine amino acids. Amino acids represented as “3ff” are 3-fluoro-phenylalanine amino acids. Amino acids represented as “St” are amino acids comprising two pentenyl-alanine olefin side chains, each of which is crosslinked to another amino acid as indicated. Amino acids represented as “St//” are amino acids comprising two pentenyl-alanine olefin side chains that are not crosslinked. Amino acids represented as “%St” are amino acids comprising two pentenyl-alanine olefin side chains, each of which is crosslinked to another amino acid as indicated via fully saturated hydrocarbon crosslinks. Amino acids represented as “Ba” are beta-alanine. The lower-case character “e” or “z” within the designation of a crosslinked amino acid (e.g., “$er8” or “$zr8”) represents the configuration of the double bond (E or Z, respectively). In other contexts, lower-case letters such as “a” or “f” represent D amino acids (e.g., D-alanine, or D-phenylalanine , respectively). Amino acids designated as “NmW” represent N-methyltryptophan. Amino acids designated as “NmY” represent N-methyltyrosine. Amino acids designated as “NmA” represent N-methylalanine. “Kbio” represents a biotin group attached to the side chain amino group of a lysine residue. Amino acids designated as “Sar” represent sarcosine. Amino acids designated as “Cha” represent cyclohexyl alanine. Amino acids designated as “Cpg” represent cyclopentyl glycine. Amino acids designated as “Chg” represent cyclohexyl glycine. Amino acids designated as “Cba” represent cyclobutyl alanine. Amino acids designated as “F₄I” represent 4-iodo phenylalanine. “7L” represents N15 isotopic leucine. Amino acids designated as “F₃Cl” represent 3-chloro phenylalanine. Amino acids designated as “F4cooh” represent 4-carboxy phenylalanine. Amino acids designated as “F₃4F₂” represent 3,4-difluoro phenylalanine. Amino acids designated as “6clW” represent 6-chloro tryptophan. Amino acids designated as “$rda6” represent alpha-Me R6-hexynyl-alanine alkynyl amino acids, crosslinked via a dialkyne bond to a second alkynyl amino acid. Amino acids designated as “$da5” represent alpha-Me S5-pentynyl-alanine alkynyl amino acids, wherein the alkyne forms one half of a dialkyne bond with a second alkynyl amino acid. Amino acids designated as “$ra9” represent alpha-Me R9-nonynyl-alanine alkynyl amino acids, crosslinked via an alkyne metathesis reaction with a second alkynyl amino acid. Amino acids designated as “$a6” represent alpha-Me S6-hexynyl-alanine alkynyl amino acids, crosslinked via an alkyne metathesis reaction with a second alkynyl amino acid. The designation “iso1” or “iso2” indicates that the peptidomimetic macrocycle is a single isomer. Amino acids designated as “Cit” represent citrulline.

Amino acids which are used in the formation of triazole crosslinkers are represented according to the legend indicated below. Stereochemistry at the alpha position of each amino acid is S unless otherwise indicated. For azide amino acids, the number of carbon atoms indicated refers to the number of methylene units between the alpha carbon and the terminal azide. For alkyne amino acids, the number of carbon atoms indicated is the number of methylene units between the alpha position and the triazole moiety plus the two carbon atoms within the triazole group derived from the alkyne.

$5a5 Alpha-Me alkyne 1,5 triazole (5 carbon) $5n3 Alpha-Me azide 1,5 triazole (3 carbon) $4rn6 Alpha-Me R-azide 1,4 triazole (6 carbon) $4a5 Alpha-Me alkyne 1,4 triazole (5 carbon)

In some embodiments, peptidomimetic macrocycles are provided which are derived from BIM. In some embodiments, the present invention provides a peptidomimetic macrocycle comprising an amino acid sequence which is at least about 60% identical to BIM, further comprising at least two macrocycle-forming linkers, wherein the first of said two macrocycle-forming linkers connects a first amino acid to a second amino acid, and the second of said two macrocycle-forming linkers connects a third amino acid to a fourth amino acid.

Two or more peptides can share a degree of homology. In some embodiments, the pair of peptides is a peptidomimetic macrocycle of the present disclosure and a peptide identical to BIM. A pair of peptides can have, for example, up to about 20% pairwise homology, up to about 25% pairwise homology, up to about 30% pairwise homology, up to about 35% pairwise homology, up to about 40% pairwise homology, up to about 45% pairwise homology, up to about 50% pairwise homology, up to about 55% pairwise homology, up to about 60% pairwise homology, up to about 65% pairwise homology, up to about 70% pairwise homology, up to about 75% pairwise homology, up to about 80% pairwise homology, up to about 85% pairwise homology, up to about 90% pairwise homology, up to about 95% pairwise homology, up to about 96% pairwise homology, up to about 97% pairwise homology, up to about 98% pairwise homology, up to about 99% pairwise homology, up to about 99.5% pairwise homology, or up to about 99.9% pairwise homology. A pair of peptides can have, for example, at least about 20% pairwise homology, at least about 25% pairwise homology, at least about 30% pairwise homology, at least about 35% pairwise homology, at least about 40% pairwise homology, at least about 45% pairwise homology, at least about 50% pairwise homology, at least about 55% pairwise homology, at least about 60% pairwise homology, at least about 65% pairwise homology, at least about 70% pairwise homology, at least about 75% pairwise homology, at least about 80% pairwise homology, at least about 85% pairwise homology, at least about 90% pairwise homology, at least about 95% pairwise homology, at least about 96% pairwise homology, at least about 97% pairwise homology, at least about 98% pairwise homology, at least about 99% pairwise homology, at least about 99.5% pairwise homology, at least about 99.9% pairwise homology.

Various methods and software programs can be used to determine the homology between two or more peptides, such as NCBI BLAST, Clustal W, MAFFT, Clustal Omega, AlignMe, Praline, or another suitable method or algorithm.

In some embodiments, a peptidomimetic macrocycle of the invention comprises a helix, for example an α-helix. In some embodiments, a peptidomimetic macrocycle of the invention comprises an α,α-disubstituted amino acid. In some embodiments, each amino acid connected by the macrocycle-forming linker is an α,α-disubstituted amino acid.

In some embodiments, a peptidomimetic macrocycle of the invention has the Formula (I):

wherein:

each A, C, D, and E is independently an amino acid (including natural or non-natural amino acids and amino acid analogs) and the terminal D and E independently optionally include a capping group;

each B is independently an amino acid (including natural or non-natural amino acids and amino acid analogs),

[—NH-L₃-CO—], [-NH-L₃-SO₂—], or [—NH-L₃-];

each R₁ and R₂ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-; or at least one of R₁ and R₂ forms a macrocycle-forming linker L′ connected to the alpha position of one of said D or E amino acids;

each R₃ is independently hydrogen, alkyl, alkenyl, alkynyl, arylalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R₅;

each L and L′ is independently a macrocycle-forming linker of the formula -L₁-L₂-,

or -L₁-S-L₂-S-L₃-;

each L₁, L₂ and L₃ is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, heterocycloarylene, or [—R₄—K—R₄—]_(n), each being optionally substituted with R₅; when L is not

or -L₁-S-L₂-S-L₃-, L₁ and L₂ are alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, or heterocycloarylene;

each R₄ is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene;

each K is independently O, S, SO, SO₂, CO, CO₂, or CONR₃;

each R₅ is independently halogen, alkyl, —OR₆, —N(R₆)₂, —SR₆, —SOR₆, —SO₂R₆, —CO₂R₆, a fluorescent moiety, a radioisotope or a therapeutic agent;

each R₆ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope or a therapeutic agent;

each R₇ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R₅, or part of a cyclic structure with a D residue;

each R₈ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R₅, or part of a cyclic structure with an E residue;

each R₉ is independently absent, hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, or heterocyclyl group, unsubstituted or optionally substituted with R_(a) or R_(b);

each R_(a) and R_(b) is independently alkyl, OCH₃, CF₃, NH₂, CH₂NH₂, F, Br, I,

each v and w is independently an integer from 0-1000, for example 0-500, 0-200, 0-100, 0-50, 0-30, 0-20, or 0-10;

u is an integer from 1-10, for example 1-5, 1-3 or 1-2;

each x, y and z is independently an integer from 0-10, for example the sum of x+y+z is 2, 3, or 6;

each n is independently an integer from 1-5; and

wherein A, B, C, D, and E, taken together with the crosslinked amino acids connected by the macrocycle-forming linker, -L₁-L₂-, form an amino acid sequence of the peptidomimetic macrocycle which is at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to BIM 1-44, BIM 1-29 or to an amino acid sequence chosen from the group consisting of the amino acid sequences in Table 1;

In some embodiments, u is 1.

In some embodiments, the sum of x+y+z is 2, 3, 6, or 10, for example 2, 3 or 6, for example 3 or 6.

In some embodiments, the sum of x+y+z is 3.

In some embodiments, each of v and w is independently an integer from 1 to 10, 1 to 15, 1 to 20, or 1 to 25.

In some embodiments, each of v and w is independently an integer from 1 to 15.

In some embodiments, v and w are integers from 1-30. In some embodiments, w is an integer from 3-1000, for example 3-500, 3-200, 3-100, 3-50, 3-30, 3-20, or 3-10. In some embodiments, the sum of x+y+z is 3 or 6. In some embodiments, the sum of x+y+z is 3. In other embodiments, the sum of x+y+z is 6.

In some embodiments, w is an integer from 3-10, for example 3-6, 3-8, 6-8, or 6-10. In some embodiments, w is 3. In other embodiments, w is 6. In some embodiments, v is an integer from 1-1000, for example 1-500, 1-200, 1-100, 1-50, 1-30, 1-20, or 1-10. In some embodiments, v is 2.

In some embodiments, L₁ and L₂ are independently alkylene, alkenylene or alkynylene.

In some embodiments, L₁ and L₂ are independently C₃-C₁₀ alkylene or alkenylene.

In some embodiments, L₁ and L₂ are independently C₃-C₆ alkylene or alkenylene.

In some embodiments, L or L′ is:

In some embodiments, L or L′ is

For example, L or L′ is

In some embodiments, R₁ and R₂ are H.

In some embodiments, R₁ and R₂ are independently alkyl.

In some embodiments, R₁ and R₂ are methyl.

In some embodiments, the present invention provides a peptidomimetic macrocycle having the Formula (Ia):

wherein:

R₈′ is —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R₅, or part of a cyclic structure with a E residue;

v′ and w′ are independently integers from 0-100; and

x′, y′ and z′ are independently integers from 0-10, for example, x′+y′+z′ is 2, 3, 6 or 10.

In some embodiments, u is 2.

In some embodiments, the peptidomimetic macrocycle of Formula (I) has the Formula (Ib):

wherein:

R₇′ is —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R₅, or part of a cyclic structure with a D residue;

R₈′ is —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R₅, or part of a cyclic structure with an E residue;

v′ and w′ are independently integers from 0-100; and

x′, y′ and z′ are independently integers from 0-10.

In some embodiments, the sum of x+y+z is 2, 3 or 6, for example 3 or 6.

In some embodiments, the sum of x′+y′+z′ is 2, 3 or 6, for example 3 or 6.

In some embodiments, each of v and w is independently an integer from 1 to 10, 1 to 15, 1 to 20, or 1 to 25.

In some embodiments, v and w are integers from 1-30. In some embodiments, w is an integer from 3-1000, for example 3-500, 3-200, 3-100, 3-50, 3-30, 3-20, or 3-10. In some embodiments, the sum of x+y+z is 3 or 6. In some embodiments, the sum of x+y+z is 3. In other embodiments, the sum of x+y+z is 6.

In some embodiments, w is an integer from 3-10, for example 3-6, 3-8, 6-8, or 6-10. In some embodiments, w is 3. In other embodiments, w is 6. In some embodiments, v is an integer from 1-1000, for example 1-500, 1-200, 1-100, 1-50, 1-30, 1-20, or 1-10. In some embodiments, v is 2.

In some embodiments, a peptidomimetic macrocycle of the invention comprises an amino acid sequence which is at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to an amino acid sequence of Table 1, and comprising at least one macrocycle-forming linker, wherein the macrocycle-forming linker connects amino acids 14 and 18.

In some embodiments, a peptidomimetic macrocycle of Formula (I) has Formula (Ic):

wherein:

each A, C, D, and E is independently a natural or non-natural amino acid;

each B is independently a natural or non-natural amino acid, amino acid analog,

[—NH-L₃-CO—], [—NH-L₃SO₂—], or [—NH-L₃];

each L is independently a macrocycle-forming linker;

each L′ is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene, each being optionally substituted with R₅, or a bond, or together with R₁ and the atom to which both R₁ and L′ are bound forms a ring;

each L″ is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene, each being optionally substituted with R₅, or a bond, or together with R₂ and the atom to which both R₂ and L″ are bound forms a ring;

each R₁ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-, or together with L′ and the atom to which both R₁ and L′ are bound forms a ring;

each R₂ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-, or together with L″ and the atom to which both R₂ and L″ are bound forms a ring;

each R₃ is independently hydrogen, alkyl, alkenyl, alkynyl, arylalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, aryl, or heteroaryl, optionally substituted with R₅;

each L₃ is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene, or [—R₄—K—R₄—]_(n), each being optionally substituted with R₅;

each R₄ is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene;

each K is independently O, S, SO, SO₂, CO, CO₂, or CONR₃;

n is an integer from 1-5;

each R₅ is independently halogen, alkyl, —OR₆, —N(R₆)₂, —SR₆, —SOR₆, —SO₂R₆, —CO₂R₆, a fluorescent moiety, a radioisotope or a therapeutic agent;

each R₆ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope or a therapeutic agent;

each R₇ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, optionally substituted with R₅, or part of a cyclic structure with a D residue;

each R₈ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, optionally substituted with R₅, or part of a cyclic structure with an E residue;

each v and w is independently an integer from 1-1000, for example 1-500, 1-200, 1-100, 1-50, 1-40, 1-25, 1-20, 1-15, or 1-10;

u is an integer from 1-10; and

each x, y and z is independently an integer from 0-10.

In some embodiments, the peptidomimetic macrocycle comprises two crosslinks, wherein a first crosslink is of a first pair of amino acid residues, and a second crosslink is of a second pair of amino acid residues. In some embodiments, the first pair of amino acid residues and the second pair of amino acid residues do not share a common amino acid residue. In some embodiments, the first pair of amino acid residues and the second pair of amino acid residues share one common amino acid residue.

In some embodiments, w is at least about 1, at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 8, at least about 9, or at least about 10. In some embodiments, w is from about 1 to about 2, from about 2 to about 3, from about 3 to about 4, from about 4 to about 5, from about 5 to about 6, from about 6 to about 7, from about 7 to about 8, from about 8 to about 9, or from about 9 to about 10.

In some embodiments, w is at least 2 and at least one of the last two E residues is a His residue. In some embodiments, w is at least 2 and at least one of the last two E residues is an Arg residue. In some embodiments, w is at least 2 and both of the last two E residues are His residues. In some embodiments, w is at least 2 and both of the last two E residues are Arg residues. The number of His residues at the peptide C-terminus, or at the E variable, can be 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. The His residues can be contiguous, or interrupted by a gap of i, i+1, i+2, i+3, or i+4.

In some embodiments, the peptidomimetic macrocycle comprises a helix. In some embodiments, the peptidomimetic macrocycle comprises an α-helix. In some embodiments, each of v and w is independently an integer from 1 to 15. In some embodiments, each of v and w is independently an integer from 3 to 10. In some embodiments, v is 8. In some embodiments, w is 6. In some embodiments, the crosslinked amino acid residues are at positions 9 and 13 of the peptidomimetic macrocycle.

In some embodiments, L is

In some embodiments, R¹ and R² are H. In some embodiments, R¹ and R² are independently alkyl. In some embodiments, R¹ and R² are methyl.

In some embodiments, the peptidomimetic macrocycles have the Formula (I):

wherein:

each A, C, D, and E is independently a natural or non-natural amino acid;

each B is independently a natural or non-natural amino acid, amino acid analog,

[—NH-L₃-CO—], [—NH-L₃-SO₂—], or [—NH-L₃-];

each R₁ and R₂ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-;

each R₃ is independently hydrogen, alkyl, alkenyl, alkynyl, arylalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, aryl, or heteroaryl, optionally substituted with R₅;

each L is independently a macrocycle-forming linker of the formula

each L₁, L₂ and L₃ is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene, or [—R₄—K—R₄—]_(n), each being optionally substituted with R₅;

each R₄ is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene;

each K is independently O, S, SO, SO₂, CO, CO₂, or CONR₃; each R₅ is independently halogen, alkyl, —OR₆, —N(R₆)₂, —SR₆, —SOR₆, —SO₂R₆, —CO₂R₆, a fluorescent moiety, a radioisotope or a therapeutic agent;

each R₆ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope or a therapeutic agent;

each R₇ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, optionally substituted with R₅, or part of a cyclic structure with a D residue;

each R₈ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, optionally substituted with R₅, or part of a cyclic structure with an E residue;

each v and w is independently an integer from 1-1000;

u is an integer from 1-10;

each x, y and z is independently an integer from 0-10; and

n is an integer from 1-5.

In other embodiments, provided are peptidomimetic macrocycles comprising Formula (II) or (IIa):

wherein:

each A, C, D, and E is independently a natural or non-natural amino acid, and the terminal D and E independently optionally include a capping group;

each B is independently a natural or non-natural amino acid, amino acid analog,

[—NH-L₃-CO—], [—NH-L₃-SO₂—], or [—NH-L₃—];

each R₁ and R₂ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-; or at least one of R₁ and R₂ forms a macrocycle-forming linker L′ connected to the alpha position of one of said D or E amino acids;

each R₃ is independently hydrogen, alkyl, alkenyl, alkynyl, arylalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R₅;

each L₁, L₂, and L₃ is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, heterocycloarylene, or [—R₄—K—R₄—]_(n), each being optionally substituted with R₅;

each R₄ is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene;

each K is independently O, S, SO, SO₂, CO, CO₂, or CONR₃; each R₅ is independently halogen, alkyl, —OR₆, —N(R₆)₂, —SR₆, —SOR₆, —SO₂R₆, —CO₂R₆, a fluorescent moiety, a radioisotope or a therapeutic agent;

each R₆ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope or a therapeutic agent;

each R₇ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R₅;

each v and w is independently an integer from 0-100;

u is an integer from 1-10;

each x, y and z is independently an integer from 0-10;

n is an integer from 1-5; and

A, B, C, and E, taken together with the crosslinked amino acids connected by the macrocycle-forming linker -L₁-L₂-, form an amino acid sequence of the peptidomimetic macrocycle which is at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a sequence of Table 1.

In some embodiments, a peptidomimetic macrocycle comprises Formula (IIIa) or (IIIb):

wherein:

each A, C, D and E is independently an amino acid, and the terminal D and E independently optionally include a capping group;

each B is independently an amino acid,

[—NH-L₃-CO—], [—NH-L₃-SO₂—], or [—NH-L₃—];

each R₁′ and R₂ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-; or R₂ forms a macrocycle-forming linker L′ connected to the alpha position of one of said E amino acids;

each R₃ is independently hydrogen, alkyl, alkenyl, alkynyl, arylalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R₅;

each L and L′ is independently a macrocycle-forming linker of the formula -L₁-L₂-,

or -L₁-S-L₂-S-L₃-;

each L₁, L₂ and L₃ is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, heterocycloarylene, or [—R₄-K-R₄—]_(n), each being optionally substituted with R₅;

each R₄ is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene;

each K is independently O, S, SO, SO₂, CO, CO₂, or CONR₃; each R₅ is independently halogen, alkyl, —OR₆, —N(R₆)₂, —SR₆, —SOR₆, —SO₂R₆, —CO₂R₆, a fluorescent moiety, a radioisotope or a therapeutic agent;

each R₆ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope or a therapeutic agent;

each R₇ or R₇′ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R₅, or part of a cyclic structure with a D residue;

each R₈ or R₈′ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R₅, or part of a cyclic structure with an E residue;

each R₉ is independently absent, hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, or heterocyclyl group, unsubstituted or optionally substituted with R_(a) or R_(b);

each R_(a) and R_(b) is independently alkyl, OCH₃, CF₃, NH₂, CH₂NH₂, F, Br, I,

each v′ and w is independently an integer from 0-1000, for example 0-500, 0-200, 0-100, 0-50, 0-30, 0-20, or 0-10;

u is an integer from 1-10, for example 1-5, 1-3 or 1-2;

each x, y, z, x′, y′ and z′ is independently an integer from 0-10, for example the sum of x+y+z is 2, 3, 6 or 10, or the sum of x′+y′+z′ is 2, 3, 6, or 10;

n is an integer from 1-5;

X is C═O, CHR_(c), or C═S;

R_(c) is alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl; and

A, B, C, and E, taken together with the crosslinked amino acids connected by the macrocycle-forming linker -L₁-L₂-, form an amino acid sequence of the peptidomimetic macrocycle which is at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a sequence of Table 1.

In some embodiments, the peptidomimetic macrocycle has the Formula:

wherein:

each R₁′ or R₂′ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-; and

each v, w, v′ or w′ is independently an integer from 0-100.

In some embodiments, the notation “Hep” is used for a macrocycle of Formula Ma, which represents an N-terminal heptenoic capping group of the following formula:

wherein AA₁, AA₂, AA₃ and AA₄ are amino acids.

In other embodiments, a C-terminal macrocycle of Formula IIIb forms the structure:

In some embodiments, the peptidomimetic macrocycle has the Formula IV:

wherein:

each A, C, D, and E is independently an amino acid;

each B is independently an amino acid,

[—NH-L₄-CO—], [—NH-L₄-SO₂—], or [—NH-L₄—];

each R₁ and R₂ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-; or at least one of R₁ and R₂ forms a macrocycle-forming linker L′ connected to the alpha position of one of said D or E amino acids;

each R₃ is independently hydrogen, alkyl, alkenyl, alkynyl, arylalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R₅;

each L₁, L₂, L₃ and L₄ is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, heterocycloarylene or [—R₄—K—R₄—]n, each being unsubstituted or substituted with R₅;

each K is independently O, S, SO, SO₂, CO, CO₂, or CONR₃;

each R₄ is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene;

each R₅ is independently halogen, alkyl, —OR₆, —N(R₆)₂, —SR₆, —SOR₆, —SO₂R₆, —CO₂R₆, a fluorescent moiety, a radioisotope or a therapeutic agent;

each R₆ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope or a therapeutic agent;

each R₇ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R₅, or part of a cyclic structure with a D residue;

each R₈ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R₅, or part of a cyclic structure with an E residue;

each v and w is independently an integer from 1-1000, for example 1-500, 1-200, 1-100, 1-50, 1-30, 1-20 or 1-10;

u is an integer from 1-10, for example 1-5, 1-3 or 1-2;

each x, y and z is independently an integer from 0-10, for example the sum of x+y+z is 2, 3, 6 or 10, for example sum of x+y+z is 2, 3or 6; and

n is an integer from 1-5.

In some embodiments, the peptidomimetic macrocycle has the Formula (V):

wherein:

each D and E is independently an amino acid residue;

R¹ and R² are independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, each being optionally substituted with halo-; or at least one of R¹ and R² forms a macrocycle-forming linker L′ connected to the alpha position of one of the D or E amino acid residues;

each L or L′ is independently a macrocycle-forming linker of the formula -L¹-L²-or -L¹-L²-L³-;

each L¹, L², and L³ is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene, or [—R⁴—K—R⁴—]_(n), each being optionally substituted with R⁵;

each R³ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, each being optionally substituted with R⁵;

each R⁴ is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene, each being optionally substituted with R⁵;

each K is independently O, S, SO, SO₂, CO, CO₂, or CONR³; each R⁵ is independently halogen, alkyl, —OR⁶, —N(R⁶)₂, —SR⁶, —SOR⁶, —SO₂R⁶, —CO₂R⁶, a fluorescent moiety, a radioisotope, or a therapeutic agent;

each R⁶ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope, or a therapeutic agent;

R⁷ is —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, each being optionally substituted with R⁵, or part of a cyclic structure with a D residue;

R⁸ is —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, each being optionally substituted with R⁵, or part of a cyclic structure with an E residue;

each of Xaa¹ and Xaa² is independently an amino acid residue or absent;

Xaa³ is Ala, Aib, Asp, Asn, Cys, Glu, Gln, His, Ile, Lys, Leu, Met, Arg, Ser, Thr, Val, Trp, Tyr, or an analogue of any of the foregoing;

v is an integer from 1-1000;

w is an integer from 0-1000; and

n is an integer from 1-5.

In some embodiments, the peptidomimetic macrocycle of Formula (V) comprises two crosslinks, wherein a first crosslink is of a first pair of amino acid residues, and a second crosslink is of a second pair of amino acid residues. In some embodiments, the first pair of amino acid residues and the second pair of amino acid residues do not share a common amino acid residue. In some embodiments, the first pair of amino acid residues and the second pair of amino acid residues share one common amino acid residue. In some embodiments, one of Xaa¹ and Xaa² is His. In some embodiments, both of Xaa¹ and Xaa² are His. In some embodiments, one of Xaa¹ and Xaa² is Arg. In some embodiments, both of Xaa¹ and Xaa² are Arg. In some embodiments, one of Xaa¹ and Xaa² is absent. In some embodiments, both of Xaa¹ and Xaa² are absent.

In some embodiments, the peptidomimetic macrocycle comprises a helix. In some embodiments, the peptidomimetic macrocycle comprises an α-helix. In some embodiments, v is an integer from 1 to 15. In some embodiments, v is an integer from 3 to 10. In some embodiments, v is 8. In some embodiments, w is an integer from 0 to 15. In some embodiments, w is an integer from 0 to 5. In some embodiments, w is an integer from 0 to 3. In some embodiments, wherein w is 0.

In some embodiments, v and w are integers from 1-30. In some embodiments, w is an integer from 3-1000, for example 3-500, 3-200, 3-100, 3-50, 3-30, 3-20, or 3-10. In some embodiments, the sum of x+y+z is 3 or 6. In some embodiments, the sum of x+y+z is 3. In other embodiments, the sum of x+y+z is 6.

In some embodiments, w is an integer from 3-10, for example 3-6, 3-8, 6-8, or 6-10. In some embodiments, w is 3. In other embodiments, w is 6. In some embodiments, v is an integer from 1-1000, for example 1-500, 1-200, 1-100, 1-50, 1-30, 1-20, or 1-10. In some embodiments, v is 2.

In some embodiments, L is the formula -L¹-L²-, and L¹ and L² are independently alkylene, alkenylene, or alkynylene. In some embodiments, wherein L is the formula -L¹-L²-, and L¹ and L² are independently C₃-C₁₀ alkylene or C₃-C₁₀ alkenylene. In some embodiments, wherein L is the formula -L¹-L²-, and L¹ and L² are independently C₃-C₆ alkylene or C₃-C₆ alkenylene. In some embodiments, L is

In some embodiments, L is the formula -L¹-L²-L³-, and L¹ and L³ are independently alkylene, alkenylene, or alkynylene, and L² is arylene or heteroarylene. In some embodiments, L is the formula -L¹-L²-L³-, and L¹ and L³ are independently C₃-C₁₀ alkylene, and L² is heteroarylene. In some embodiments, L is the formula -L¹-L²-L³-, and L¹ and L³ are independently C₃-C₆ alkylene, and L² is heteroarylene.

In some embodiments, R¹ and R² are H. In some embodiments, R¹ and R² are independently alkyl. In some embodiments, R¹ and R² are methyl.

In some embodiments, the peptidomimetic macrocycle has the Formula (VI) (SEQ ID NO: 1783):

wherein:

each D and E is independently an amino acid residue;

R¹ and R² are independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, each being optionally substituted with halo-; or at least one of R¹ and R² forms a macrocycle-forming linker L′ connected to the alpha position of one of the D or E amino acid residues;

each L or L′ is independently a macrocycle-forming linker of the formula -L¹-L²-or -L¹-L²-L³-;

each L¹, L², and L³ is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene, or [—R⁴—K—R⁴—]_(n), each being optionally substituted with R⁵;

each R³ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, each being optionally substituted with R⁵;

each R⁴ is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene, each being optionally substituted with R⁵;

each K is independently O, S, SO, SO₂, CO, CO₂, or CONR³; each R⁵ is independently halogen, alkyl, —OR⁶, —N(R⁶)₂, —SR⁶, —SOR⁶, —SO₂R⁶, —CO₂R⁶, a fluorescent moiety, a radioisotope, or a therapeutic agent;

each R⁶ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope, or a therapeutic agent;

R⁷ is —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, each being optionally substituted with R⁵, or part of a cyclic structure with a D residue;

R⁸ is —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, each being optionally substituted with R⁵, or part of a cyclic structure with an E residue;

each of Xaa¹ and Xaa² is independently an amino acid residue or absent;

v is an integer from 1-1000;

w is an integer from 0-1000; and

n is an integer from 1-5.

In some embodiments, the peptidomimetic macrocycle of Formula (VI) comprises two crosslinks, wherein a first crosslink is of a first pair of amino acid residues, and a second crosslink is of a second pair of amino acid residues. In some embodiments, the first pair of amino acid residues and the second pair of amino acid residues do not share a common amino acid residue. In some embodiments, the first pair of amino acid residues and the second pair of amino acid residues share one common amino acid residue. In some embodiments, one of Xaa¹ and Xaa² is His. In some embodiments, both of Xaa¹ and Xaa² are His. In some embodiments, one of Xaa¹ and Xaa² is Arg. In some embodiments, both of Xaa¹ and Xaa² are Arg. In some embodiments, one of Xaa¹ and Xaa² is absent. In some embodiments, both of Xaa¹ and Xaa² are absent.

In some embodiments, the peptidomimetic macrocycle comprises a helix. In some embodiments, the peptidomimetic macrocycle comprises an α-helix. In some embodiments, v is an integer from 1 to 15. In some embodiments, v is an integer from 3 to 10. In some embodiments, v is 8. In some embodiments, w is an integer from 0 to 15. In some embodiments, w is an integer from 0 to 5. In some embodiments, w is an integer from 0 to 3. In some embodiments, wherein w is 0.

In some embodiments, v and w are integers from 1-30. In some embodiments, w is an integer from 3-1000, for example 3-500, 3-200, 3-100, 3-50, 3-30, 3-20, or 3-10. In some embodiments, the sum of x+y+z is 3 or 6. In some embodiments, the sum of x+y+z is 3. In other embodiments, the sum of x+y+z is 6.

In some embodiments, w is an integer from 3-10, for example 3-6, 3-8, 6-8, or 6-10. In some embodiments, w is 3. In other embodiments, w is 6. In some embodiments, v is an integer from 1-1000, for example 1-500, 1-200, 1-100, 1-50, 1-30, 1-20, or 1-10. In some embodiments, v is 2.

In some embodiments, L is the formula -L¹-L²-, and L¹ and L² are independently alkylene, alkenylene, or alkynylene. In some embodiments, wherein L is the formula -L₁-L²-, and L¹ and L² are independently C₃-C₁₀ alkylene or C₃-C₁₀ alkenylene. In some embodiments, wherein L is the formula -L¹-L²-, and L¹ and L² are independently C₃-C₆ alkylene or C₃-C₆ alkenylene. In some embodiments, L is

In some embodiments, L is the formula -L¹-L²-L³-, and L¹ and L³ are independently alkylene, alkenylene, or alkynylene, and L² is arylene or heteroarylene. In some embodiments, L is the formula -L¹-L²-L³-, and L¹ and L³ are independently C₃-C₁₀ alkylene, and L² is heteroarylene. In some embodiments, L is the formula -L¹-L²-L³-, and L¹ and L³ are independently C₃-C₆ alkylene, and L² is heteroarylene.

In some embodiments, R¹ and R² are H. In some embodiments, R¹ and R² are independently alkyl. In some embodiments, R¹ and R² are methyl.

In one example, at least one of R₁ and R₂ is alkyl, unsubstituted or substituted with halo-. In another example, both R₁ and R₂ are independently alkyl, unsubstituted or substituted with halo-. In some embodiments, at least one of R₁ and R₂ is methyl. In other embodiments, R₁ and R₂ are methyl.

In some embodiments of the invention, the sum of the sum of x+y+z is at least 3, or the sum of x′+y′+z′ is at least 3. In other embodiments of the invention, the sum of the sum of x+y+z is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 (for example 2, 3 or 6) or the sum of x′+y′+z′ is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 (for example 2, 3 or 6).

Each occurrence of A, B, C, D or E in a macrocycle or macrocycle precursor of the invention is independently selected. For example, a sequence represented by the formula [A]_(x), when x is 3, encompasses embodiments where the amino acids are not identical, e.g. Gln-Asp-Ala as well as embodiments where the amino acids are identical, e.g. Gln-Gln-Gln. This applies for any value of x, y, or z in the indicated ranges Similarly, when u is greater than 1, each compound of the invention may encompass peptidomimetic macrocycles which are the same or different. For example, a compound of the invention may comprise peptidomimetic macrocycles comprising different linker lengths or chemical compositions.

In some embodiments, the peptidomimetic macrocycle of the invention comprises a secondary structure which is an α-helix and R₈ is —H, allowing intrahelical hydrogen bonding. In some embodiments, at least one of A, B, C, D or E is an α,α-disubstituted amino acid. In one example, B is an α,α-disubstituted amino acid. For instance, at least one of A, B, C, D or E is 2-aminoisobutyric acid. In other embodiments, at least one of A, B, C, D or E is

In other embodiments, the length of the macrocycle-forming linker L as measured from a first Cα to a second Cα is selected to stabilize a desired secondary peptide structure, such as an cc-helix formed by residues of the peptidomimetic macrocycle including, but not necessarily limited to, those between the first Cα to a second Cα.

In one embodiment, the peptidomimetic macrocycle of Formula (I) is:

wherein each R₁ and R₂ is independently independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-.

In related embodiments, the peptidomimetic macrocycle comprises a structure of Formula (I) which is:

In other embodiments, the peptidomimetic macrocycle of Formula (I) is a compound of any of the formulas shown below:

wherein “AA” represents any natural or non-natural amino acid side chain and “

” is [D]_(v), [E]_(w) as defined above, and n is an integer between 0 and 20, 50, 100, 200, 300, 400 or 500. In some embodiments, the substituent “n” shown in the preceding paragraph is 0. In other embodiments, the substituent “n” shown in the preceding paragraph is less than 50, 40, 30, 20, 10, or 5.

Exemplary embodiments of the macrocycle-forming linker L are shown below.

In other embodiments, D or E in the compound of Formula I are further modified in order to facilitate cellular uptake. In some embodiments, lipidating or PEGylating a peptidomimetic macrocycle facilitates cellular uptake, increases bioavailability, increases blood circulation, alters pharmacokinetics, decreases immunogenicity or decreases the needed frequency of administration.

In other embodiments, at least one of [D] and [E] in the compound of Formula I represents a moiety comprising an additional macrocycle-forming linker such that the peptidomimetic macrocycle comprises at least two macrocycle-forming linkers. In a specific embodiment, a peptidomimetic macrocycle comprises two macrocycle-forming linkers.

In the peptidomimetic macrocycles of the invention, any of the macrocycle-forming linkers described herein may be used in any combination with any of the sequences shown in Tables 1-2 and also with any of the R— substituents indicated herein.

In some embodiments, the peptidomimetic macrocycle comprises at least one α-helix motif. For example, A, B or C in the compound of Formula I include one or more α-helices. As a general matter, α-helices include between 3 and 4 amino acid residues per turn. In some embodiments, the α-helix of the peptidomimetic macrocycle includes 1 to 5 turns and, therefore, 3 to 20 amino acid residues. In specific embodiments, the α-helix includes 1 turn, 2 turns, 3 turns, 4 turns, or 5 turns. In some embodiments, the macrocycle-forming linker stabilizes an α-helix motif included within the peptidomimetic macrocycle. Thus, in some embodiments, the length of the macrocycle-forming linker L from a first Cα to a second Cα is selected to increase the stability of an α-helix. In some embodiments, the macrocycle-forming linker spans from 1 turn to 5 turns of the α-helix. In some embodiments, the macrocycle-forming linker spans approximately 1 turn, 2 turns, 3 turns, 4 turns, or 5 turns of the α-helix. In some embodiments, the length of the macrocycle-forming linker is approximately 5 Å to 9 Å per turn of the α-helix, or approximately 6 Å to 8 Å per turn of the α-helix. Where the macrocycle-forming linker spans approximately 1 turn of an α-helix, the length is equal to approximately 5 carbon-carbon bonds to 13 carbon-carbon bonds, approximately 7 carbon-carbon bonds to 11 carbon-carbon bonds, or approximately 9 carbon-carbon bonds. Where the macrocycle-forming linker spans approximately 2 turns of an α-helix, the length is equal to approximately 8 carbon-carbon bonds to 16 carbon-carbon bonds, approximately 10 carbon-carbon bonds to 14 carbon-carbon bonds, or approximately 12 carbon-carbon bonds. Where the macrocycle-forming linker spans approximately 3 turns of an α-helix, the length is equal to approximately 14 carbon-carbon bonds to 22 carbon-carbon bonds, approximately 16 carbon-carbon bonds to 20 carbon-carbon bonds, or approximately 18 carbon-carbon bonds. Where the macrocycle-forming linker spans approximately 4 turns of an α-helix, the length is equal to approximately 20 carbon-carbon bonds to 28 carbon-carbon bonds, approximately 22 carbon-carbon bonds to 26 carbon-carbon bonds, or approximately 24 carbon-carbon bonds. Where the macrocycle-forming linker spans approximately 5 turns of an α-helix, the length is equal to approximately 26 carbon-carbon bonds to 34 carbon-carbon bonds, approximately 28 carbon-carbon bonds to 32 carbon-carbon bonds, or approximately 30 carbon-carbon bonds. Where the macrocycle-forming linker spans approximately 1 turn of an α-helix, the linkage contains approximately 4 atoms to 12 atoms, approximately 6 atoms to 10 atoms, or approximately 8 atoms. Where the macrocycle-forming linker spans approximately 2 turns of the α-helix, the linkage contains approximately 7 atoms to 15 atoms, approximately 9 atoms to 13 atoms, or approximately 11 atoms. Where the macrocycle-forming linker spans approximately 3 turns of the α-helix, the linkage contains approximately 13 atoms to 21 atoms, approximately 15 atoms to 19 atoms, or approximately 17 atoms. Where the macrocycle-forming linker spans approximately 4 turns of the α-helix, the linkage contains approximately 19 atoms to 27 atoms, approximately 21 atoms to 25 atoms, or approximately 23 atoms. Where the macrocycle-forming linker spans approximately 5 turns of the α-helix, the linkage contains approximately 25 atoms to 33 atoms, approximately 27 atoms to 31 atoms, or approximately 29 atoms. Where the macrocycle-forming linker spans approximately 1 turn of the α-helix, the resulting macrocycle forms a ring containing approximately 17 members to 25 members, approximately 19 members to 23 members, or approximately 21 members. Where the macrocycle-forming linker spans approximately 2 turns of the α-helix, the resulting macrocycle forms a ring containing approximately 29 members to 37 members, approximately 31 members to 35 members, or approximately 33 members. Where the macrocycle-forming linker spans approximately 3 turns of the α-helix, the resulting macrocycle forms a ring containing approximately 44 members to 52 members, approximately 46 members to 50 members, or approximately 48 members. Where the macrocycle-forming linker spans approximately 4 turns of the α-helix, the resulting macrocycle forms a ring containing approximately 59 members to 67 members, approximately 61 members to 65 members, or approximately 63 members. Where the macrocycle-forming linker spans approximately 5 turns of the α-helix, the resulting macrocycle forms a ring containing approximately 74 members to 82 members, approximately 76 members to 80 members, or approximately 78 members.

In some embodiments, L is a macrocycle-forming linker of the formula

Exemplary embodiments of such macrocycle-forming linkers L are shown below.

In some embodiments, the peptidomimetic macrocycle comprises an amino acid sequence of formula:

X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17-X18-X19-X20- X21

wherein:

In some embodiments, X1 is Ile, Arg, Ala, Lys, Pro, Leu, Asp, Glu, His, Ser, Gln, Phe, an analog thereof, or absent.

In some embodiments, X2 is Trp, Arg, Ala, Asn, Phe, Pro, Leu, Ser, Lys, Tyr, His, Cou, Cou2, Cou4, Cou7, an analog thereof, a crosslinked amino acid, or absent.

In some embodiments, X3 is Ile, Ala, Leu, Phe, Tyr,Val, Asp, Trp, Pro, Gln, Chg, Ac5c, Ac6c, Tba, Bip, Cha, Adm, hCha, an analog thereof, or absent.

In some embodiments, X4 is Ala, Gln, Asp, Val, Gly, Ser, Leu, Phe, Cha, A4, an analog, thereof, a crosslinked amino acid, or absent.

In some embodiments, X5 is Gln, Ala, Leu, Phe, Tyr, Gly, Ile, Val, Arg, Glu, Pro, Asp, MO, M02, an analog thereof, a crosslinked amino acid, or absent.

In some embodiments, X6 is Glu, Gln, His, Ala, Ser, Arg, Ile, Leu, Thr, Phe, Val, Tyr, Gly, Nle, St, an analog thereof, or absent.

In some embodiments, X7 is Ala, Leu, Phe, Ile, 2Nal, 1Nal, 3cf, Chg, Cha, Adm, hCha, Igl, Bip, an analog thereof, or absent.

In some embodiments, X8 is Arg, Ala, Asp, Glu, Thr, His, Gln, Gly, Asn, Phe, Cit, St, an analog thereof, a crosslinked amino acid, or absent.

In some embodiments, X9 is Arg, Ala, Asp, Lys, Asn, Gly, Ser, Gln, Cys, Nle, St, an analog thereof, or a crosslinked amino acid.

In some embodiments, X10 is Ile, Val, Ala, Asp, Asn, Phe, Tba, hL, hhL, Nle, Chg, Cha, an analog thereof, or a crosslinked amino acid.

In some embodiments, X11 is Gly, Val, Ala, Leu, Ile, Asp, Glu, Cha, Aib, Abu, an analog thereof, or a crosslinked amino acid.

In some embodiments, X12 is Asp, Ala, Asn, Gly, Arg, Glu, Lys, Leu, Nle, an analog thereof, or a crosslinked amino acid.

In some embodiments, X13 is Ala, Glu, Gln, Leu, Lys, Asp, Tyr, Ile, Ser, Cys, St, Sta5, Aib, Nle, an analog thereof, or a crosslinked amino acid.

In some embodiments, X14 is Phe, Ala, Leu, Val, Tyr, Glu, His, Ile, Nle, 1Nal, 2Nal, Chg, Cha, BiP, an analog thereof, or a crosslinked amino acid.

In some embodiments, X15 is Asn, Gln, Ser, His, Glu, Asp, Ala, Leu, Ile, St, Nle, Aib, an analog thereof, a crosslinked amino acid, or absent.

In some embodiments, X16 is Ala, Glu, Asp, Arg, Lys, Phe, Gly, Gln, Aib, Cha, St, an analog thereof, a crosslinked amino acid, or absent.

In some embodiments, X17 is Phe, Tyr, Ala, Leu, Asn, Ser, Gln, Arg, His, Thr, Cou2, Cou3, Cou7, Dpr, Amf, Damf, Amye, an analog thereof, a crosslinked amino acid, or absent.

In some embodiments, X18 is Tyr, Ala, Ile, Phe, His, Arg, Lys, Trp, Orn, Amf, Amye, Cha, 2Nal, an analog thereof, or absent.

In some embodiments, X19 is Ala, Lys, Arg, His, Ser, Gln, Glu, Asp, Thr, Aib, Cha, an analog thereof, a crosslinked amino acid, or absent.

In some embodiments, X20 is Arg, His, Ala, Thr, Lys, Amr, an analog thereof, a crosslinked amino acid, or absent.

In some embodiments, X21 is Arg, His, Ala, Amr, an analog thereof, or absent.

In some embodiments, the peptidomimetic macrocycle comprises a helix.

In some embodiments, the peptidomimetic macrocycle comprises an α-helix.

In some embodiments, the peptidomimetic macrocycle comprises an α,α-disubstituted amino acid.

In some embodiments, each amino acid connected by the macrocycle-forming linker is an α,α-disubstituted amino acid.

Preparation of Peptidomimetic Macrocycles

Peptidomimetic macrocycles of the invention may be prepared by any of a variety of methods known in the art. For example, any of the residues indicated by “X”, “Z” or “XX” in Tables 1 or 2 may be substituted with a residue capable of forming a crosslinker with a second residue in the same molecule or a precursor of such a residue.

Various methods to effect formation of peptidomimetic macrocycles are known in the art. For example, the preparation of peptidomimetic macrocycles of Formula I is described in Schafmeister et al., J. Am. Chem. Soc. 122:5891-5892 (2000); Schafmeister & Verdin, J. Am. Chem. Soc. 122:5891 (2005); Walensky et al., Science 305:1466-1470 (2004); U.S. Pat. No. 7,192,713 and PCT application WO 2008/121767. The α,α-disubstituted amino acids and amino acid precursors disclosed in the cited references may be employed in synthesis of the peptidomimetic macrocycle precursor polypeptides. For example, the “S5-olefin amino acid” is (S)-α-(2′-pentenyl) alanine and the “R8 olefin amino acid” is (R)-α-(2′-octenyl) alanine. Following incorporation of such amino acids into precursor polypeptides, the terminal olefins are reacted with a metathesis catalyst, leading to the formation of the peptidomimetic macrocycle. In various embodiments, the following amino acids may be employed in the synthesis of the peptidomimetic macrocycle:

In some embodiments, x+y+z is 3, and A, B and C are independently natural or non-natural amino acids. In other embodiments, x+y+z is 6, and A, B and C are independently natural or non-natural amino acids.

In some embodiments, the contacting step is performed in a solvent selected from the group consisting of protic solvent, aqueous solvent, organic solvent, and mixtures thereof. For example, the solvent may be chosen from the group consisting of H₂O, THF, THF/H₂O, tBuOH/H₂O, DMF, DIPEA, CH₃CN or CH₂Cl₂, ClCH₂CH₂Cl or a mixture thereof. The solvent may be a solvent which favors helix formation.

Alternative but equivalent protecting groups, leaving groups or reagents are substituted, and certain of the synthetic steps are performed in alternative sequences or orders to produce the desired compounds. Synthetic chemistry transformations and protecting group methodologies (protection and deprotection) useful in synthesizing the compounds described herein include, for example, those such as described in Larock, Comprehensive Organic Transformations, VCH Publishers (1989); Greene and Wuts, Protective Groups in Organic Synthesis, 2d. Ed., John Wiley and Sons (1991); Fieser and Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995), and subsequent editions thereof.

The peptidomimetic macrocycles disclosed herein are made, for example, by chemical synthesis methods, such as described in Fields et al., Chapter 3 in Synthetic Peptides: A User's Guide, ed. Grant, W. H. Freeman & Co., New York, N. Y., 1992, p. 77. Hence, for example, peptides are synthesized using the automated Merrifield techniques of solid phase synthesis with the amine protected by either tBoc or Fmoc chemistry using side chain protected amino acids on, for example, an automated peptide synthesizer (e.g., Applied Biosystems (Foster City, Calif.), Model 430A, 431, or 433).

One manner of producing the peptidomimetic precursors and peptidomimetic macrocycles described herein uses solid phase peptide synthesis (SPPS). The C-terminal amino acid is attached to a cross-linked polystyrene resin via an acid labile bond with a linker molecule. This resin is insoluble in the solvents used for synthesis, making it relatively simple and fast to wash away excess reagents and by-products. The N-terminus is protected with the Fmoc group, which is stable in acid, but removable by base. Side chain functional groups are protected as necessary with base stable, acid labile groups.

Longer peptidomimetic precursors are produced, for example, by conjoining individual synthetic peptides using native chemical ligation. Alternatively, the longer synthetic peptides are biosynthesized by well known recombinant DNA and protein expression techniques. Such techniques are provided in well-known standard manuals with detailed protocols. To construct a gene encoding a peptidomimetic precursor of this invention, the amino acid sequence is reverse translated to obtain a nucleic acid sequence encoding the amino acid sequence, preferably with codons that are optimum for the organism in which the gene is to be expressed. Next, a synthetic gene is made, typically by synthesizing oligonucleotides which encode the peptide and any regulatory elements, if necessary. The synthetic gene is inserted in a suitable cloning vector and transfected into a host cell. The peptide is then expressed under suitable conditions appropriate for the selected expression system and host. The peptide is purified and characterized by standard methods.

The peptidomimetic precursors are made, for example, in a high-throughput, combinatorial fashion using, for example, a high-throughput polychannel combinatorial synthesizer (e.g., Thuramed TETRAS multichannel peptide synthesizer from CreoSalus, Louisville, Ky. or Model Apex 396 multichannel peptide synthesizer from AAPPTEC, Inc., Louisville, Ky.).

In some embodiments, the peptidomimetic macrocyles of the invention comprise triazole macrocycle-forming linkers. For example, the synthesis of such peptidomimetic macrocycles involves a multi-step process that features the synthesis of a peptidomimetic precursor containing an azide moiety and an alkyne moiety; followed by contacting the peptidomimetic precursor with a macrocyclization reagent to generate a triazole-linked peptidomimetic macrocycle. Such a process is described, for example, in US Application 12/037,041, filed on February 25, 2008. Macrocycles or macrocycle precursors are synthesized, for example, by solution phase or solid-phase methods, and can contain both naturally-occurring and non-naturally-occurring amino acids. See, for example, Hunt, “The Non-Protein Amino Acids” in Chemistry and Biochemistry of the Amino Acids, edited by G. C. Barrett, Chapman and Hall, 1985.

In some embodiments, an azide is linked to the α-carbon of a residue and an alkyne is attached to the α-carbon of another residue. In some embodiments, the azide moieties are azido-analogs of amino acids L-lysine, D-lysine, alpha-methyl-L-lysine, alpha-methyl-D-lysine, L-ornithine, D-ornithine, alpha-methyl-L-ornithine or alpha-methyl-D-ornithine. In another embodiment, the alkyne moiety is L-propargylglycine. In yet other embodiments, the alkyne moiety is an amino acid selected from the group consisting of L-propargylglycine, D-propargylglycine, (S)-2-amino-2-methyl-4-pentynoic acid, (R)-2-amino-2-methyl-4-pentynoic acid, (S)-2-amino-2-methyl-5-hexynoic acid, (R)-2-amino-2-methyl-5-hexynoic acid, (S)-2-amino-2-methyl-6-heptynoic acid, (R)-2-amino-2-methyl-6-heptynoic acid, (S)-2-amino-2-methyl-7-octynoic acid, (R)-2-amino-2-methyl-7-octynoic acid, (S)-2-amino-2-methyl-8-nonynoic acid and (R)-2-amino-2-methyl-8-nonynoic acid.

The following synthetic schemes are provided solely to illustrate the present invention and are not intended to limit the scope of the invention, as described herein. To simplify the drawings, the illustrative schemes depict azido amino acid analogs ε-azido-α-methyl-L-lysine and ε-azido-α-methyl-D-lysine, and alkyne amino acid analogs L-propargylglycine, (S)-2-amino-2-methyl-4-pentynoic acid, and (S)-2-amino-2-methyl-6-heptynoic acid. Thus, in the following synthetic schemes, each R₁, R₂, R₇ and R₈ is —H; each L₁ is —(CH₂)₄—; and each L₂ is —(CH₂)—. However, as noted throughout the detailed description above, many other amino acid analogs can be employed in which R₁, R₂, R₇, R₈, L₁ and L₂ can be independently selected from the various structures disclosed herein.

Synthetic Scheme 1 describes the preparation of several compounds of the invention. Ni(II) complexes of Schiff bases derived from the chiral auxiliary (S)-2-[N-(N′-benzylprolyl)amino]benzophenone (BPB) and amino acids such as glycine or alanine are prepared as described in Belokon et al. (1998), Tetrahedron Asymm. 9:4249-4252. The resulting complexes are subsequently reacted with alkylating reagents comprising an azido or alkynyl moiety to yield enantiomerically enriched compounds of the invention. If desired, the resulting compounds can be protected for use in peptide synthesis.

In the general method for the synthesis of peptidomimetic macrocycles shown in Synthetic Scheme 2, the peptidomimetic precursor contains an azide moiety and an alkyne moiety and is synthesized by solution-phase or solid-phase peptide synthesis (SPPS) using the commercially available amino acid N-α-Fmoc-L-propargylglycine and the N-α-Fmoc-protected forms of the amino acids (S)-2-amino-2-methyl-4-pentynoic acid, (S)-2-amino-6-heptynoic acid, (S)-2-amino-2-methyl-6-heptynoic acid, N-methyl-ε-azido-L-lysine, and N-methyl-ε-azido-D-lysine. The peptidomimetic precursor is then deprotected and cleaved from the solid-phase resin by standard conditions (e.g., strong acid such as 95% TFA). The peptidomimetic precursor is reacted as a crude mixture or is purified prior to reaction with a macrocyclization reagent such as a Cu(I) in organic or aqueous solutions (Rostovtsev et al. (2002), Angew. Chem. Int. Ed. 41:2596-2599; Tornoe et al. (2002), J. Org. Chem. 67:3057-3064; Deiters et al. (2003), J. Am. Chem. Soc. 125:11782-11783; Punna et al. (2005), Angew. Chem. Int. Ed. 44:2215-2220). In one embodiment, the triazole forming reaction is performed under conditions that favor α-helix formation. In one embodiment, the macrocyclization step is performed in a solvent chosen from the group consisting of H₂O, THF, CH₃CN, DMF , DIPEA, tBuOH or a mixture thereof. In another embodiment, the macrocyclization step is performed in DMF. In some embodiments, the macrocyclization step is performed in a buffered aqueous or partially aqueous solvent.

In the general method for the synthesis of peptidomimetic macrocycles shown in Synthetic Scheme 3, the peptidomimetic precursor contains an azide moiety and an alkyne moiety and is synthesized by solid-phase peptide synthesis (SPPS) using the commercially available amino acid N-α-Fmoc-L-propargylglycine and the N-α-Fmoc-protected forms of the amino acids (S)-2-amino-2-methyl-4-pentynoic acid, (S)-2-amino-6-heptynoic acid, (S)-2-amino-2-methyl-6-heptynoic acid, N-methyl-ε-azido-L-lysine, and N-methyl-ε-azido-D-lysine. The peptidomimetic precursor is reacted with a macrocyclization reagent such as a Cu(I) reagent on the resin as a crude mixture (Rostovtsev et al. (2002), Angew. Chem. Int. Ed. 41:2596-2599; Tornoe et al. (2002), J. Org. Chem. 67:3057-3064; Deiters et al. (2003), J. Am. Chem. Soc. 125:11782-11783; Punna et al. (2005), Angew. Chem. Int. Ed. 44:2215-2220). The resultant triazole-containing peptidomimetic macrocycle is then deprotected and cleaved from the solid-phase resin by standard conditions (e.g., strong acid such as 95% TFA). In some embodiments, the macrocyclization step is performed in a solvent chosen from the group consisting of CH₂Cl₂, ClCH₂CH₂Cl, DMF, THF, NMP, DIPEA, 2,6-lutidine, pyridine, DMSO, H₂O or a mixture thereof. In some embodiments, the macrocyclization step is performed in a buffered aqueous or partially aqueous solvent.

In the general method for the synthesis of peptidomimetic macrocycles shown in Synthetic Scheme 4, the peptidomimetic precursor contains an azide moiety and an alkyne moiety and is synthesized by solution-phase or solid-phase peptide synthesis (SPPS) using the commercially available amino acid N-α-Fmoc-L-propargylglycine and the N-α-Fmoc-protected forms of the amino acids (S)-2-amino-2-methyl-4-pentynoic acid, (S)-2-amino-6-heptynoic acid, (S)-2-amino-2-methyl-6-heptynoic acid, N-methyl-ε-azido-L-lysine, and N-methyl-ε-azido-D-lysine. The peptidomimetic precursor is then deprotected and cleaved from the solid-phase resin by standard conditions (e.g., strong acid such as 95% TFA). The peptidomimetic precursor is reacted as a crude mixture or is purified prior to reaction with a macrocyclization reagent such as a Ru(II) reagents, for example Cp*RuCl(PPh₃)₂ or [Cp*RuCl]₄ (Rasmussen et al. (2007), Org. Lett. 9:5337-5339; Zhang et al. (2005), J. Am. Chem. Soc. 127:15998-15999). In some embodiments, the macrocyclization step is performed in a solvent chosen from the group consisting of DMF, CH₃CN and THF.

In the general method for the synthesis of peptidomimetic macrocycles shown in Synthetic Scheme 5, the peptidomimetic precursor contains an azide moiety and an alkyne moiety and is synthesized by solid-phase peptide synthesis (SPPS) using the commercially available amino acidN-α-Fmoc-L-propargylglycine and the N-α-Fmoc-protected forms of the amino acids (S)-2-amino-2-methyl-4-pentynoic acid, (S)-2-amino-6-heptynoic acid, (S)-2-amino-2-methyl-6-heptynoic acid, N-methyl-ε-azido-L-lysine, and N-methyl-ε-azido-D-lysine. The peptidomimetic precursor is reacted with a macrocyclization reagent such as a Ru(II) reagent on the resin as a crude mixture. For example, the reagent can be Cp*RuCl(PPh₃)₂ or [Cp*RuCl]₄ (Rasmussen et al. (2007), Org. Lett. 9:5337-5339; Zhang et al. (2005), J. Am. Chem. Soc. 127:15998-15999). In some embodiments, the macrocyclization step is performed in a solvent chosen from the group consisting of CH₂Cl₂, ClCH₂CH₂Cl, CH₃CN, DMF, and THF.

In some embodiments, a peptidomimetic macrocycle of Formula I comprises a halogen group substitution on a triazole moiety, for example an iodo substitution. Such peptidomimetic macrocycles may be prepared from a precursor having the partial structure and using the cross-linking methods taught herein. Crosslinkers of any length, as described herein, may be prepared comprising such substitutions. In one embodiment, the peptidomimetic macrocycle is prepared according to the scheme shown below. The reaction is peformed, for example, in the presence of CuI and an amine ligand such as TEA or TTTA. See, e.g., Hein et al. Angew. Chem., Int. Ed. 2009, 48, 8018-8021.

In other embodiments, an iodo-substituted triazole is generated according to the scheme shown below. For example, the second step in the reaction scheme below is performed using, for example, CuI and N-bromosuccinimide (NBS) in the presence of THF (see, e.g. Zhang et al., J. Org. Chem. 2008, 73, 3630-3633). In other embodiments, the second step in the reaction scheme shown below is performed, for example, using CuI and an iodinating agent such as ICl (see, e.g. Wu et al., Synthesis 2005, 1314-1318.)

In some embodiments, an iodo-substituted triazole moiety is used in a cross-coupling reaction, such as a Suzuki or Sonogashira coupling, to afford a peptidomimetic macrocycle comprising a substituted crosslinker. Sonogashira couplings using an alkyne as shown below may be performed, for example, in the presence of a palladium catalyst such as Pd(PPh₃)₂Cl₂, CuI, and in the presence of a base such as triethylamine. Suzuki couplings using an arylboronic or substituted alkenyl boronic acid as shown below may be performed, for example, in the presence of a catalyst such as Pd(PPh₃)_(4,) and in the presence of a base such as K₂CO₃.

Any suitable triazole substituent groups which reacts with the iodo-substituted triazole can be used in Suzuki couplings described herein. Example triazole substituents for use in Suzuki couplings are shown below:

wherein “Cyc” is a suitable aryl, cycloalkyl, cycloalkenyl, heteroaryl, or heterocyclyl group, unsubstituted or optionally substituted with an R_(a) or R_(b) group as described below.

In some embodiments, the substituent is:

Any suitable substituent group which reacts with the iodo-substituted triazole can be used in Sonogashira couplings described herein. Example triazole substituents for use in Sonogashira couplings are shown below:

wherein “Cyc” is a suitable aryl, cycloalkyl, cycloalkenyl, heteroaryl, or heterocyclyl group, unsubstituted or optionally substituted with an R_(a) or R_(b) group as described below.

In some embodiments, the triazole substituent is:

In some embodiments, the Cyc group shown above is further substituted by at least one R_(a) or R_(b) substituent. In some embodiments, at least one of R_(a) and R_(b) is independently:

In other embodiments, the triazole substituent is

and at least one of R_(a) and R_(b) is alkyl (including hydrogen, methyl, or ethyl), or:

The present invention contemplates the use of non-naturally-occurring amino acids and

The present invention contemplates the use of non-naturally-occurring amino acids and amino acid analogs in the synthesis of the peptidomimetic macrocycles described herein. Any amino acid or amino acid analog amenable to the synthetic methods employed for the synthesis of stable triazole containing peptidomimetic macrocycles can be used in the present invention. For example, L-propargylglycine is contemplated as a useful amino acid in the present invention. However, other alkyne-containing amino acids that contain a different amino acid side chain are also useful in the invention. For example, L-propargylglycine contains one methylene unit between the α-carbon of the amino acid and the alkyne of the amino acid side chain. The invention also contemplates the use of amino acids with multiple methylene units between the α-carbon and the alkyne. Also, the azido-analogs of amino acids L-lysine, D-lysine, alpha-methyl-L-lysine, and alpha-methyl-D-lysine are contemplated as useful amino acids in the present invention. However, other terminal azide amino acids that contain a different amino acid side chain are also useful in the invention. For example, the azido-analog of L-lysine contains four methylene units between the α-carbon of the amino acid and the terminal azide of the amino acid side chain. The invention also contemplates the use of amino acids with fewer than or greater than four methylene units between the α-carbon and the terminal azide. Table 2 shows some amino acids useful in the preparation of peptidomimetic macrocycles disclosed herein.

TABLE 2

In some embodiments the amino acids and amino acid analogs are of the D-configuration. In other embodiments they are of the L-configuration. In some embodiments, some of the amino acids and amino acid analogs contained in the peptidomimetic are of the D-configuration while some of the amino acids and amino acid analogs are of the L-configuration. In some embodiments the amino acid analogs are α,α-disubstituted, such as α-methyl-L-propargylglycine, α-methyl-D-propargylglycine, ε-azido-alpha-methyl-L-lysine, and ε-azido-alpha-methyl-D-lysine. In some embodiments the amino acid analogs are N-alkylated, e.g., N-methyl-L-propargylglycine, N-methyl-D-propargylglycine, N-methyl-ε-azido-L-lysine, and N-methyl-ε-azido-D-lysine.

In some embodiments, the —NH moiety of the amino acid is protected using a protecting group, including without limitation -Fmoc and -Boc. In other embodiments, the amino acid is not protected prior to synthesis of the peptidomimetic macrocycle.

In some embodiments, the —NH moiety of the amino acid is protected using a protecting group, including without limitation -Fmoc and -Boc. In other embodiments, the amino acid is not protected prior to synthesis of the peptidomimetic macrocycle.

The preparation of macrocycles of Formula IV is described, for example, in U.S. application Ser. No. 11/957,325, filed on Dec. 17, 2007 and herein incorporated by reference. Synthetic Schemes 6-9 describe the preparation of such compounds of Formula IV. To simplify the drawings, the illustrative schemes depict amino acid analogs derived from L-or D-cysteine, in which L₁ and L₃ are both —(CH₂)—. However, as noted throughout the detailed description above, many other amino acid analogs can be employed in which L₁ and L₃ can be independently selected from the various structures disclosed herein. The symbols “[AA]_(m)”, “[AA]_(n)”, “[AA]_(o)” represent a sequence of amide bond-linked moieties such as natural or unnatural amino acids. As described previously, each occurrence of “AA” is independent of any other occurrence of “AA”, and a formula such as “[AA]_(m)” encompasses, for example, sequences of non-identical amino acids as well as sequences of identical amino acids.

In Scheme 6, the peptidomimetic precursor contains two —SH moieties and is synthesized by solid-phase peptide synthesis (SPPS) using commercially available N-α-Fmoc amino acids such as N-α-Fmoc-S-trityl-L-cysteine or N-α-Fmoc-S-trityl-D-cysteine. Alpha-methylated versions of D-cysteine or L-cysteine are generated by known methods (Seebach et al. (1996), Angew. Chem. Int. Ed. Engl. 35:2708-2748, and references therein) and then converted to the appropriately protected N-α-Fmoc-S-trityl monomers by known methods (“Bioorganic Chemistry: Peptides and Proteins”, Oxford University Press, New York: 1998, the entire contents of which are incorporated herein by reference). The precursor peptidomimetic is then deprotected and cleaved from the solid-phase resin by standard conditions (e.g., strong acid such as 95% TFA). The precursor peptidomimetic is reacted as a crude mixture or is purified prior to reaction with X-L₂-Y in organic or aqueous solutions. In some embodiments the alkylation reaction is performed under dilute conditions (i.e. 0.15 mmol/L) to favor macrocyclization and to avoid polymerization. In some embodiments, the alkylation reaction is performed in organic solutions such as liquid NH₃ (Mosberg et al. (1985), J. Am.Chem. Soc. 107:2986-2987; Szewczuk et al. (1992), Int. J. Peptide Protein Res. 40 :233-242), NH₃/MeOH, or NH₃/DMF (Or et al. (1991), J. Org. Chem. 56:3146-3149). In other embodiments, the alkylation is performed in an aqueous solution such as 6M guanidinium HCL, pH 8 (Brunel et al. (2005), Chem. Commun. (20):2552-2554). In other embodiments, the solvent used for the alkylation reaction is DMF or dichloroethane.

In Scheme 7, the precursor peptidomimetic contains two or more —SH moieties, of which two are specially protected to allow their selective deprotection and subsequent alkylation for macrocycle formation. The precursor peptidomimetic is synthesized by solid-phase peptide synthesis (SPPS) using commercially available N-α-Fmoc amino acids such as N-α-Fmoc-S-p-methoxytrityl-L-cysteine or N-α-Fmoc-S-p-methoxytrityl-D-cysteine. Alpha-methylated versions of D-cysteine or L-cysteine are generated by known methods (Seebach et al. (1996), Angew. Chem. Int. Ed. Engl. 35:2708-2748, and references therein) and then converted to the appropriately protected N-α-Fmoc-S-p-methoxytrityl monomers by known methods (Bioorganic Chemistry: Peptides and Proteins, Oxford University Press, New York: 1998, the entire contents of which are incorporated herein by reference). The Mmt protecting groups of the peptidomimetic precursor are then selectively cleaved by standard conditions (e.g., mild acid such as 1% TFA in DCM). The precursor peptidomimetic is then reacted on the resin with X-L₂-Y in an organic solution. For example, the reaction takes place in the presence of a hindered base such as diisopropylethylamine. In some embodiments, the alkylation reaction is performed in organic solutions such as liquid NH₃ (Mosberg et al. (1985), J. Am. Chem. Soc. 107:2986-2987; Szewczuk et al. (1992), Int. J. Peptide Protein Res. 40 :233-242), NH₃/MeOH or NH₃/DMF (Or et al. (1991), J. Org. Chem. 56:3146-3149). In other embodiments, the alkylation reaction is performed in DMF or dichloroethane. The peptidomimetic macrocycle is then deprotected and cleaved from the solid-phase resin by standard conditions (e.g., strong acid such as 95% TFA).

In Scheme 8, the peptidomimetic precursor contains two or more —SH moieties, of which two are specially protected to allow their selective deprotection and subsequent alkylation for macrocycle formation. The peptidomimetic precursor is synthesized by solid-phase peptide synthesis (SPPS) using commercially available N-α-Fmoc amino acids such as N-α-Fmoc-S-p-methoxytrityl-L-cysteine, N-α-Fmoc-S-p-methoxytrityl-D-cysteine, N-α-Fmoc-S-S-t-butyl-L-cysteine, and N-α-Fmoc-S-S-t-butyl-D-cysteine. Alpha-methylated versions of D-cysteine or L-cysteine are generated by known methods (Seebach et al. (1996), Angew. Chem. Int. Ed. Engl. 35:2708-2748, and references therein) and then converted to the appropriately protected N-α-Fmoc-S-p-methoxytrityl or N-α-Fmoc-S-S-t-butyl monomers by known methods (Bioorganic Chemistry: Peptides and Proteins, Oxford University Press, New York: 1998, the entire contents of which are incorporated herein by reference). The S-S-tButyl protecting group of the peptidomimetic precursor is selectively cleaved by known conditions (e.g., 20% 2-mercaptoethanol in DMF, reference: Galande et al. (2005), J. Comb. Chem. 7:174-177). The precursor peptidomimetic is then reacted on the resin with a molar excess of X-L₂-Y in an organic solution. For example, the reaction takes place in the presence of a hindered base such as diisopropylethylamine. The Mmt protecting group of the peptidomimetic precursor is then selectively cleaved by standard conditions (e.g., mild acid such as 1% TFA in DCM). The peptidomimetic precursor is then cyclized on the resin by treatment with a hindered base in organic solutions. In some embodiments, the alkylation reaction is performed in organic solutions such as NH₃/MeOH or NH₃/DMF (Or et al. (1991), J. Org. Chem. 56:3146-3149). The peptidomimetic macrocycle is then deprotected and cleaved from the solid-phase resin by standard conditions (e.g., strong acid such as 95% TFA).

In Scheme 9, the peptidomimetic precursor contains two L-cysteine moieties. The peptidomimetic precursor is synthesized by known biological expression systems in living cells or by known in vitro, cell-free, expression methods. The precursor peptidomimetic is reacted as a crude mixture or is purified prior to reaction with X-L2-Y in organic or aqueous solutions. In some embodiments the alkylation reaction is performed under dilute conditions (i.e. 0.15 mmol/L) to favor macrocyclization and to avoid polymerization. In some embodiments, the alkylation reaction is performed in organic solutions such as liquid NH₃ (Mosberg et al. (1985), J. Am.Chem. Soc. 107:2986-2987; Szewczuk et al. (1992), Int. J. Peptide Protein Res. 40 :233-242), NH₃/MeOH, or NH₃/DMF (Or et al. (1991), J. Org. Chem. 56:3146-3149). In other embodiments, the alkylation is performed in an aqueous solution such as 6M guanidinium HCL, pH 8 (Brunel et al. (2005), Chem. Commun. (20):2552-2554). In other embodiments, the alkylation is performed in DMF or dichloroethane. In another embodiment, the alkylation is performed in non-denaturing aqueous solutions, and in yet another embodiment the alkylation is performed under conditions that favor α-helical structure formation. In yet another embodiment, the alkylation is performed under conditions that favor the binding of the precursor peptidomimetic to another protein, so as to induce the formation of the bound α-helical conformation during the alkylation.

Various embodiments for X and Y are envisioned which are suitable for reacting with thiol groups. In general, each X or Y is independently be selected from the general category shown in Table 3. For example, X and Y are halides such as —Cl, —Br or —I. Any of the macrocycle-forming linkers described herein may be used in any combination with any of the sequences shown and also with any of the R— substituents indicated herein.

TABLE 3 Examples of Reactive Groups Capable of Reacting with Thiol Groups and Resulting Linkages Resulting Covalent X or Y Linkage acrylamide Thioether halide (e.g. alkyl or aryl halide) Thioether sulfonate Thioether aziridine Thioether epoxide Thioether haloacetamide Thioether maleimide Thioether sulfonate ester Thioether

The present invention contemplates the use of both naturally occurring and non-naturally-occurring amino acids and amino acid analogs in the synthesis of the peptidomimetic macrocycles of Formula IV. Any amino acid or amino acid analog amenable to the synthetic methods employed for the synthesis of stable bis-sulfhydryl containing peptidomimetic macrocycles can be used in the present invention. For example, cysteine is contemplated as a useful amino acid in the present invention. However, sulfur containing amino acids other than cysteine that contain a different amino acid side chain are also useful. For example, cysteine contains one methylene unit between the α-carbon of the amino acid and the terminal —SH of the amino acid side chain. The invention also contemplates the use of amino acids with multiple methylene units between the α-carbon and the terminal —SH. Non-limiting examples include α-methyl-L-homocysteine and α-methyl-D-homocysteine. In some embodiments the amino acids and amino acid analogs are of the D-configuration. In other embodiments they are of the L-configuration. In some embodiments, some of the amino acids and amino acid analogs contained in the peptidomimetic are of the D-configuration while some of the amino acids and amino acid analogs are of the L-configuration. In some embodiments the amino acid analogs are α,α-disubstituted, such as α-methyl-L-cysteine and α-methyl-D-cysteine.

The invention includes macrocycles in which macrocycle-forming linkers are used to link two or more —SH moieties in the peptidomimetic precursors to form the peptidomimetic macrocycles disclosed herein. As described above, the macrocycle-forming linkers impart conformational rigidity, increased metabolic stability or increased cell penetrability. Furthermore, in some embodiments, the macrocycle-forming linkages stabilize the α-helical secondary structure of the peptidomimetic macrocyles. The macrocycle-forming linkers are of the formula X-L₂-Y, wherein both X and Y are the same or different moieties, as defined above. Both X and Y have the chemical characteristics that allow one macrocycle-forming linker -L₂- to bis alkylate the bis-sulfhydryl containing peptidomimetic precursor. As defined above, the linker -L₂- includes alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, or heterocycloarylene, or —R₄—K—R₄—, all of which can be optionally substituted with an R₅ group, as defined above. Furthermore, one to three carbon atoms within the macrocycle-forming linkers -L₂-, other than the carbons attached to the —SH of the sulfhydryl containing amino acid, are optionally substituted with a heteroatom such as N, S or O.

The L₂ component of the macrocycle-forming linker X-L₂-Y may be varied in length depending on, among other things, the distance between the positions of the two amino acid analogs used to form the peptidomimetic macrocycle. Furthermore, as the lengths of L₁ or L₃ components of the macrocycle-forming linker are varied, the length of L₂ can also be varied in order to create a linker of appropriate overall length for forming a stable peptidomimetic macrocycle. For example, if the amino acid analogs used are varied by adding an additional methylene unit to each of L₁ and L₃, the length of L₂ are decreased in length by the equivalent of approximately two methylene units to compensate for the increased lengths of L₁ and L₃.

In some embodiments, L₂ is an alkylene group of the formula —(CH₂)_(n)—, where n is an integer between about 1 and about 15. For example, n is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. In other embodiments, L₂ is an alkenylene group. In still other embodiments, L₂ is an aryl group.

Table 4 shows additional embodiments of X-L₂-Y groups.

TABLE 4 Exemplary X—L₂—Y groups.

Each X and Y in this Table, is, for example, independently Cl—, Br— or I—.

Additional methods of forming peptidomimetic macrocycles which are envisioned as suitable to perform the present invention include those disclosed by Mustapa, M. Firouz Mohd et al., J. Org. Chem (2003), 68, pp. 8193-8198; Yang, Bin et al. Bioorg Med. Chem. Lett. (2004), 14, pp. 1403-1406; U.S. Pat. No. 5,364,851; U.S. Pat. No. 5,446,128; U.S. Pat. No. 5,824,483; U.S. Pat. No. 6,713,280; and U.S. Pat. No. 7,202,332. In such embodiments, amino acid precursors are used containing an additional substituent R— at the alpha position. Such amino acids are incorporated into the macrocycle precursor at the desired positions, which may be at the positions where the crosslinker is substituted or, alternatively, elsewhere in the sequence of the macrocycle precursor. Cyclization of the precursor is then performed according to the indicated method.

For example, a peptidomimetic macrocycle of Formula (II) is prepared as indicated:

wherein each AA1, AA2, AA3 is independently an amino acid side chain.

In other embodiments, a peptidomimetic macrocycle of Formula (II) is prepared as indicated:

wherein each AA1, AA2, AA3 is independently an amino acid side chain.

In some embodiments, a peptidomimetic macrocycle is obtained in more than one isomer, for example due to the configuration of a double bond within the structure of the crosslinker (E vs Z). Such isomers can or can not be separable by conventional chromatographic methods. In some embodiments, one isomer has improved biological properties relative to the other isomer. In one embodiment, an E crosslinker olefin isomer of a peptidomimetic macrocycle has better solubility, better target affinity, better in vivo or in vitro efficacy, higher helicity, or improved cell permeability relative to its Z counterpart. In another embodiment, a Z crosslinker olefin isomer of a peptidomimetic macrocycle has better solubility, better target affinity, better in vivo or in vitro efficacy, higher helicity, or improved cell permeability relative to its E counterpart.

A compound described herein can be at least 1% pure, at least 2% pure, at least 3% pure, at least 4% pure, at least 5% pure, at least 6% pure, at least 7% pure, at least 8% pure, at least 9% pure, at least 10% pure, at least 11% pure, at least 12% pure, at least 13% pure, at least 14% pure, at least 15% pure, at least 16% pure, at least 17% pure, at least 18% pure, at least 19% pure, at least 20% pure, at least 21% pure, at least 22% pure, at least 23% pure, at least 24% pure, at least 25% pure, at least 26% pure, at least 27% pure, at least 28% pure, at least 29% pure, at least 30% pure, at least 31% pure, at least 32% pure, at least 33% pure, at least 34% pure, at least 35% pure, at least 36% pure, at least 37% pure, at least 38% pure, at least 39% pure, at least 40% pure, at least 41% pure, at least 42% pure, at least 43% pure, at least 44% pure, at least 45% pure, at least 46% pure, at least 47% pure, at least 48% pure, at least 49% pure, at least 50% pure, at least 51% pure, at least 52% pure, at least 53% pure, at least 54% pure, at least 55% pure, at least 56% pure, at least 57% pure, at least 58% pure, at least 59% pure, at least 60% pure, at least 61% pure, at least 62% pure, at least 63% pure, at least 64% pure, at least 65% pure, at least 66% pure, at least 67% pure, at least 68% pure, at least 69% pure, at least 70% pure, at least 71% pure, at least 72% pure, at least 73% pure, at least 74% pure, at least 75% pure, at least 76% pure, at least 77% pure, at least 78% pure, at least 79% pure, at least 80% pure, at least 81% pure, at least 82% pure, at least 83% pure, at least 84% pure, at least 85% pure, at least 86% pure, at least 87% pure, at least 88% pure, at least 89% pure, at least 90% pure, at least 91% pure, at least 92% pure, at least 93% pure, at least 94% pure, at least 95% pure, at least 96% pure, at least 97% pure, at least 98% pure, at least 99% pure, at least 99.1% pure, at least 99.2% pure, at least 99.3% pure, at least 99.4% pure, at least 99.5% pure, at least 99.6% pure, at least 99.7% pure, at least 99.8% pure, or at least 99.9% pure on a chemical, optical, isomeric, enantiomeric, or diastereomeric basis. Purity can be assessed, for example, by HPLC, MS, LC/MS, melting point, or NMR.

Assays

The properties of the peptidomimetic macrocycles of the invention are assayed, for example, by using the methods described below. In some embodiments, a peptidomimetic macrocycle of the invention has improved biological properties relative to a corresponding polypeptide lacking the substituents described herein.

In some embodiments, a peptidomimetic macrocycle disclosed herein binds MCL-1 selectively over another protein that has a BH3 domain. In some embodiments, the selectivity is a ratio of about 2 to about 1, about 3 to about 1, about 4 to about 1, about 5 to about 1, about 6 to about 1, about 7 to about 1, about 8 to about 1, about 9 to about 1, about 10 to about 1, about 20 to about 1, about 30 to about 1, about 40 to about 1, about 50 to about 1, about 60 to about 1, about 70 to about 1, about 80 to about 1, about 90 to about 1, about 100 to about 1, about 200 to about 1, about 300 to about 1, about 400 to about 1, about 500 to about 1, about 600 to about 1, about 700 to about 1, about 800 to about 1, about 900 to about 1, or about 1000 to about 1.

In some embodiments, a peptidomimetic macrocycle disclosed herein non-selectively binds additional types of proteins that have a BH3 domain. In some embodiments, the non-selectivity is at least about 2 types of proteins, at least about 3 types of proteins, at least about 4 types of proteins, at least about 5 types of proteins, at least about 6 types of proteins, at least about 7 types of proteins, at least about 8 types of proteins, at least about 9 types of proteins, at least about 10 types of proteins, at least about 11 types of protein, at least about 12 types of proteins, at least about 13 types of proteins, at least about 14 types of proteins, at least about 15 types of proteins, at least about 16 types of proteins, at least about 17 types of proteins, at least about 18 types of proteins, at least about 19 types of proteins, or at least about 20 types of proteins. In some embodiments, the non-selectivity is from about 2 types of protein to about 3 types of protein, from about 3 types of protein to about 4 types of protein, from about 4 types of protein to about 5 types of protein, from about 5 types of protein to about 6 types of protein, from about 6 types of protein to about 7 types of protein, from about 7 types of protein to about 8 types of protein, from about 8 types of protein to about 9 types of protein, from about 9 types of protein to about 10 types of protein, from about 10 types of protein to about 11 types of protein, from about 11 types of protein to about 12 types of protein, from about 12 types of protein to about 13 types of protein, from about 13 types of protein to about 14 types of protein, from about 14 types of protein to about 15 types of protein, from about 15 types of protein to about 16 types of protein, from about 16 types of protein to about 17 types of protein, from about 17 types of protein to about 18 types of protein, from about 18 types of protein to about 19 types of protein, or from about 19 types of protein to about 20 types of protein.

Assay to Determine α-Helicity.

In solution, the secondary structure of polypeptides with α-helical domains will reach a dynamic equilibrium between random coil structures and α-helical structures, often expressed as a “percent helicity”. Thus, for example, alpha-helical domains are predominantly random coils in solution, with α-helical content usually under 25%. Peptidomimetic macrocycles with optimized linkers, on the other hand, possess, for example, an alpha-helicity that is at least two-fold greater than that of a corresponding uncrosslinked polypeptide. In some embodiments, macrocycles of the invention will possess an alpha-helicity of greater than 50%. To assay the helicity of peptidomimetic macrocyles of the invention, the compounds are dissolved in an aqueous solution (e.g. 50 mM potassium phosphate solution at pH 7, or distilled H₂O, to concentrations of 25-50 μM). Circular dichroism (CD) spectra are obtained on a spectropolarimeter (e.g., Jasco J-710) using standard measurement parameters (e.g. temperature, 20° C.; wavelength, 190-260 nm; step resolution, 0.5 nm; speed, 20 nm/sec; accumulations, 10; response, 1 sec; bandwidth, 1 nm; path length, 0.1 cm). The α-helical content of each peptide is calculated by dividing the mean residue ellipticity (e.g. [Φ]222obs) by the reported value for a model helical decapeptide (Yang et al. (1986), Methods Enzymol. 130:208)).

Assay to Determine Melting Temperature (Tm).

A peptidomimetic macrocycle of the invention comprising a secondary structure such as an α-helix exhibits, for example, a higher melting temperature than a corresponding uncrosslinked polypeptide. Typically peptidomimetic macrocycles of the invention exhibit Tm of >60° C. representing a highly stable structure in aqueous solutions. To assay the effect of macrocycle formation on melting temperature, peptidomimetic macrocycles or unmodified peptides are dissolved in distilled H2 ₂O (e.g. at a final concentration of 50 μM) and the Tm is determined by measuring the change in ellipticity over a temperature range (e.g. 4 to 95° C.) on a spectropolarimeter (e.g., Jasco J-710) using standard parameters (e.g. wavelength 222 nm; step resolution, 0.5 nm; speed, 20 nm/sec; accumulations, 10; response, 1 sec; bandwidth, 1 nm; temperature increase rate: 1° C./min; path length, 0.1 cm).

Protease Resistance Assay.

The amide bond of the peptide backbone is susceptible to hydrolysis by proteases, thereby rendering peptidic compounds vulnerable to rapid degradation in vivo. Peptide helix formation, however, typically buries the amide backbone and therefore may shield it from proteolytic cleavage. The peptidomimetic macrocycles of the present invention may be subjected to in vitro trypsin proteolysis to assess for any change in degradation rate compared to a corresponding uncrosslinked polypeptide. For example, the peptidomimetic macrocycle and a corresponding uncrosslinked polypeptide are incubated with trypsin agarose and the reactions quenched at various time points by centrifugation and subsequent HPLC injection to quantitate the residual substrate by ultraviolet absorption at 280 nm. Briefly, the peptidomimetic macrocycle and peptidomimetic precursor (5 mcg) are incubated with trypsin agarose (Pierce) (S/E˜125) for 0, 10, 20, 90, and 180 minutes. Reactions are quenched by tabletop centrifugation at high speed; remaining substrate in the isolated supernatant is quantified by HPLC-based peak detection at 280 nm. The proteolytic reaction displays first order kinetics and the rate constant, k, is determined from a plot of ln[S] versus time (k=−1×slope).

Ex Vivo Stability Assay.

Peptidomimetic macrocycles with optimized linkers possess, for example, an ex vivo half-life that is at least two-fold greater than that of a corresponding uncrosslinked polypeptide, and possess an ex vivo half-life of 12 hours or more. For ex vivo serum stability studies, a variety of assays may be used. For example, a peptidomimetic macrocycle and a corresponding uncrosslinked polypeptide (2 mcg) are incubated with fresh mouse, rat or human serum (2 mL) at 37° C. for 0, 1, 2, 4, 8, and 24 hours. To determine the level of intact compound, the following procedure may be used: The samples are extracted by transferring 100 μl of sera to 2 ml centrifuge tubes followed by the addition of 10 μL of 50% formic acid and 500 μL acetonitrile and centrifugation at 14,000 RPM for 10 min at 4±2° C. The supernatants are then transferred to fresh 2 ml tubes and evaporated on Turbovap under N₂<10 psi, 37° C. The samples are reconstituted in 100 μL of 50:50 acetonitrile:water and submitted to LC-MS/MS analysis.

In vitro Binding Assays.

To assess the binding and affinity of peptidomimetic macrocycles and peptidomimetic precursors to acceptor proteins, a fluorescence polarization assay (FPA) isused, for example. The FPA technique measures the molecular orientation and mobility using polarized light and fluorescent tracer. When excited with polarized light, fluorescent tracers (e.g., FITC) attached to molecules with high apparent molecular weights (e.g. FITC-labeled peptides bound to a large protein) emit higher levels of polarized fluorescence due to their slower rates of rotation as compared to fluorescent tracers attached to smaller molecules (e.g. FITC-labeled peptides that are free in solution).

For example, fluoresceinated peptidomimetic macrocycles (25 nM) are incubated with the acceptor protein (25-1000 nM) in binding buffer (140 mM NaCl, 50 mM Tris-HCL, pH 7.4) for 30 minutes at room temperature. Binding activity is measured, for example, by fluorescence polarization on a luminescence spectrophotometer (e.g. Perkin-Elmer LS50B). Kd values may be determined by nonlinear regression analysis using, for example, Graphpad Prism software (GraphPad Software, Inc., San Diego, Calif.). A peptidomimetic macrocycle of the invention shows, in some instances, similar or lower Kd than a corresponding uncrosslinked polypeptide.

In vitro Displacement Assays to Characterize Antagonists of Peptide-Protein Interactions.

To assess the binding and affinity of compounds that antagonize the interaction between a peptide and an acceptor protein, a fluorescence polarization assay (FPA) utilizing a fluoresceinated peptidomimetic macrocycle derived from a peptidomimetic precursor sequence is used, for example. The FPA technique measures the molecular orientation and mobility using polarized light and fluorescent tracer. When excited with polarized light, fluorescent tracers (e.g., FITC) attached to molecules with high apparent molecular weights (e.g. FITC-labeled peptides bound to a large protein) emit higher levels of polarized fluorescence due to their slower rates of rotation as compared to fluorescent tracers attached to smaller molecules (e.g. FITC-labeled peptides that are free in solution). A compound that antagonizes the interaction between the fluoresceinated peptidomimetic macrocycle and an acceptor protein will be detected in a competitive binding FPA experiment.

For example, putative antagonist compounds (1 nM to 1 mM) and a fluoresceinated peptidomimetic macrocycle (25 nM) are incubated with the acceptor protein (50 nM) in binding buffer (140mM NaCl, 50 mM Tris-HCL, pH 7.4) for 30 minutes at room temperature. Antagonist binding activity is measured, for example, by fluorescence polarization on a luminescence spectrophotometer (e.g. Perkin-Elmer LS50B). Kd values may be determined by nonlinear regression analysis using, for example, Graphpad Prism software (GraphPad Software, Inc., San Diego, Calif.).

Any class of molecule, such as small organic molecules, peptides, oligonucleotides or proteins can be examined as putative antagonists in this assay.

Assay for Protein-Ligand Binding by Affinity Selection-Mass Spectrometry.

To assess the binding and affinity of test compounds for proteins, an affinity-selection mass spectrometry assay is used, for example. Protein-ligand binding experiments are conducted according to the following representative procedure outlined for a system-wide control experiment using 1 μM peptidomimetic macrocycle plus 5 μM target protein. A 1 μL DMSO aliquot of a 40 μM stock solution of peptidomimetic macrocycle is dissolved in 19 μL of PBS (Phosphate-buffered saline: 50 mM, pH 7.5 Phosphate buffer containing 150 mM NaCl). The resulting solution is mixed by repeated pipetting and clarified by centrifugation at 10 000 g for 10 min. To a 4 μL aliquot of the resulting supernatant is added 4 μL of 10 μM target protein in PBS. Each 8.0 μL experimental sample thus contains 40 pmol (1.5 μg) of protein at 5.0 μM concentration in PBS plus 1 μM peptidomimetic macrocycle and 2.5% DMSO. Duplicate samples thus prepared for each concentration point are incubated for 60 min at room temperature, and then chilled to 4° C. prior to size-exclusion chromatography-LC-MS analysis of 5.0 μL injections. Samples containing a target protein, protein-ligand complexes, and unbound compounds are injected onto an SEC column, where the complexes are separated from non-binding component by a rapid SEC step. The SEC column eluate is monitored using UV detectors to confirm that the early-eluting protein fraction, which elutes in the void volume of the SEC column, is well resolved from unbound components that are retained on the column. After the peak containing the protein and protein-ligand complexes elutes from the primary UV detector, it enters a sample loop where it is excised from the flow stream of the SEC stage and transferred directly to the LC-MS via a valving mechanism. The (M+3H)³⁺ ion of the peptidomimetic macrocycle is observed by ESI-MS at the expected m/z, confirming the detection of the protein-ligand complex.

Assay for Protein-Ligand K_(d) Titration Experiments.

To assess the binding and affinity of test compounds for proteins, a protein-ligand Kd titration experiment is performed. Protein-ligand K_(d) titrations experiments are conducted as follows: 2 μL DMSO aliquots of a serially diluted stock solution of titrant peptidomimetic macrocycle (5, 2.5, . . . , 0.098 mM) are prepared then dissolved in 38 μL of PBS. The resulting solutions are mixed by repeated pipetting and clarified by centrifugation at 10 000 g for 10 min. To 4.0 μL aliquots of the resulting supernatants is added 4.0 μL of 10 μM target protein in PBS. Each 8.0 μL experimental sample thus contains 40 pmol (1.5 μg) of protein at 5.0 μM concentration in PBS, varying concentrations (125, 62.5, . . . , 0.24 μM) of the titrant peptide, and 2.5% DMSO. Duplicate samples thus prepared for each concentration point are incubated at room temperature for 30 min, then chilled to 4° C. prior to SEC-LC-MS analysis of 2.0 μL injections. The (M+H)¹⁺, (M+2H)²⁺, (M+3H)³⁺, or (M+Na)¹⁺ ion is observed by ESI-MS; extracted ion chromatograms are quantified, then fit to equations to derive the binding affinity K_(d) as described in “A General Technique to Rank Protein-Ligand Binding Affinities and Determine Allosteric vs. Direct Binding Site Competition in Compound Mixtures.” Annis, D. A.; Nazef, N.; Chuang, C. C.; Scott, M. P.; Nash, H. M. J. Am. Chem. Soc. 2004, 126, 15495-15503; also in “ALIS: An Affinity Selection-Mass Spectrometry System for the Discovery and Characterization of Protein-Ligand Interactions” D. A. Annis, C.-C. Chuang, and N. Nazef. In Mass Spectrometry in Medicinal Chemistry. Edited by Wanner K, Höfner G: Wiley-VCH; 2007:121-184. Mannhold R, Kubinyi H, Folkers G (Series Editors): Methods and Principles in Medicinal Chemistry.

Assay for Competitive Binding Experiments by Affinity Selection-Mass Spectrometry.

To determine the ability of test compounds to bind competitively to proteins, an affinity selection mass spectrometry assay is performed, for example. A mixture of ligands at 40 μM per component is prepared by combining 2 μL aliquots of 400 μM stocks of each of the three compounds with 14 μL of DMSO. Then, 1 μL aliquots of this 40 μM per component mixture are combined with 1 μL DMSO aliquots of a serially diluted stock solution of titrant peptidomimetic macrocycle (10, 5, 2.5, . . . , 0.078 mM). These 2 μL samples are dissolved in 38 μL of PBS. The resulting solutions were mixed by repeated pipetting and clarified by centrifugation at 10 000 g for 10 min. To 4.0 μL aliquots of the resulting supernatants is added 4.0 μL of 10 μM target protein in PBS. Each 8.0 μL experimental sample thus contains 40 pmol (1.5 μg) of protein at 5.0 μM concentration in PBS plus 0.5 μM ligand, 2.5% DMSO, and varying concentrations (125, 62.5, . . . , 0.98 μM) of the titrant peptidomimetic macrocycle. Duplicate samples thus prepared for each concentration point are incubated at room temperature for 60 min, then chilled to 4° C. prior to SEC-LC-MS analysis of 2.0 μL injections. Additional details on these and other methods are provided in “A General Technique to Rank Protein-Ligand Binding Affinities and Determine Allosteric vs. Direct Binding Site Competition in Compound Mixtures.” Annis, D. A.; Nazef, N.; Chuang, C. C.; Scott, M. P.; Nash, H. M. J. Am. Chem. Soc. 2004, 126, 15495-15503; also in “ALIS: An Affinity Selection-Mass Spectrometry System for the Discovery and Characterization of Protein-Ligand Interactions” D. A. Annis, C.-C. Chuang, and N. Nazef. In Mass Spectrometry in Medicinal Chemistry. Edited by Wanner K, Höfner G: Wiley-VCH; 2007:121-184. Mannhold R, Kubinyi H, Folkers G (Series Editors): Methods and Principles in Medicinal Chemistry.

Binding Assays in Intact Cells.

It is possible to measure binding of peptides or peptidomimetic macrocycles to their natural acceptors in intact cells by immunoprecipitation experiments. For example, intact cells are incubated with fluoresceinated (FITC-labeled) compounds for 4 hrs in the absence of serum, followed by serum replacement and further incubation that ranges from 4-18 hrs. Cells are then pelleted and incubated in lysis buffer (50 mM Tris [pH 7.6], 150 mM NaCl, 1% CHAPS and protease inhibitor cocktail) for 10 minutes at 4° C. Extracts are centrifuged at 14,000 rpm for 15 minutes and supernatants collected and incubated with 10 μl goat anti-FITC antibody for 2 hrs, rotating at 4° C. followed by further 2 hrs incubation at 4° C. with protein A/G Sepharose (50 μl of 50% bead slurry). After quick centrifugation, the pellets are washed in lysis buffer containing increasing salt concentration (e.g., 150, 300, 500 mM). The beads are then re-equilibrated at 150 mM NaCl before addition of SDS-containing sample buffer and boiling. After centrifugation, the supernatants are optionally electrophoresed using 4%-12% gradient Bis-Tris gels followed by transfer into Immobilon-P membranes. After blocking, blots are optionally incubated with an antibody that detects FITC and also with one or more antibodies that detect proteins that bind to the peptidomimetic macrocycle.

Cellular Penetrability Assays.

To measure the cell penetrability of peptidomimetic macrocycles and corresponding uncrosslinked macrocycle, intact cells are incubated with fluoresceinated peptidomimetic macrocycles or corresponding uncrosslinked macrocycle (10 μM) for 4 hrs in serum free media at 37° C., washed twice with media and incubated with trypsin (0.25%) for 10 min at 37° C. The cells are washed again and resuspended in PBS. Cellular fluorescence is analyzed, for example, by using either a FACSCalibur flow cytometer or Cellomics' KineticScan® HCS Reader.

In Vivo Stability Assays.

To investigate the in vivo stability of the peptidomimetic macrocycles, the compounds are, for example, administered to mice or rats by IV, IP, PO or inhalation routes at concentrations ranging from 0.1 to 50 mg/kg and blood specimens withdrawn at 0′, 5′, 15′, 30′, 1 hr, 4 hrs, 8 hrs and 24 hours post-injection. Levels of intact compound in 25 μL of fresh serum are then measured by LC-MS/MS as above.

Clinical Trials.

To determine the suitability of the peptidomimetic macrocycles of the invention for treatment of humans, clinical trials are performed. For example, patients diagnosed with a muscle wasting disease or lipodystrophy and in need of treatment are selected and separated in treatment and one or more control groups, wherein the treatment group is administered a peptidomimetic macrocycle of the invention, while the control groups receive a placebo or a known BH3 mimetic. The treatment safety and efficacy of the peptidomimetic macrocycles of the invention can thus be evaluated by performing comparisons of the patient groups with respect to factors such as survival and quality-of-life. In this example, the patient group treated with a peptidomimetic macrocycle show improved long-term survival compared to a patient control group treated with a placebo.

Pharmaceutical Compositions and Routes of Administration

In some embodiments, the present invention provides a pharmaceutical composition comprising a peptidomimetic macrocycle of the invention and a pharmaceutically acceptable carrier.

The peptidomimetic macrocycles of the invention also include pharmaceutically acceptable derivatives or prodrugs thereof. A “pharmaceutically acceptable derivative” means any pharmaceutically acceptable salt, ester, salt of an ester, pro-drug or other derivative of a compound of this invention which, upon administration to a recipient, is capable of providing (directly or indirectly) a compound of this invention. Particularly favored pharmaceutically acceptable derivatives are those that increase the bioavailability of the compounds of the invention when administered to a mammal (e.g., by increasing absorption into the blood of an orally administered compound) or which increases delivery of the active compound to a biological compartment (e.g., the brain or lymphatic system) relative to the parent species. Some pharmaceutically acceptable derivatives include a chemical group which increases aqueous solubility or active transport across the gastrointestinal mucosa.

In some embodiments, the peptidomimetic macrocycles of the invention are modified by covalently or non-covalently joining appropriate functional groups to enhance selective biological properties. Such modifications include those which increase biological penetration into a given biological compartment (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism, and alter rate of excretion.

Pharmaceutically acceptable salts of the compounds of this invention include those derived from pharmaceutically acceptable inorganic and organic acids and bases. Examples of suitable acid salts include acetate, adipate, benzoate, benzenesulfonate, butyrate, citrate, digluconate, dodecylsulfate, formate, fumarate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, lactate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, palmoate, phosphate, picrate, pivalate, propionate, salicylate, succinate, sulfate, tartrate, tosylate and undecanoate. Salts derived from appropriate bases include alkali metal (e.g., sodium), alkaline earth metal (e.g., magnesium), ammonium and N-(alkyl)₄ ⁺ salts.

For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers include either solid or liquid carriers. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances, which also acts as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material. Details on techniques for formulation and administration are well described in the scientific and patent literature, see, e.g., the latest edition of Remington's Pharmaceutical Sciences, Maack Publishing Co, Easton Pa.

In powders, the carrier is a finely divided solid, which is in a mixture with the finely divided active component. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

Suitable solid excipients are carbohydrate or protein fillers include, but are not limited to sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; and gums including arabic and tragacanth; as well as proteins such as gelatin and collagen. If desired, disintegrating or solubilizing agents are added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate.

Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water/propylene glycol solutions. For parenteral injection, liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.

The pharmaceutical preparation is preferably in unit dosage form. In such form the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.

When the compositions of this invention comprise a combination of a peptidomimetic macrocycle and one or more additional therapeutic or prophylactic agents, both the compound and the additional agent should be present at dosage levels of between about 1 to 100%, and more preferably between about 5 to 95% of the dosage normally administered in a monotherapy regimen. In some embodiments, the additional agents are administered separately, as part of a multiple dose regimen, from the compounds of this invention. Alternatively, those agents are part of a single dosage form, mixed together with the compounds of this invention in a single composition.

In some embodiments, the compositions are present as unit dosage forms that can deliver, for example, from about 0.0001 mg to about 1,000 mg of the peptidomimetic macrocycles, salts thereof, prodrugs thereof, derivatives thereof, or any combination of these. Thus, the unit dosage forms can deliver, for example, in some embodiments, from about 1 mg to about 900 mg, from about 1 mg to about 800 mg, from about 1 mg to about 700 mg, from about 1 mg to about 600 mg, from about 1 mg to about 500 mg, from about 1 mg to about 400 mg, from about 1 mg to about 300 mg, from about 1 mg to about 200 mg, from about 1 mg to about 100 mg, from about 1 mg to about 10 mg, from about 1 mg to about 5 mg, from about 0.1 mg to about 10 mg, from about 0.1 mg to about 5 mg, from about 10 mg to about 1,000 mg, from about 50 mg to about 1,000 mg, from about 100 mg to about 1,000 mg, from about 200 mg to about 1,000 mg, from about 300 mg to about 1,000 mg, from about 400 mg to about 1,000 mg, from about 500 mg to about 1,000 mg, from about 600 mg to about 1,000 mg, from about 700 mg to about 1,000 mg, from about 800 mg to about 1,000 mg, from about 900 mg to about 1,000 mg, from about 10 mg to about 900 mg, from about 100 mg to about 800 mg, from about 200 mg to about 700 mg, or from about 300 mg to about 600 mg of the peptidomimetic macrocycles, salts thereof, prodrugs thereof, derivatives thereof, or any combination of these.

In some embodiments, the compositions are present as unit dosage forms that can deliver, for example, about 1 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, or about 1000 mg of peptidomimetic macrocycles, salts thereof, prodrugs thereof, derivatives thereof, or any combination of these.

Suitable routes of administration include, but are not limited to, oral, intravenous, rectal, aerosol, parenteral, ophthalmic, pulmonary, transmucosal, transdermal, vaginal, otic, nasal, and topical administration. In addition, by way of example only, parenteral delivery includes intramuscular, subcutaneous, intravenous, intramedullary injections, as well as intrathecal, direct intraventricular, intraperitoneal, intralymphatic, and intranasal injections.

In certain embodiments, a composition as described herein is administered in a local rather than systemic manner, for example, via injection of the compound directly into an organ. In specific embodiments, long acting formulations are administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Furthermore, in other embodiments, the drug is delivered in a targeted drug delivery system, for example, in a liposome coated with organ-specific antibody. In such embodiments, the liposomes are targeted to and taken up selectively by the organ. In yet other embodiments, the compound as described herein is provided in the form of a rapid release formulation, in the form of an extended release formulation, or in the form of an intermediate release formulation. In yet other embodiments, the compound described herein is administered topically.

In another embodiment, compositions described herein are formulated for oral administration. Compositions described herein are formulated by combining a peptidomimetic macrocycle with, e.g., pharmaceutically acceptable carriers or excipients. In various embodiments, the compounds described herein are formulated in oral dosage forms that include, by way of example only, tablets, powders, pills, dragees, capsules, liquids, gels, syrups, elixirs, slurries, suspensions and the like.

In certain embodiments, pharmaceutical preparations for oral use are obtained by mixing one or more solid excipient with one or more of the peptidomimetic macrocycles described herein, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as: for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methylcellulose, microcrystalline cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose; or others such as: polyvinylpyrrolidone (PVP or povidone) or calcium phosphate. In specific embodiments, disintegrating agents are optionally added. Disintegrating agents include, by way of example only, cross-linked croscarmellose sodium, polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.

In one embodiment, dosage forms, such as dragee cores and tablets, are provided with one or more suitable coating. In specific embodiments, concentrated sugar solutions are used for coating the dosage form. The sugar solutions, optionally contain additional components, such as by way of example only, gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments are also optionally added to the coatings for identification purposes. Additionally, the dyestuffs or pigments are optionally utilized to characterize different combinations of active compound doses.

In certain embodiments, therapeutically effective amounts of at least one of the peptidomimetic macrocycles described herein are formulated into other oral dosage forms. Oral dosage forms include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. In specific embodiments, push-fit capsules contain the active ingredients in admixture with one or more filler. Fillers include, by way of example only, lactose, binders such as starches, or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In other embodiments, soft capsules, contain one or more active compound that is dissolved or suspended in a suitable liquid. Suitable liquids include, by way of example only, one or more fatty oil, liquid paraffin, or liquid polyethylene glycol. In addition, stabilizers are optionally added.

In other embodiments, therapeutically effective amounts of at least one of the peptidomimetic macrocycles described herein are formulated for buccal or sublingual administration. Formulations suitable for buccal or sublingual administration include, by way of example only, tablets, lozenges, or gels. In still other embodiments, the peptidomimetic macrocycles described herein are formulated for parenteral injection, including formulations suitable for bolus injection or continuous infusion. In specific embodiments, formulations for injection are presented in unit dosage form (e.g., in ampoules) or in multi-dose containers. Preservatives are, optionally, added to the injection formulations. In still other embodiments, pharmaceutical compositions are formulated in a form suitable for parenteral injection as a sterile suspensions, solutions or emulsions in oily or aqueous vehicles. Parenteral injection formulations optionally contain formulatory agents such as suspending, stabilizing or dispersing agents. In specific embodiments, pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. In additional embodiments, suspensions of the active compounds are prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles for use in the pharmaceutical compositions described herein include, by way of example only, fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. In certain specific embodiments, aqueous injection suspensions contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension contains suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. Alternatively, in other embodiments, the active ingredient is in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

Pharmaceutical compositions herein can be administered, for example, once or twice or three or four or five or six times per day, or once or twice or three or four or five or six times per week, and can be administered, for example, for a day, a week, a month, 3 months, six months, a year, five years, or for example ten years. In some embodiments, a pharmaceutical formulation of the invention is administered no more frequently than once daily, no more frequently than every other day, no more frequently than twice weekly, no more frequently than three times weekly, no more frequently than four times weekly, no more frequently than five times weekly, or no more frequently than every other week. In some embodiments, a pharmaceutical formulation of the invention is administered no more than once weekly. In some embodiments, a pharmaceutical formulation of the invention is administered no more than twice weekly. In some embodiments, a pharmaceutical formulation of the invention is administered no more than three times weekly. In some embodiments, a pharmaceutical formulation of the invention is administered no more than four times weekly. In some embodiments, a pharmaceutical formulation of the invention is administered no more than five times weekly.

Methods of Use

As used herein, the term “treatment” is defined as the application or administration of a therapeutic agent to a patient, or application or administration of a therapeutic agent to an isolated tissue or cell line from a patient, who has a disease, a symptom of disease or a predisposition toward a disease, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve or affect the disease, the symptoms of disease or the predisposition toward disease. In some embodiments, a peptidomimetic macrocycle disclosed herein is used for treating a disease or condition in a subject in need thereof. In some embodiments, a peptidomimetic macrocycle disclosed herein is used for manufacture of a medicament for treating a disease or condition in a subject in need thereof.

In one aspect, the present invention provides novel peptidomimetic macrocycles that are useful in competitive binding assays to identify agents which bind to a natural ligand of the proteins or peptides upon which the peptidomimetic macrocycles are modeled. For example, labeled peptidomimetic macrocycles based on BIM can be used in a binding assay along with small molecules that competitively bind to MCL-1. Competitive binding studies allow for rapid in vitro evaluation and determination of drug candidates specific the BIM/MCL-1 interaction. Such binding studies may be performed with any of the peptidomimetic macrocycles disclosed herein and their binding partners.

The invention further provides for the generation of antibodies against the peptidomimetic macrocycles. In some embodiments, these antibodies specifically bind both the peptidomimetic macrocycle and the precursor peptides, such as BIM, to which the peptidomimetic macrocycles are related. Such antibodies, for example, disrupt the native protein-protein interactions, for example, between BIM and MCL-1.

In another aspect, the present invention provides methods to inhibit MCL-1, thereby stimulating death of a cell or tissue. In some embodiments, a subject suffering from a condition of suppressed cell death, such as B-cell lymphoma, is treated using pharmaceutical compositions of the invention.

In yet another aspect, the present invention provides methods for treating a disease driven by over-expression of MCL-1. In some embodiments, the disease driven by over-expression is a cancer. The cancer can be a liquid cancer or a solid cancer. Non-limiting examples of a liquid cancer include leukemia, lymphoma, myeloma, and myeloid dysplasia. Non-limiting examples of a solid cancer include lung cancer, breast cancer, colon cancer, brain cancer, liver cancer, soft-tissue sarcoma, pancreatic cancer, and melanoma. In some embodiments, the cancer is resistant, non-responsive, or determined unlikely to respond to a BCL-2 inhibitor. In some embodiments, the BCL-2 inhibitor is a BH3 mimetic. In some embodiments, the BCL-2 inhibitor is navitoclax (ABT-263) or obatoclax (GX15-070). These methods comprise administering an effective amount of a compound of the invention to a warm blooded animal, including a human. In some embodiments, a pharmaceutical composition provided herein used in the treatment of an MCL-1 over-expressing cancer is administered no more frequently than once daily, no more frequently than every other day, no more frequently than twice weekly, no more frequently than weekly, or no more frequently than every other week.

In some embodiments, provided herein are methods for treating neurodegenerative disorders. Many neurodegenerative diseases are a result of neurodegenerative processes including progressive loss of structure or function of neurons. These methods comprise administering an effective amount of at least one peptidomimetic macrocycles of the invention or a pharmaceutical composition thereof to a warm blooded animal, including a human. Non limiting neurodegenerative disorders that may be treated by the methods of the present invention include Parkinson's disease, Alzheimer's, Amyotrophic lateral sclerosis (ALS) and Huntington's disease.

In some embodiments, provided herein are methods for treating cardiac disorders. These methods comprise administering an effective amount of at least one peptidomimetic macrocycles of the invention or a pharmaceutical composition thereof to a warm blooded animal, including a human. Non limiting examples of cardiac disorders that may be treated by the methods of the present invention include coronary heart disease (also known as isohaemic heart disease or coronary artery disease), cardiomyopathy (diseases of cardiac muscle), hypertensive heart disease (diseases of the heart secondary to high blood pressure), heart failure, cor pulmonale (failure of the right side of the heart), cardiac dysrhythmias (abnormalities of heart rhythm), inflammatory heart disease, endocarditis (inflammation of the inner layer of the heart, the endocardium), inflammatory cardiomegaly, myocarditis (inflammation of the myocardium, the muscular part of the heart), valvular heart disease, cerebrovascular disease (disease of blood vessels that supplies to the brain such as stroke), peripheral arterial disease (disease of blood vessels that supplies to the arms and legs), congenital heart disease, and rheumatic heart disease. In some embodiments, the methods of the present invention may be used for the treatment of acute myocardial infarction or chromic ischemic heart disease.

Also provided herein are methods for promoting cardiac regeneration in a subject in need thereof. These methods comprise administering an effective amount of at least one peptidomimetic macrocycles of the invention or a pharmaceutical composition thereof to a warm blooded animal, including a human.

In some embodiments, provided herein are methods for treating diabetes or diabetes mellitus. Diabetes is a group of metabolic diseases in which a person has high blood sugar, either because the pancreas does not produce enough insulin, or because cells do not respond to the insulin that is produced. The diabetes may be Type 1 diabetes mellitus, type 2 diabetes, gestational diabetes, congenital diabetes, cystic fibrosis-related diabetes or several forms of monogenic diabetes. Treatment of diabetes may be by islet/beta cell transplantation.

In another aspect the invention provides methods of treating a subject by administering to the subject a beta cell, wherein the beta cell has been treated with an effective amount of a peptidomimetic macrocycle of the invention or a pharmaceutical composition thereof. Similarly, In another aspect the invention provides methods of treating a subject by administering to the subject a islet cell, wherein the islet cell has been treated with an effective amount of a peptidomimetic macrocycle of the invention or a pharmaceutical composition thereof.

In some embodiments, provided herein are methods for treating cancer. These methods comprise administering an effective amount of at least one peptidomimetic macrocycles of the invention or a pharmaceutical composition thereof to a warm blooded animal, including a human. Non-limiting examples of cancers that may be treated by the methods of the present invention include breast cancer such as a ductal carcinoma in duct tissue in a mammary gland, medullary carcinomas, colloid carcinomas, tubular carcinomas, and inflammatory breast cancer; ovarian cancer, including epithelial ovarian tumors such as adenocarcinoma in the ovary and an adenocarcinoma that has migrated from the ovary into the abdominal cavity; uterine cancer; cervical cancer such as adenocarcinoma in the cervix epithelial including squamous cell carcinoma and adenocarcinomas; prostate cancer, such as a prostate cancer selected from the following: an adenocarcinoma or an adenocarinoma that has migrated to the bone; pancreatic cancer such as epitheliod carcinoma in the pancreatic duct tissue and an adenocarcinoma in a pancreatic duct; bladder cancer such as a transitional cell carcinoma in urinary bladder, urothelial carcinomas (transitional cell carcinomas), tumors in the urothelial cells that line the bladder, squamous cell carcinomas, adenocarcinomas, and small cell cancers; leukemia such as acute myeloid leukemia (AML), acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, hairy cell leukemia, myelodysplasia, myeloproliferative disorders, acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), mastocytosis, chronic lymphocytic leukemia (CLL), multiple myeloma (MM), and myelodysplastic syndrome (MDS); bone cancer; lung cancer such as non-small cell lung cancer (NSCLC), which is divided into squamous cell carcinomas, adenocarcinomas, and large cell undifferentiated carcinomas, and small cell lung cancer; skin cancer such as basal cell carcinoma, melanoma, squamous cell carcinoma and actinic keratosis, which is a skin condition that sometimes develops into squamous cell carcinoma; eye retinoblastoma; cutaneous or intraocular (eye) melanoma; primary liver cancer (cancer that begins in the liver); kidney cancer; thyroid cancer such as papillary, follicular, medullary and anaplastic; AIDS-related lymphoma such as diffuse large B-cell lymphoma, B-cell immunoblastic lymphoma and small non-cleaved cell lymphoma; Kaposi's Sarcoma; viral-induced cancers including hepatitis B virus (HBV), hepatitis C virus (HCV), and hepatocellular carcinoma; human lymphotropic virus-type 1 (HTLV-1) and adult T-cell leukemia/lymphoma; and human papilloma virus (HPV) and cervical cancer; central nervous system cancers (CNS) such as primary brain tumor, which includes gliomas (astrocytoma, anaplastic astrocytoma, or glioblastoma multiforme), Oligodendroglioma, Ependymoma, Meningioma, Lymphoma, Schwannoma, and Medulloblastoma; peripheral nervous system (PNS) cancers such as acoustic neuromas and malignant peripheral nerve sheath tumor (MPNST) including neurofibromas and schwannomas, malignant fibrous cytoma, malignant fibrous histiocytoma, malignant meningioma, malignant mesothelioma, and malignant mixed Müllerian tumor; oral cavity and oropharyngeal cancer such as, hypopharyngeal cancer, laryngeal cancer, nasopharyngeal cancer, and oropharyngeal cancer; stomach cancer such as lymphomas, gastric stromal tumors, and carcinoid tumors; testicular cancer such as germ cell tumors (GCTs), which include seminomas and nonseminomas, and gonadal stromal tumors, which include Leydig cell tumors and Sertoli cell tumors; thymus cancer such as to thymomas, thymic carcinomas, Hodgkin disease, non-Hodgkin lymphomas carcinoids or carcinoid tumors; rectal cancer; and colon cancer.

In some embodiments, a peptidomimetic macrocycle disclosed herein is administered in combination with an additional therapy to treat a cancer. Non-limiting examples of the additional therapy include surgery, radiation therapy, chemotherapy, or immunotherapy. In some embodiments, the combination of the peptidomimetic macrocycle and surgery is on an adjuvant basis or a neo-adjuvant basis.

Non-limiting examples of chemotherapy include alkylating agents, angiogenesis inhibitors, antimetabolites, Bcr-Abl kinase inhibitors, cyclin-dependent kinase inhibitors, cyclooxygenase-2 inhibitors, epidermal growth factor receptor (EGFR) inhibitors, leukemia viral oncogene homolog (ErbB2) receptor inhibitors, histone deacetylase (HDAC) inhibitors, heat shock protein (HSP)-90 inhibitors, inhibitors of inhibitors of apoptosis proteins (IAPs), antibody drug conjugates, activators of death receptor pathway, kinesin inhibitors, JAK-2 inhibitors, mitogen-activated extracellular signal-regulated kinase (MEK) inhibitors, mammalian target of rapamycin (mTOR) inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), platelet-derived growth factor receptor (PDGFR) inhibitors, platinum chemotherapeutics, polo-like kinase (Plk) inhibitors, phosphoinositide-3 kinase (PI3K) inhibitors, thrombospondin analogs, vascular endothelial growth factor receptor (VEGFR) inhibitors, intercalating antibiotics, topoisomerase inhibitors, antibodies, hormonal therapies, deltoids and retinoids, poly ADP (adenosine diphosphate)-ribose polymerase (PARP) inhibitors, plant alkaloids, proteasome inhibitors, biologic response modifiers, pyrimidine analogs, purine analogs, antimitotics, taxanes, and ubiquitin ligase inhibitors.

Non-limiting examples of alkylating agents include: altretamine, AMD-473, AP-5280, apaziquone, bendamustine, brostallicin, busulfan, carboquone, carmustine, chlorambucil, laromustine, cyclophosphamide, decarbazine, estramustine, fotemustine, glufosfamide, ifosfamide, KW-2170, lomustine, mafosfamide, melphalan, mitobronitol, mitolactol, nimustine, nitrogen mustard N-oxide, ranimustine, temozolomide, thiotepa, bendamustine, treosulfan, and rofosfamide.

Non-limiting examples of angiogenesis inhibitors include: endothelial-specific receptor tyrosine kinase (Tie-2) inhibitors, epidermal growth factor receptor (EGFR) inhibitors, insulin growth factor-2 receptor (IGFR-2) inhibitors, matrix metalloproteinase-2 (MMP-2) inhibitors, matrix metalloproteinase-9 (MMP-9) inhibitors, platelet-derived growth factor receptor (PDGFR) inhibitors, thrombospondin analogs, and vascular endothelial growth factor receptor tyrosine kinase (VEGFR) inhibitors.

Non-limiting examples of antimetabolites include: pemetrexed disodium, 5-azacitidine, capecitabine, carmofur, cladribine, clofarabine, cytarabine, cytarabine ocfosfate, cytosine arabinoside, decitabine, deferoxamine, doxifluridine, eflornithine, EICAR, enocitabine, ethnylcytidine, fludarabine, 5-fluorouracil, leucovorin, gemcitabine, hydroxyurea, melphalan, mercaptopurine, 6-mercaptopurine riboside, methotrexate, mycophenolic acid, nelarabine, nolatrexed, ocfosfate, pelitrexol, pentostatin, raltitrexed, Ribavirin, triapine, trimetrexate, S-1, tiazofurin, tegafur, TS-1, vidarabine, and UFT.

Non-limiting examples of Bcr-Abl kinase inhibitors include: dasatinib, nilotinib, and imatinib.

Non-limiting examples of CDK inhibitors include: AZD-5438, BMI-1040, BMS-032, BMS-387, CVT-2584, flavopyridol, GPC-286199, MCS-5A, PD0332991, PHA-690509, seliciclib, and ZK-304709.

Non-limiting examples of COX-2. inhibitors include: ABT-963, etoricoxib, valdecoxib, BMS347070, celecoxib, lumiracoxib, CT-3, deracoxib, JTE-522, 4-methyl-2-(3,4-dimethylphenyl)-1-(4-sulfamoylphenyl-1H-pyrrole), etoricoxib, NS-398, parecoxib, RS-57067, SC-58125, SD-8381, SVT-2016, S-2474, T-614, and rofecoxib.

Non-limiting examples of EGFR inhibitors include: ABX-EGF, anti-EGFR immunoliposomes, EGF-vaccine, EMD-7200, cauximab, HR3, IgA antibodies, gefitinib, erlotinib, TP-38, EGER fusion protein, and lapatinib.

Non-limiting examples of ErbB2 receptor inhibitors include: CP-724-714, canertinib, trastuzumab, lapatinib, petuzumab, TAK-165, ionafarnib, GW-282974, EKB-569, PI-166, dHER2 HER2. vaccine, APC-8024 HER-2 vaccine, anti-HER2/neu bispecific antibody, B7.her21gG3, AS HER2 trifunctional bispecific antibodies, mAB AR-209, and mAB 2B-1.

Non-limiting examples of histone deacetylase inhibitors include: depsipeptide, LAQ-824, MS-275, trapoxin, suberoylanilide hydroxamic acid (SAHA), TSA, and valproic acid.

Non-limiting examples of HSP-90 inhibitors include: 17-AAG-nab, 17-AAG, CNE-101, CNF-1010, CNF-2024, 17-DMAG, geldanamycin, IPI-504, KOS-953, human recombinant antibody to HSP-90, NCS-683664, PU24FC1, PU-3, radicicol, SNX-2112, or STA-9090 VER49009.

Non-limiting examples of inhibitors of inhibitors of apoptosis proteins include: HGS1029, GDC-0145, GDC-0152, LCL-161, and LBW-242.

Non-limiting examples of antibody-drug conjugates include: anti-CD22-MC-MMAF, anti-CD22-MC-MMAE, anti-CD22-MCC-DM1, CR-0,1-veMMAE, PSMA-ADC, MEDI-547, SGN-19Am SGN-35, and SGN-75.

Non-limiting examples of activators of death receptor pathway include: TRAIL, antibodies or other agents that target TRAIL or death receptors (e.g., DR4 and DRS) such as apomab, conatumumab, ETR2-ST01, GDC0145, lexatumumab, HGS-1029, LBY-135, PRO-1762, and trastuzumab.

Non-limiting examples of kinesin inhibitors include: Eg5 inhibitors such as AZD4877, ARRY-520; and CENPE inhibitors such as GSK923295A.

Non-limiting examples of JAK-2 inhibitors include: lesaurtinib, XL019 or INCB018424.

Non-limiting examples of MEK inhibitors include: trametmib, ARRY-142886, ARRY-438162 PD-325901, C1-1040, and PD-98059.

Non-limiting examples of mTOR inhibitors include: AP-23573, CCI-779, everolimus, RAD-001, rapamycin, temsirolimus, ATP-competitive TORC1/TORC2 inhibitors, comprising PI-103, PP242, PP30, and Torin 1.

Non-limiting examples of non-steroidal anti-inflammatory drugs include: salsalate, diflunisal, ibuprofen, ketoprofen, nabumetone, piroxicam, ibuprofen cream, naproxen, diclofenac, indomethacin, sulindac, tolmetin, etodolac, ketorolac, and oxaprozin.

Non-limiting examples of PDGFR inhibitors include: C-451, CP-673, and CP-868596.

Non-limiting examples of platinum chemotherapeutics include: cisplatin, oxaliplatin, eptaplatin, lobaplatin, nedaplatin, carboplatin, satraplatin, and picoplatin.

Non-limiting examples of polo-like kinase inhibitors include: B1-2536.

Non-limiting examples of phosphoinositide-3 kinase (PI3K) inhibitors include: wortmannin, LY294002, XL-147, CAL-120, ONC-21, AEZS-127, ETP-45658, PX-866, GDC-0941, BGT226, BEZ235, and XL765.

Non-limiting examples of thrombospondin analogs include: ABT-510, ABT-567, ABT-898, and TSP-1.

Non-limiting examples of VEGFR inhibitors include: bevacizumab, ABT-869, AEE-788, ANGIOZYME™ (a ribozyme that inhibits angiogenesis, axitinib, AZD-2171, CP-547,632, IM-862, pegaptamib, sorafenib, pazopanib, vatalanib, sunitinib, VEGF trap, and vandetanib.

Non-limiting examples of antibiotics include: intercalating antibiotics aclarubicin, actinomycin D, amrubicin, annamycin, adriamycin, bleomycin, daunorubicin, liposomal doxorubicin, doxorubicin, elsamitrucin, epirbucin, glarbuicin, idarubicin, mitomycin C, nemorubicin, neocarzinostatin, peplomycin, pirarubicin, rebeccamycin, stimalamer, streptozocin, valrubicin, and zinostatin.

Non-limiting examples of topoisomerase inhibitors include: aclarubicin, 9-aminocamptothecin, amonafide, amsacrine, hecatecarin, belotecan, BN-80915, irinotecan, camptothecin, dexrazoxine, diflomotecan, edotecarin, epirubicin, etoposide, exatecan, 10-hydroxycamptothecin, gimatecan, lurtotecan, mitoxantrone, orathecin, pirarbucin, pixantrone, rubitecan, sobuzoxane, SN-38, tafluposide, and topotecan.

Non-limiting examples of antibodies include: bevacizumab, CD40 antibodies, chTNT-1/B, denosumab, cetuximab, zanolimumab, IGF1R antibodies, llintuzumab, edrecolomab, WX G250, rituximab, ticilimumab, trastuzumab, CD20 antibodies types I and II, pembrolizumab, ipilumimab, nivolumab, rituximab, and panituommab.

Non-limiting examples of hormonal therapies include: anastrozole, exemestane, arzoxifene, bicalutamide, cetrorelix, degarelix, deslorelin, trilostane, dexamethasone, flutamide, raloxifene, fadrozole, toremifene, fulvestrant, letrozole, formestane, glucocorticoids, doxercalciferol, sevelamer carbonate, lasofoxifene, leuprolide acetate, megesterol, mifepristone, nilutamide, tamoxifen citrate, aharelix, prednisone, finasteride, rilostane, buserelin, luteinizing hormone releasing hormone (LHRH), histrelin implant, trilostane, modrastane, fosrelin, and goserelin.

Non-limiting examples of deltoids and retinoids include: seocalcitol, lexacalcitrol, fenretinide, aliretinoin, liposomal tretinoin, bexarotene, and LGD-1550.

Non-limiting examples of PARP inhibitors include: ABT-888, olaparib, KU-59436, AZD-2281, AG-014699, BSI-201, BGP-15, INO-1001, and ONO-2231.

Non-limiting examples of plant alkaloids include: vincristine, vinblastine, vindesine, and vinorelbine.

Non-limiting examples of proteasome inhibitors include: bortezomib, carfilzomib, MG132, and NPI-0052.

Non-limiting examples of biological response modifiers include: krestin, lentinan, sizofuran, picibanil, PF-3512676, and ubenimex.

Non-limiting examples of pyrimidine analogs include: cytarabine, cytosine arabinoside, doxifluridine, fludarabine, 5-fluorouracil, floxuridine, gemcitabine, ratitrexed, and triacetyluridine troxacitabine.

Non-limiting examples of purine analogs include: thioguanine, and mercaptopurine.

Non-limiting examples of antimitotic agents include: batabulin, epothilone D, N-(2-((4-hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide, ixabepilone, paclitaxel, docetaxel, PNU100940, patupilone, XRP-9881 larotaxel, vinflunine, and epothilone.

Non-limiting examples of ubiquitin ligase inhibitors include paclitaxel and docetaxel.

Non-limiting examples of ubiquitin ligase inhibitors include: MDM2 inhibitors, such as nutlins, and NEDD8 inhibitors such as MLN4924.

Non-limiting examples of immunotherapies include: interferons or immune-enhancing agents. Interferons comprise interferon alpha, interferon alpha-2a, interferon alpha-2b, interferon beta, interferon gamma-1a, interferon gamma-1b, interferon gamma-n1. Other immune-enhancing agents comprise oxidized glutathione, tasonermin, tositurnornab, alemtuzumab, CTLA4, decarbazine, denileukin, epratuzumab, lenograstim, lentinan, leukocyte alpha interferon, imiquimod, ipilumimab, melanoma vaccine, niitumomab, molgramostim, nivolumab, pembrolizumab, gemtuzumab ozogamicin, filgrastim, OncoVAC-CL, oregovomab, pemtumomab, sipuleucel-T, sargaramostim, sizofilan, teceleukin, Bacillus Calmette-Guerin, ubenimex, virulizin, Z-100, Tetrachlorodecaoxide (TCDO), aldesleukin, thymalfasin, daclizumab, and 90Y-Ibritumomab tiuxetan.

While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.

EXAMPLES Example 1 Peptidomimetic Macrocycles of the Invention

Peptidomimetic macrocycles were synthesized, purified and analyzed as previously described and as described below (Schafmeister et al., J. Am. Chem. Soc. 122:5891-5892 (2000); Schafmeister & Verdin, J. Am. Chem. Soc. 122:5891 (2005); Walensky et al., Science 305:1466-1470 (2004); and U.S. Pat. No. 7,192,713). Peptidomimetic macrocycles were designed by replacing two or more naturally occurring amino acids with the corresponding synthetic amino acids. Substitutions were made at i and i+4, and i and i+7 positions. Peptide synthesis was performed either manually or on an automated peptide synthesizer (Applied Biosystems, model 433A), using solid phase conditions, rink amide AM resin (Novabiochem), and Fmoc main-chain protecting group chemistry. For the coupling of natural Fmoc-protected amino acids (Novabiochem), 10 equivalents of amino acid and a 1:1:2 molar ratio of coupling reagents HBTU/HOBt (Novabiochem)/DIEA were employed. Non-natural amino acids (4 equiv) were coupled with a 1:1:2 molar ratio of HATU (Applied Biosystems)/HOBt/DIEA. The N-termini of the synthetic peptides were acetylated, while the C-termini were amidated.

Purification of cross-linked compounds was achieved by high performance liquid chromatography (HPLC) (Varian ProStar) on a reverse phase C18 column (Varian) to yield the pure compounds. Chemical composition of the pure products was confirmed by LC/MS mass spectrometry (Micromass LCT interfaced with Agilent 1100 HPLC system) and amino acid analysis (Applied Biosystems, model 420A).

Example 2 Metabolism by Purified Protease

Linear peptides and cross-linked peptidomimetic macrocycles are tested for stability to proteolysis by Trypsin (MP Biomedicals, Solon Ohio) by solubilizing each peptide at 10 μM concentration in 200 μL 100 mM NH4OAc (pH 7.5). The reaction is initiated by adding 3.5 μl of Trypsin (12.5 μg protease per 500 μL reaction) and shaking continually in sealed vials while incubating in a Room Temperature (22±2° C.). The enzyme/substrate ratio is 1:102 (w/w). After incubation times of 0, 5, 30, 60 and 135 min the reaction is stopped by addition of equal volume of 0.2% trifluoroacetic acid. Then, the solution is immediately analyzed by LC-MS in positive detection mode. The reaction half-life for each peptide is calculated in GraphPad Prism by a non-linear fit of uncalibrated MS response versus enzyme incubation time.

SEQ ID NO: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 1626 Ac— I W I A Q A L R $r8 I G D E F N 1627 Ac— I W I A Q E L R $r8 I G D E F N 1628 Ac— W I A Q A L R $r8 I G D A F N 1629 Ac— I A Q A L R $r8 I G D A F A 1630 Ac— I A Q A L R $r8 I G D A F N 1631 Ac— I W I A Q A L R $r8 I G D A F N 1632 Ac— W I A Q A L R $r8 I G D A F N 1633 Ac— I A Q A L R $r8 I G D A F N 1634 Ac— I A A A L R $r8 I G D A F N 1635 Ac— I A Q A L A $r8 I G D A F N 1636 Ac— I A Q A L R $r8 I A D A F N 1637 Ac— I A Q A L R $r8 I G D A A N 1638 Ac— I A Q A L R $r8 I G D A F N 1639 Ac— I $ I A Q $ L R $r8 I G D E F N 1640 Ac— I W I A Q A L R %r8 I G D A F N 1641 Ac— I W I A Q A L R $r8 I G D E F A 1642 Ac— I W I A Q A L R $r8 I G D Q A N 1643 FITC- Ba I W I A Q A L R $r8 I G D A F N 1644 5-FAM- Ba I W I A Q A L R $r8 I G D A F N 1645 5-FAM- Ba I W I A Q A L R $r8 I G D E F N 1646 Ac— I A I A Q A L R $r8 I G D A F N 1647 Ac— I W I A Q A L R $r8 I G D E F N 1648 Ac— I W I A Q A L R $r8 I G D Q F N 1649 Ac— I W I A A A L R $r8 I G D E F N 1650 Ac— I W I A A A L R $r8 I G D Q F N 1651 Ac— I W I A A A L R $r8 I G D A F N 1652 Ac— I W I A Q A L R $r8 I G D A F A 1653 Ac— I W I A Q A L Cit $r8 I G D A F N 1654 Ac— I W I A Q A L Cit $r8 I G D Q F N 1655 Ac— I W I A Q A L H $r8 I G D A F N 1656 Ac— I W I A Q A L H $r8 I G D Q F N 1657 Ac— I W I A Q A L Q $r8 I G D A F N 1658 Ac— I W I A Q A L Q $r8 I G D Q F N 1659 Ac— I W I A Q A L R $r8 I G D A A N 1660 Ac— I W I A Q A L R $r8 I G D A I N 1661 Ac— I W I A Q A L R $r8 I G D Q I N 1662 Ac— I W I A Q A A R $r8 I G D A A N 1663 Ac— I W I A Q A L R $r8 I A D A F N 1664 Ac— I W I A Q A L R $r8 I A D Q F N 1665 Ac— I W I A Q A L R $r8 A G D A F N 1666 Ac— I W I A Q A L R $r8 A G D Q F N 1667 Ac— I W I A Q A L R $r8 F G D A F N 1668 Ac— I W I A Q A L R $r8 F G D Q F N 1669 Ac— I W F A Q A L R $r8 I G D A F N 1670 Ac— I W F A Q A L R $r8 I G D Q F N 1671 Ac— I W I A Q A L A $r8 I G D A F N 1672 Ac— I W I A Q A L R $r8 I G N A F N 1673 Ac— I W I A Q A A R $r8 I G D A F N 1674 Ac— I W I A Q A L R $r8 I G D Q F A 1675 Ac— I W Cha A Q A L R $r8 I G D A F N 1676 Ac— I W hhL A Q A L R $r8 I G D A F N 1677 Ac— I W Adm A Q A L R $r8 I G D A F N 1678 Ac— I W hCha A Q A L R $r8 I G D A F N 1679 Ac— I W hF A Q A L R $r8 I G D A F N 1680 Ac— I W Igl A Q A L R $r8 I G D A F N 1681 Ac— I W F4CF3 A Q A L R $r8 I G D A F N 1682 Ac— I W F4tBu A Q A L R $r8 I G D A F N 1683 Ac— I W 2Nal A Q A L R $r8 I G D A F N 1684 Ac— I W Bip A Q A L R $r8 I G D A F N 1685 Ac— I W I A Q A Cha R $r8 I G D A F N 1686 Ac— I W I A Q A hhL R $r8 I G D A F N 1687 Ac— I W I A Q A Adm R $r8 I G D A F N 1688 Ac— I W I A Q A hCha R $r8 I G D A F N 1689 Ac— I W I A Q A hAdm R $r8 I G D A F N 1690 Ac— I W I A Q A hF R $r8 I G D A F N 1691 Ac— I W I A Q A Igl R $r8 I G D A F N 1692 Ac— I W I A Q A F4CF3 R $r8 I G D A F N 1693 Ac— I W I A Q A F4tBu R $r8 I G D A F N 1694 Ac— I W I A Q A 2Nal R $r8 I G D A F N 1695 Ac— I W I A Q A Bip R $r8 I G D A F N 1696 Ac— I W I A Q A L R $r8 Cba G D A F N 1697 Ac— I W I A Q A L R $r8 hL G D A F N 1698 Ac— I W I A Q A L R $r8 Cha G D A F N 1699 Ac— I W I A Q A L R $r8 Tba G D A F N 1700 Ac— I W I A Q A L R $r8 hhL G D A F N 1701 Ac— I AmW I A Q A L R $r8 I G D A F N 1702 Ac— I Aib I A Q A L R $r8 I G D A F N 1703 Ac— AmL W I A Q A L R $r8 I G D A F N 1704 Ac— I W AmL A Q A L R $r8 I G D A F N 1705 Ac— I W I Aib Q A L R $r8 I G AmD A F N 1706 Ac— I W I A Aib A L R $r8 I G D A F N 1707 Ac— I W I A Q A L R $r8 I G AmD A F N 1708 Ac— I W I A Q A L R $r8 I G D A F N 1709 Ac— I W Tba A Q A L R $r8 I G D A F N 1710 Ac— I W hL A Q A L R $r8 I G D A F N 1711 Ac— I W Chg A Q A L R $r8 I G D A F N 1712 Ac— I W Ac6c A Q A L R $r8 I G D A F N 1713 Ac— I W Ac5c A Q A L R $r8 I G D A F N 1714 Ac— E W I A A A L R $r8 I G D A F N 1715 Ac— R W I A A A L R $r8 I G D A F N 1716 Ac— K W I A A A L R $r8 I G D A F N 1717 Ac— H W I A A A L R $r8 I G D A F N 1718 Ac— S W I A A A L R $r8 I G D A F N 1719 Ac— Q W I A A A L R $r8 I G D A F N 1720 Ac— A W I A A A L R $r8 I G D A F N 1721 Ac— Aib W I A A A L R $r8 I G D A F N 1722 Ac— F W I A A A L R $r8 I G D A F N 1723 Ac— I D I A A A L R $r8 I G D A F N 1724 Ac— I R I A A A L R $r8 I G D A F N 1725 Ac— I H I A A A L R $r8 I G D A F N 1726 Ac— I S I A A A L R $r8 I G D A F N 1727 Ac— I N I A A A L R $r8 I G D A F N 1728 Ac— I L I A A A L R $r8 I G D A F N 1729 Ac— I F I A A A L R $r8 I G D A F N 1730 Ac— I 2Nal I A A A L R $r8 I G D A F N 1731 Ac— I W I S A A L R $r8 I G D A F N 1732 Ac— I W I L A A L R $r8 I G D A F N 1733 Ac— I W I F A A L R $r8 I G D A F N 1734 Ac— I W I A L A L R $r8 I G D A F N 1735 Ac— I W I A A A L K $r8 I G D A F N 1736 Ac— I W I A A A L R $r8 I Abu D A F N 1737 Ac— I W I A A A L R $r8 I V D A F N 1738 Ac— I W I A A A L R $r8 I G E A F N 1739 Ac— I W I A A A L R $r8 I G D A G N 1740 Ac— I W I A Q A L R $r8 I G D A W N 1741 Ac— I W I A Q A L R $r8 I G D A hF N 1742 Ac— I W I A Q A L R $r8 I G D A F4CF3 N 1743 Ac— I W I A Q A L R $r8 I G D A F4tBu N 1744 Ac— I W I A Q A L R $r8 I G D A 2Nal N 1745 Ac— I W I A Q A L R $r8 I G D A Bip N 1746 Ac— I W I A A A L R $r8 I G D A F D 1747 Ac— I W I A A A L R $r8 I G D A F E 1748 Ac— I W I A A A L R $r8 I G D A F Q 1749 Ac— I W I A A A L R $r8 I G D A F S 1750 Ac— I W I A A A L R $r8 I G D A F H 1751 Ac— I W I A A A L R $r8 I G D A F N 1752 Ac— I W I A Q A L R $r8 I G D A F N 1753 Ac— I W I A Q A L R $r8 I G D A F N 1754 Ac— I W I A Q A L R $r8 I G D A F N 1755 Ac— I W I A Q A L R $r8 I G D A F N 1756 Ac— I W I A Q A L R $r8 I G D A F N 1757 Ac— I W I A Q A L R $r8 I G D A F N 1758 Ac— I W I A A A L R $r8 I G D A F N 1759 Ac— I W I A A A L R $r8 I G D A F N 1760 Ac— I W I A A A L R $r8 I G D A F N 1761 Ac— I W I A A A L R $r8 I G D A F N 1762 Ac— I W I A A A L R $r8 I G D A F N 1763 Ac— I W I A A A L R $r8 I G D A F N 1764 Ac— I W I A A A L R $r8 I G D A F N 1765 Ac— I W I A Q A AmL R $r8 I G D A F N 1766 Ac— I W I A Q A L R $r8 I G AmD A F N 1767 Ac— I W I A Q A L R $r8 I G D A F N 1768 Ac— I W I A Q A L R $r8 I G D A F N 1769 Ac— I W I A Q A A Cit $r8 I G D A F N 1770 Ac— I W I A Q A L Cit $r8 I G N A F N 1771 Ac— I W I A Q A L Cit $r8 I G D A A N 1772 Ac— I W I A Q A L Cit $r8 I G D A V N 1773 Ac— I W I A Q A L R $r8 I G D A F N 1774 Ac— I W I A Q A L R $r8 hL G D A F N 1775 Ac— I W I A Q A L R $r8 hL G D A F N 1776 Ac— I W I A Q A L R $r8 hL G D A F N 1777 Ac— A W I A A A L R $r8 hL G D A F N 1778 Ac— A W I A A A L R $r8 hL G D A F N 1779 Ac— I W I A Q A A R $r8 hL G D A F N 1780 Ac— I $r8 I A Q A L R St I G D E F N 1781 Ac— I W I A $ A L R St I G D E F N 1782 Ac— I W I A Q A L R $r8 I G D E F N SEQ ID Calc. Found EC₅₀ Ki Ki Ki NO: 16 17 18 19 20 21 (M + 2)/2 mass (μM)* MCL-1 BCL-X_(L) BCL-2 1626 $ Y Y A R R —NH₂ 1344.74 1345.7 10.6 3.9 12.9 1627 $ Y Y A R R —NH₂ 1373.75 1373.56 9.2 23.5 1628 $ Y Y A —NH₂ 1103.1 1103.12 212.6 423.8 1629 $ Y Y A —NH₂ 988.55 988.45 373.6 877.5 1630 $ Y A A —NH₂ 964.04 963.94 >1000 >1000 1631 $ Y Y A —NH₂ 1159.64 1159.87 6.6 8.4 22.4 84.8 1632 $ Y Y A —NH₂ 1103.1 1102.94 410.2 1633 $ Y Y A —NH₂ 1010.06 1009.9 308.6 519.2 1634 $ Y Y A —NH₂ 981.55 981.86 255.9 318.7 1635 $ Y Y A —NH₂ 967.53 967.45 >1000 >1000 1636 $ Y Y A —NH₂ 1017.07 1016.93 243.1 272.5 1637 $ Y Y A —NH₂ 972.04 971.89 >1000 >1000 1638 $ A Y A —NH₂ 964.04 963.94 471.5 803.9 1639 $ Y Y A —NH₂ 1185.17 1185.61 >40 19.5 11.6 8.7 1640 % Y Y A —NH₂ 1160.14 1161.28 1641 $ Y Y A —NH₂ 1167.14 1168.2 7.0 15.4 21.9 1642 $ Y Y A —NH₂ 1150.13 1151.09 1643 $ Y Y A —NH₂ 1368.67 1369.79 ND ND ND 1644 $ Y Y A —NH₂ 1353.18 1354.13 ND ND ND 1645 $ Y Y A —NH₂ 1382.18 1382.99 ND ND ND 1646 $ Y Y A —NH₂ 1102.12 1103.17 19.7 22.3 37.7 1647 $ Y Y A —NH₂ 1188.64 1189.57 >40 1.8 1.4 3.2 1648 $ Y Y A —NH₂ 1188.15 1189.1 5.2 12.0 67.0 1649 $ Y Y A —NH₂ 1160.13 1161.17 1.0 1.0 6.0 1650 $ Y Y A —NH₂ 1159.64 1160.34 6.0 4.0 22.0 1651 $ Y Y A —NH₂ 1131.13 1132.12 6.7 25.6 65.4 1652 $ Y Y A —NH₂ 1138.14 1139.15 7.4 55.7 114.6 1653 $ Y Y A —NH₂ 1160.13 1160.98 9.1 7.5 109.0 211.6 1654 $ Y Y A —NH₂ 1188.64 1189.66 1.7 28.8 88.2 1655 $ Y Y A —NH₂ 1150.12 1151.09 >1000 >1000 >1000 1656 $ Y Y A —NH₂ 1178.63 1179.67 >1000 >1000 >1000 1657 $ Y Y A —NH₂ 1145.62 1146.55 76.2 325.4 364.7 1658 $ Y Y A —NH₂ 1174.13 1175.14 14.8 6.3 27.5 1659 $ Y Y A —NH₂ 1121.62 1122.5 7.5 401.7 139.7 1660 $ Y Y A —NH₂ 1142.65 1143.59 3.4 14.1 113.0 1661 $ Y Y A —NH₂ 1171.16 1171.9 1662 $ Y Y A —NH₂ 1100.6 1101.5 177.0 154.0 502.0 1663 $ Y Y A —NH₂ 1166.65 1167.83 96.3 7.7 84.0 1664 $ Y Y A —NH₂ 1195.16 1196.23 116.2 7.7 25.6 1665 $ Y Y A —NH₂ 1138.62 1139.61 182.7 18.1 59.6 1666 $ Y Y A —NH₂ 1167.13 1168.11 122.1 1.9 4.8 1667 $ Y Y A —NH₂ 1176.63 1177.63 27.8 15.8 68.5 1668 $ Y Y A —NH₂ 1205.14 1205.94 74.1 25.6 66.1 1669 $ Y Y A —NH₂ 1176.63 1177.63 22.0 28.0 179.4 1670 $ Y Y A —NH₂ 1205.14 1206.13 29.3 25.9 204.6 1671 $ Y Y A —NH₂ 1117.11 1118.15 73.8 386.4 >1000 1672 $ Y Y A —NH₂ 1159.15 1159.63 194.7 416.0 404.9 1673 $ Y Y A —NH₂ 1138.62 1139.2 >1000 >1000 >1000 1674 $ Y Y A —NH₂ 1166.65 1167.3 22.8 53.5 84.9 1675 $ Y Y A —NH₂ 1179.65 1180.15 3.9 43.8 14.4 104.9 1676 $ Y Y A —NH₂ 1173.65 1174.39 5.7 21.2 11.9 160.7 1677 $ Y Y A —NH₂ 1198.66 1199.28 21.6 7.3 59.0 1678 $ Y Y A —NH₂ 1186.66 1186.98 22.2 13.1 182.3 1679 $ Y Y A —NH₂ 1183.64 1184.48 7.2 53.1 69.7 221.2 1680 $ Y Y A —NH₂ 1190.65 1190.41 5.9 12.8 145.5 246.4 1681 $ Y Y A —NH₂ 1210.62 1211.31 76.7 9.1 237.0 1682 $ Y Y A —NH₂ 1204.66 1205.39 150.8 16.9 >1000 1683 $ Y Y A —NH₂ 1201.64 1202.2 4.8 163.2 151.1 264.6 1684 $ Y Y A —NH₂ 1214.65 1215.43 6.4 11.0 3.0 >1000 1685 $ Y Y A —NH₂ 1179.65 1180.22 4.2 81.1 >1000 1686 $ Y Y A —NH₂ 1173.65 1174.4 3.1 135.9 231.4 1687 $ Y Y A —NH₂ 1198.66 1199.05 0.5 40.2 109.5 >1000 1688 $ Y Y A —NH₂ 1186.66 1187.25 3.8 >1000 >1000 1689 $ Y Y A —NH₂ 1205.67 1206.4 16.6 >1000 240.3 1690 $ Y Y A —NH₂ 1183.64 1184.29 7.5 >1000 >1000 1691 $ Y Y A —NH₂ 1190.65 1190.4 47.7 146.7 >1000 1692 $ Y Y A —NH₂ 1210.62 1210.94 188.1 10.8 >1000 1693 $ Y Y A —NH₂ 1204.66 1205.29 169.0 12.7 288.0 1694 $ Y Y A —NH₂ 1201.64 1202.15 119.7 17.3 234.4 1695 $ Y Y A —NH₂ 1214.65 1214.91 83.7 8.0 280.1 1696 $ Y Y A —NH₂ 1165.64 1166.07 26.6 27.5 89.0 1697 $ Y Y A —NH₂ 1166.65 1167.37 13.0 6.0 12.7 1698 $ Y Y A —NH₂ 1179.65 1180.22 15.9 7.1 109.1 1699 $ Y Y A —NH₂ 1166.65 1167.18 13.7 35.4 227.1 1700 $ Y Y A —NH₂ 1173.65 1173.93 34.6 4.0 23.1 1701 $ Y Y A —NH₂ 1166.65 1167.18 9.9 17.4 70.6 1702 $ Y Y A —NH₂ 1109.13 1109.46 42.5 83.5 97.9 1703 $ Y Y A —NH₂ 1166.65 1167.27 5.2 8.4 48.3 1704 $ Y Y A —NH₂ 1166.65 1137.37 19.8 7.2 24.8 1705 $ Y Y A —NH₂ 1173.65 1173.93 >1000 >1000 >1000 1706 $ Y Y A —NH₂ 1138.14 1138.32 5.5 59.0 120.1 1707 $ Y Y A —NH₂ 1166.65 1167.37 >40 >1000 15.5 >1000 1708 $ Y F4F A —NH₂ 1160.64 1161.45 2.1 4.8 9.5 91.8 1709 $ Y Y A —NH₂ 1166.65 1167.37 10.9 17.2 36.6 1710 $ Y Y A —NH₂ 1166.65 1167.37 3.7 17.0 36.5 1711 $ Y Y A —NH₂ 1172.65 1173.47 4.6 20.9 38.9 1712 $ Y Y A —NH₂ 1165.64 1166.44 10.4 7.7 25.7 1713 $ Y Y A —NH₂ 1158.63 1159.32 8.9 8.4 68.2 1714 $ Y Y A —NH₂ 1139.11 1139.52 2.2 72.0 117.8 1715 $ Y Y A —NH₂ 1152.64 1153.49 4.5 32.8 47.8 1716 $ Y Y A —NH₂ 1138.63 1138.97 3.9 27.2 49.7 1717 $ Y Y A —NH₂ 1143.12 1143.87 3.6 25.2 52.0 1718 $ Y Y A —NH₂ 1118.1 1118.8 3.9 33.4 53.2 1719 $ Y Y A —NH₂ 1138.62 1139.24 4.8 35.9 64.9 1720 $ Y Y A —NH₂ 1110.1 1110.75 3.8 32.6 63.9 1721 $ Y Y A —NH₂ 1117.11 1117.78 4.0 20.3 56.0 1722 $ Y Y A —NH₂ 1148.12 1148.96 6.2 33.9 76.7 1723 $ Y Y A —NH₂ 1095.6 1096.32 3.0 36.3 41.1 1724 $ Y Y A —NH₂ 1116.14 1116.95 9.8 20.5 39.1 1725 $ Y Y A —NH₂ 1106.62 1107.24 6.6 19.5 43.0 1726 $ Y Y A —NH₂ 1081.6 1181.98 15.3 56.2 89.5 1727 $ Y Y A —NH₂ 1095.11 1095.58 11.2 37.3 62.5 1728 $ Y Y A —NH₂ 1094.63 1095.3 10.2 71.8 125.6 1729 $ Y Y A —NH₂ 1111.62 1112.33 10.2 45.3 95.9 1730 $ Y Y A —NH₂ 1136.63 1137.3 13.7 55.3 144.3 1731 $ Y Y A —NH₂ 1139.13 1139.89 3.6 67.8 117.2 1732 $ Y Y A —NH₂ 1152.15 1152.94 19.7 96.2 170.5 1733 $ Y Y A —NH₂ 1169.14 1169.86 17.2 109.9 125.0 1734 $ Y Y A —NH₂ 1152.15 1152.84 11.6 37.9 75.8 1735 $ Y Y A —NH₂ 1117.13 1117.97 23.2 11.7 25.6 1736 $ Y Y A —NH₂ 1145.14 1145.9 106.2 112.2 130.6 1737 $ Y Y A —NH₂ 1152.15 1152.94 104.3 139.5 119.8 1738 $ Y Y A —NH₂ 1138.14 1138.87 63.6 135.4 141.9 1739 $ Y Y A —NH₂ 1086.1 1086.89 29.7 171.4 145.1 1740 $ Y Y A —NH₂ 1179.14 1180.04 2.3 14.5 17.7 1741 $ Y Y A —NH₂ 1166.65 1167.46 2.7 16.6 38.9 1742 $ Y Y A —NH₂ 1193.63 1194.38 8.2 107.4 103.8 1743 $ Y Y A —NH₂ 1187.67 1188.36 21.2 154.1 158.3 1744 $ Y Y A —NH₂ 1184.65 1185.5 4.4 19.1 35.1 1745 $ Y Y A —NH₂ 1197.65 1198.54 6.5 100.2 113.5 1746 $ Y Y A —NH₂ 1131.62 1132.4 1.5 25.9 35.3 1747 $ Y Y A —NH₂ 1138.63 1139.02 1.8 17.9 30.7 1748 $ Y Y A —NH₂ 1138.14 1138.84 4.9 36.5 71.6 1749 $ Y Y A —NH₂ 1117.62 1118.5 8.0 44.1 67.5 1750 $ Y Y A —NH₂ 1142.64 1143.25 8.0 36.3 57.4 1751 $ L Y A —NH₂ 1106.14 1107.05 17.6 69.9 124.9 1752 $ Y A A —NH₂ 1113.63 1114.27 20.3 51.8 102.0 1753 $ Y L A —NH₂ 1134.65 1135.33 23.4 9.0 18.9 1754 $ Y Cha A —NH₂ 1154.66 1155.31 24.1 8.6 28.9 1755 $ Y hF A —NH₂ 1158.65 1159.5 8.0 12.1 30.7 1756 $ Y W A —NH₂ 1171.15 1171.78 3.9 15.4 23.5 1757 $ Y 2Nal A —NH₂ 1176.65 1177 8.0 26.1 65.2 1758 $ Y Y D —NH₂ 1153.12 1153.77 2.2 116.4 137.9 1759 $ Y Y E —NH₂ 1160.13 1160.8 1.4 45.4 56.4 1760 $ Y Y Q —NH₂ 1159.64 1160.26 4.6 41.1 64.7 1761 $ Y Y S —NH₂ 1139.13 1139.47 4.7 36.0 62.4 1762 $ Y Y H —NH₂ 1164.14 1165.05 10.6 73.8 98.8 1763 $ Y Y R —NH₂ 1173.66 1174.4 18.5 185.9 141.8 1764 $ Y Y K —NH₂ 1159.66 1160.26 6.6 66.3 43.4 1765 $ Y Y A —NH₂ 1166.65 1167.18 0.98 86.6 >1000 >1000 1766 $ Y Y A —NH₂ 1166.65 1167.46 15.2 >1000 205.5 >1000 1767 $ F4F Y A —NH₂ 1160.64 1161.26 1.4 14.9 26.0 199.8 1768 $ Y Y Aib —NH₂ 1166.65 1167.46 4.6 29.0 >1000 218.1 1769 $ Y Y A —NH₂ 1139.11 1139.71 15.3 >1000 85.0 >1000 1770 $ Y Y A —NH₂ 1159.64 1160.4 5.0 >1000 >1000 >1000 1771 $ Y Y A —NH₂ 1122.12 1122.87 19.3 39.5 >1000 >1000 1772 $ Y Y A —NH₂ 1136.13 1136.47 5.8 0.8 >1000 >1000 1773 $ A Y A —NH₂ 1113.63 1113.9 4.0 5.3 12.6 111.6 1774 $ F4F Y A —NH₂ 1167.64 1168.57 1.0 58.0 43.0 1775 $ Y F4F A —NH₂ 1167.64 1168.2 0.7 27.0 13.0 1776 $ F4F F4F A —NH₂ 1168.64 1169.59 0.7 127.0 121.0 1777 $ Y F4F A —NH₂ 1118.11 1118.89 0.6 52.0 37.0 1778 $ A F4F A —NH₂ 1072.1 1072.92 0.9 23.0 9.0 1779 $ F4F F4F A —NH₂ 1147.62 1148.59 0.5 >1000 >1000 1780 $s8 Y Y A —NH₂ 1199.18 1199.74 >40 1.1 1.1 22.0 1781 $s8 Y Y A —NH₂ 1207.17 1207.7 >40 1.6 1.6 19.2 1782 St Y Y A $r5 A —NH₂ 1306.72 1307.42 >40 11.6 24.2 57.7 *Raji Cell Viability, 48 h, 5% serum

Example 3 Dose-Dependent Cell Killing By Peptidomimetic Macrocycles

BIM peptidomimetic macrocycles were tested for cell killing at various concentrations. Human Raji cells were treated with increasing doses of peptidomimetic macrocycles corresponding to SEQ ID NO. 763 (FIGS. 1 and 2), 1143 (FIGS. 1-3), and 1621 (FIGS. 3 and 4). An % Viable cells was calculated for each dose of the peptidomimetic macrocycle from a non-linear fit of response vs dose (GraphPad Prism). The effect of the peptidomimetic macrocycles corresponding to SEQ ID NO. 763 are presented in FIGS. 1 and 2. The effect of the peptidomimetic macrocycles corresponding to SEQ ID NO. 1143 are presented in FIGS. 1-3. The effect of the peptidomimetic macrocycles corresponding to SEQ ID NO. 1621 are presented in FIGS. 3 and 4.

Example 4 MCL-1 Displacement Study

BIM peptidomimetic macrocycles were tested for displacement of MCL-1 from a BAK fluorescence resonance energy transfer (FRET) peptide. Human Raji cells were treated with DMSO, ABT-263, and peptidomimetic macrocycles corresponding to SEQ ID NO. 763 and 1143. FIG. 5 shows the effect of the compounds on normalized BAK peptide FRET signal.

Example 5 Pharmacokinetic (PK) and Biodistribution Study in Mice

A peptidomimetic macrocycle corresponding to SEQ ID NO. 763 was administered to mice at a 5 mg/kg dose. Mice were sacrificed at specific timepoints both before and after dosing, up to 24 hours post-administration. Blood, liver, and spleen were collected from the mice at the specific time points. Plasma was prepared from the blood using K2EDTA tubes by centrifuging for 20 minutes at 4° C. at 2000G maximum 30 minutes after collection. From each plasma sample, an aliquot was transferred to a fresh tube for PK studies. From each liver and spleen sample, tissue was homogenized and extracts were prepared for biodistribution studies. FIG. 6 shows the PK and biodistribution results for this study by concentration in nanograms of peptidomimetic macrocycle per gram mouse body weight (ng/g) over time.

Example 6 Human Plasma Stability Study

Peptidomimetic macrocycles corresponding to SEQ ID NO. 763 or 1143 were administered to humans. Blood was collected at specific timepoints both before and after dosing, up to 24 hours post-administration. Plasma was prepared from the blood using K2EDTA tubes by centrifuging for 20 minutes at 4° C. at 2000G maximum 30 minutes after collection. From each plasma sample, an aliquot was transferred to a fresh tube for plasma stability studies. FIG. 7 shows the plasma stability results for this study as a percentage of peptidomimetic macrocycle remaining in plasma over time, with the dashed line corresponding to the initial amount of peptidomimetic macrocycle dosed. 

1-162. (canceled)
 163. A peptidomimetic macrocycle of Formula (I):

or a pharmaceutically acceptable salt thereof, wherein each A, B, C, D, and E is independently an amino acid and the terminal D and E independently optionally include a capping group; L is a macrocycle-forming linker; L′ is alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene, optionally substituted with R₅, or a bond; R₁ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, each being optionally substituted with halo-; or R₁ and L′ together with the atom to which both R₁ and L′ are bound form a ring; L″ is alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene, optionally substituted with R₅, or a bond; R₂ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, each being optionally substituted with halo-; or R₂ and L″ together with the atom to which both R₂ and L″ are bound form a ring; each R₅ is independently halogen, alkyl, —OR₆, —N(R₆)₂, —SR₆, —SOR₆, —SO₂R₆, —CO₂R₆, a fluorescent moiety, a radioisotope, or a therapeutic agent; each R₆ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope, or a therapeutic agent; each R₇ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, each being optionally substituted with R₅, or part of a cyclic structure with a D residue; each R₈ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, each being optionally substituted with R₅, or part of a cyclic structure with an E residue; v is 1-10; w is an integer from 1-1000; u is 1; and each x, y, and z is an integer such that x+y+z is 3; wherein [A]_(x)-[B]_(y)-[C]_(z) comprises an isoleucine (Ile) and an aspartic acid (Asp) and [E]_(w) comprises an arginine (Arg) and a histidine (His).
 164. The peptidomimetic macrocycle of claim 163, wherein R₁ and L′ together with the atom to which both R₁ and L′ are bound form a ring.
 165. The peptidomimetic macrocycle of claim 163, wherein R₂ and L″ together with the atom to which both R₂ and L″ are bound form a ring.
 166. The peptidomimetic macrocycle of claim 163, wherein the peptidomimetic macrocycle comprises an α-helix.
 167. The peptidomimetic macrocycle of claim 163, wherein -[A]_(x)-[B]_(y)-[C]_(z)- is -Ile-[B]₁-Asp-.
 168. The peptidomimetic macrocycle of claim 163, wherein B is a hydrophobic amino acid.
 169. The peptidomimetic macrocycle of claim 163, wherein [E]_(w) comprises two arginines.
 170. The peptidomimetic macrocycle of claim 163, wherein R₂ is methyl.
 171. The peptidomimetic macrocycle of claim 163, wherein both R₇ and R₈ are hydrogen.
 172. The peptidomimetic macrocycle of claim 163, wherein w is an integer from 1-15.
 173. The peptidomimetic macrocycle of claim 163, wherein L′ and L″ is each independently alkylene, alkenylene, or alkynylene.
 174. A pharmaceutical composition comprising (i) a peptidomimetic macrocycle of Formula (I):

or a pharmaceutically acceptable salt thereof, wherein each A, B, C, D, and E is independently an amino acid and the terminal D and E independently optionally include a capping group; L is a macrocycle-forming linker; L′ is alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene, optionally substituted with R₅, or a bond; R₁ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, each being optionally substituted with halo-; or R₁ and L′ together with the atom to which both R₁ and L′ are bound form a ring; L″ is alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene, optionally substituted with R₅, or a bond; R₂ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, each being optionally substituted with halo-; or R₂ and L″ together with the atom to which both R₂ and L″ are bound form a ring; each R₅ is independently halogen, alkyl, —OR₆, —N(R₆)₂, —SR₆, —SOR₆, —SO₂R₆, —CO₂R₆, a fluorescent moiety, a radioisotope, or a therapeutic agent; each R₆ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope, or a therapeutic agent; each R₇ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, each being optionally substituted with R₅, or part of a cyclic structure with a D residue; each R₈ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, each being optionally substituted with R₅, or part of a cyclic structure with an E residue; v is 1-10; w is an integer from 1-1000; u is 1; and each x, y, and z is an integer such that x+y+z is 3; wherein [A]_(x)-[B]_(y)-[C]_(z) comprises an isoleucine (Ile) and an aspartic acid (Asp) and [E]_(w) comprises an arginine (Arg) and a histidine (His); and (ii) a pharmaceutically-acceptable carrier.
 175. A method of treating a cancer in a subject, the method comprising administering to the subject suffering from the cancer a therapeutically-effective amount of a peptidomimetic macrocycle of Formula (I):

or a pharmaceutically acceptable salt thereof, wherein each A, B, C, D, and E is independently an amino acid and the terminal D and E independently optionally include a capping group; L is a macrocycle-forming linker; L′ is alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene, optionally substituted with R₅, or a bond; R₁ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, each being optionally substituted with halo-; or R₁ and L′ together with the atom to which both R₁ and L′ are bound form a ring; L″ is alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene, optionally substituted with R₅, or a bond; R₂ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, each being optionally substituted with halo-; or R₂ and L″ together with the atom to which both R₂ and L″ are bound form a ring; each R₅ is independently halogen, alkyl, —OR₆, —N(R₆)₂, —SR₆, —SOR₆, —SO₂R₆, —CO₂R₆, a fluorescent moiety, a radioisotope, or a therapeutic agent; each R₆ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope, or a therapeutic agent; each R₇ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, each being optionally substituted with R₅, or part of a cyclic structure with a D residue; each R₈ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, each being optionally substituted with R₅, or part of a cyclic structure with an E residue; v is 1-10; w is an integer from 1-1000; u is 1; and each x, y, and z is an integer such that x+y+z is 3; wherein [A]_(x)-[B]_(y)-[C]_(z) comprises an isoleucine (Ile) and an aspartic acid (Asp) and [E]_(w) comprises at an arginine (Arg) and a histidine (His).
 176. The method of claim 176, wherein R₁ and L′ together with the atom to which both R₁ and L′ are bound form a ring.
 177. The method of claim 176, wherein R₂ and L″ together with the atom to which both R₂ and L″ are bound form a ring.
 178. The method of claim 176, wherein the peptidomimetic macrocycle comprises an a-helix.
 179. The method of claim 176, wherein -[A]_(x)-[B]_(y)-[C]_(z)- is -Ile-[B]₁-Asp-.
 180. The method of claim 176, wherein the cancer is colorectal cancer, liver cancer, breast cancer, prostate cancer, uterine cancer, or lung cancer.
 181. The method of claim 176, further comprising administering to the subject an additional therapy to treat the cancer. 